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1When a pathogen such as a virus, bacterium or fungus invades the host, it first encounters the skin and/or mucosa, which represent the first line of defense of the immune system. In 
these tissues, pathogen-associated molecular patterns (PAMPs) like lipopolysaccharide (LPS) 
or viral DNA/RNA fragments of pathogens, are recognized by pattern recognition receptors 
(PRRs), such as Toll-like receptors (TLRs; TLR4 for LPS, TLR3,7,8,9 in viral infection) present 
on innate immune cells of the host. Innate immune cells include macrophages, monocytes, 
and dendritic cells(1, 2). Subsequently, a pro-inflammatory response is initiated, in which the 
production of pro-inflammatory cytokines such as TNF-α, IFN-γ, IL-1β, IL-6 and GM-CSF, and 
chemokines such as IL-8 and CXCL-10 play a crucial role in the recruitment and activation of 
innate immune cells leading to pathogen recognition and uptake. This leads to the initiation 
of an adaptive immune response, important for long-term immunological memory toward 
specific pathogens. Expansion of specific T-cell populations upon presentation of pathogen-
derived antigens and the development of T and B-cell memory mediate accelerated and 
enhanced recall responses to secondary infections with the same pathogen, and activate 
B-cells to produce specific antibodies that protect against re-infection with the same 
pathogen. In the ideal situation, these mechanisms result in swift eradication of the invading 
pathogen followed by the immune system returning to a state of homeostasis. However, 
when the pro-inflammatory innate immune response exaggerates into a hyperinflammatory 
phenotype, this can result in immunopathology and organ damage(3, 4). 
Simultaneously with the pro-inflammatory immune response, also anti-inflammatory 
mechanisms are induced, leading to the production of key anti-inflammatory cytokines, 
such as IL-10 and IL1-RA, and decreased recruitment and/or attenuated function of innate 
and adaptive immune cells. Where traditionally innate and adaptive immunity were strict 
binary classifications with separated functions, it is now becoming more evident that it is 
one overlapping system, influencing each other at various levels of the immune response(5). 
Anti-inflammatory mechanisms are aimed to ameliorate the pro-inflammatory response to 
regain homeostasis. However, the anti-inflammatory immune response may be exaggerated 
as well, resulting in an immunocompromised, or immunological ‘tolerant’ state. In this 
tolerant state, commensal pathogens such as bacteria and fungi that normally do not cause 
disease may be able to replicate unbridledly and induce opportunistic infections, which are 
associated with high mortality and morbidity(4, 6). Immunosuppression induced by bacterial 
infections is relatively well-described, in particular following severe systemic bacterial 
infections such as sepsis, where it was coined “sepsis-induced immunoparalysis”(6), known 
to induce increased susceptibility toward secondary bacterial and fungal infections. Hence 
in the last decade, instead of aiming for inhibition of the too pronounced pro-inflammatory 
innate immune response, the concept of immunostimulatory therapy for sepsis-induced 
immunoparalysis has gained increased attention. Several in vivo animal, and ex vivo studies 
with human cells have identified promising immunostimulatory treatments(6, 7). However, 
whether these compounds actually reverse immunosuppression in vivo in humans remains 
elusive. Previous work has also revealed that bacterial sepsis is associated with reactivation 
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of viruses that reside latent in the host, such as cytomegalovirus (CMV), epstein barr virus 
(EBV) and herpes simplex virus (HSV), and that this phenomenon is associated with increased 
mortality(8). Although it has become apparent that the immunosuppressive mechanisms 
observed in sepsis also play an important role in non-infectious inflammation such as 
observed trauma patients(9, 10), it remains to be determined whether the immunosuppressive 
process in trauma patients is of a similar extent to induce viral reactivation and whether this 
is of clinical relevance. Furthermore, it is unknown whether bacterial infection alters the 
response to a de novo viral infection. 
Next to bacterial infections, respiratory virus infections such as influenza can induce 
hyperinflammation(11-13) and severe disease courses, necessitating ICU admission and 
leading to high mortality rates(1). Influenza patients represent a heterogeneous population 
which makes it difficult to predict which patients are at risk for severe disease. Identifying 
patient factors that are related to ICU admission and ICU mortality may facilitate timely 
and tailor-made treatment, and improve the prognosis of influenza infection. Some studies 
report that, similar to bacterial sepsis, influenza may induce tolerance mechanisms and 
thereby promote the development of secondary infections(14-16). However, available data on 
immunomodulatory effects of influenza is not straight forward, with other studies reporting 
enhancing effects on the immune response toward a secondary infectious challenge; 
a phenomenon known as immunological ‘priming’(14, 16, 17). Theoretically, this enhanced 
immune response could lead to increased protection against secondary infections, but 
could also result in immunopathology leading to collateral damage to the host, including 
organ damage as described above(1, 3). These apparently contrasting data may be due to 
timing-related effects and the use of different animal models of primary and secondary 
infections. Nevertheless, mortality can be the result of both immunopathology, as well as 
secondary infections(12, 18-20). Early treatment of these infections could reduce the risk of ICU 
admission and thereby improve patients outcome. The underlying mechanisms behind 
influenza’s putative immunomodulatory effects are far from clear. Although equivocal, 
there exists a relatively large body of literature on the immunological effects of influenza 
infection on secondary pathogenic challenges, but there is virtually no data on such effects 
of milder respiratory viruses, such as the human rhinovirus (HRV), the predominant causative 
pathogen of the ‘common cold’(21, 22). It is important to further elucidate these viral-induced 
effects, because respiratory virus infections are very common and can have severe disease 
courses as well(21, 23-27). 
In summary, the host response toward sequential infections with the same or different 
pathogens is a clinically relevant issue that is far from elucidated. As such, further investigations 
are required in order to increase our insight that may possibly facilitate developments and/or 
improvements of immunomodulatory therapies. The aim of this thesis is to investigate the 
host response toward subsequent challenges with bacterial, viral and fungal pathogens 
in vivo, predominantly using experimental human challenge models. In addition, the 
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1clinical implications of these immunological interactions are assessed in patients. Finally, several methodological considerations of the various human challenge models are described 
in this thesis emphasizing their applicability beyond their current use. The outline of this 
thesis is described below.
PART I: IMMUNOLOGICAL PATHOGEN-HOST INTERACTIONS 
The current knowledge on mechanisms underpinning bacterial and viral-induced 
immunosuppression, and the susceptibility toward various secondary infections is described 
in a review article in chapter 2. In chapters 3-6, host responses to sequential challenges 
with a variety of pathogens or pathogenic stimuli are investigated using various bacterial 
and viral challenge models in humans and mice. In chapter 3, we used the experimental 
human endotoxemia model to evaluate whether in vivo endotoxin tolerance can be reversed 
by immunostimulatory therapies. LPS or “endotoxin”, is a part of the outer membrane of 
Gram-negative bacteria and is recognized by Toll-like receptor 4. When LPS is administered a 
second time (after 7-14 days) to healthy volunteers, the innate immune response is blunted, 
a phenomenon called endotoxin tolerance. This immunosuppressive state mimics sepsis-
induced immunoparalysis(28, 29). We administrated GM-CSF, IFN-γ, or placebo in between the 
LPS-challenges to investigate whether these immunostimulatory therapies could reverse 
endotoxin tolerance, and would therefore be a viable option for the treatment of sepsis-
induced immunoparalysis. 
In chapter 4, we investigated whether bacterial-compound-induced immunosuppression 
influences the host response toward a de novo viral infection. Therefore, the experimental 
human endotoxemia model described above was followed by the administration of Fluenz, 
a live-attenuated influenza vaccine (LAIV) that serves as a model for an actual influenza virus 
infection(30). Fluenz was administered intranasally to endotoxin-tolerant subjects and local 
(nasal) and systemic inflammatory effects were measured.
It is unknown whether a mild respiratory virus such as HRV induces similar 
immunomodulatory effects compared to more virulent viruses such as influenza. In chapter 5, 
we used repeated HRV challenges to shed light on this question. We set up the HRV model in 
our department in which healthy volunteers were inoculated intranasally with HRV twice in 
seven days, to investigate whether the primary HRV infection modulates the innate immune 
response against the second HRV exposure. 
Influenza infections increase the susceptibility toward secondary infections, 
associated with increased mortality, suggesting that influenza profoundly influences the 
immune response toward a subsequent pathogenic challenge. However, as outlined in 
the introduction, studies reporting on these effects are conflicting, with some describing 
influenza-induced priming(13, 15, 31), whereas others observed immunological tolerance(14, 16, 17). 
In chapter 6, this viral-bacterial interaction was investigated in a standardized manner, 
using a murine challenge model in which mice were inoculated intranasally with pathogenic 
influenza virus followed by an intravenous injection of LPS in the tail vein. To assess the 
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kinetics of the influenza-induced effects, LPS challenges were performed in either the acute 
(day 4) or the recovery phase (day 10) of influenza infection. The systemic and pulmonary 
innate immune response was assessed.
PART II: CLINICAL IMPLICATIONS OF PATHOGEN-HOST INTERACTIONS
In part I, we employed human and murine challenge models. Although they are highly 
standardized and provide mechanistic insight, these models cannot fully recapitulate the 
complex diseases states observed in clinical patients. In part II of this thesis, we investigated 
the clinical implications of immunological host response interactions between pathogens in 
critically ill patients. 
Influenza patients represent a heterogeneous population and it has not been clarified which 
factors are protective and which are associated with increased mortality. Identifying these 
factors could lead to early recognition of influenza patients at risk for a complicated disease 
course and facilitate early treatment of secondary infections, which could theoretically reduce 
the risk of ICU admission and improve outcome. In chapter 7, we examined a database of 
influenza patients admitted to two academic hospitals located in the Netherlands to identify 
factors associated with ICU admission, as well as factors related to ICU mortality. In addition, 
secondary infections that are frequently encountered following influenza infection were 
investigated. 
The most important influenza-induced fungal secondary infection is caused by Aspergillus 
fumigatus, associated with high mortality rates despite a the availability of a wide variety 
of antifungal drugs(32-38). A high incidence of A. fumigatus infections was indeed also found 
in the influenza database used in chapter 7 of this thesis. This led us to hypothesize that 
there might be a specific immune defect present in influenza patients that is responsible 
for the increased susceptibility toward a secondary infection with A. fumigatus. In chapter 
8, we investigated immunological profiles at various levels of the immune response in 
patients with severe influenza infections that were admitted to the ICU to investigate whether 
influenza induces systemic immunoparalysis that explains the increased susceptibility toward 
A. fumigatus. We compared these patients to various groups of other ICU patients as well as 
with healthy controls. 
Reactivation of multiple viruses is frequently observed in sepsis patients and this 
phenomenon is associated with increased mortality(8). In an earlier study from our group, 
we reported that an immunosuppressive phenotype with similarities to that observed 
in sepsis is present in multiple-trauma patients who suffer from sterile inflammation(9). In 
chapter 9, we investigated whether these trauma patients also display viral reactivation, and 
evaluated whether this is associated with clinically relevant endpoints, such as the incidence 
of secondary bacterial infections and increased ICU length of stay. 
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1PART III: METHODOLOGICAL CONSIDERATIONS AND BROAD APPLICABILITY OF HUMAN IN VIVO CHALLENGE MODELS 
In this thesis, multiple human challenge models are used to investigate the immune response 
induced by bacterial or viral pathogens. Various methodological considerations apply to the 
use of these models. In addition, except for assessment of immunological parameters, these 
human models can be used to investigate broader objectives, such as sickness behavior and 
microbiota dynamics. 
In the experimental human endotoxemia model, LPS is normally administered as 
a bolus to induce a systemic inflammatory response which captures several hallmarks of 
that observed in sepsis. However, patients suffering from systemic inflammation are often 
exposed to inflammatory stimuli for a more extended period of time. Furthermore, as the 
LPS-induced inflammatory response is rapidly orchestrated and relatively short-lived 
after bolus administration, investigational treatments are typically initiated before LPS 
administration. Hence, a model using continuous infusion of LPS may be more relevant to 
the clinical situation and expand the time-window to administer investigative treatments. 
In chapter 10, we compared models of bolus LPS administration in various dosages with 
continuous LPS infusion.
In chapter 11, the effects of experimental human endotoxemia on sickness behavior are 
assessed. Sickness behavior is characterized by low mood and fatigue and defined by effort 
and subjective motivation to receive an award. Most will recognize that during an infection 
this may be attenuated. Inflammation-induced sickness behavior was measured by a series 
of accept/reject decisions on whether the stake offered was ‘worth the effort’. Motivation was 
measured by self-reported depression and fatigue. As the kinetics of the endotoxin-induced flu-
like symptoms and cytokine profiles are very similar across the healthy volunteers studied, we 
investigated whether inflammation-induced symptoms would influence psychological tests. 
To optimize the HRV challenge model for future trials, the effects of HRV-serostatus 
and gender on the HRV-induced immune response, which were hitherto unknown, were 
investigated in chapter 12. 
The nasal “microbiome”, the composition of bacteria, viruses and fungi in the nasal 
mucosa, represent a primary pathogen-host interface. Bacterial or viral infections may alter 
the composition of the microbiome, leading to secondary invasion by bacterial pathogens 
and/or the overgrowth of one of the commensals turning into pathogens, eventually causing 
respiratory diseases (39). In chapter 13, a new and simplified method for microbiome analysis 
based on real-time PCR was assessed in samples obtained from volunteers challenged with 
HRV or S. pneumoniae.
Finally, this thesis is concluded with a summary in chapter 15 and a general discussion 
of the findings and future perspectives in chapter 16.
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ABSTRACT
Immunosuppression renders the host increased susceptible for secondary infections. It is 
becoming increasingly clear that not only bacterial sepsis, but also respiratory viruses with 
both severe and mild disease courses such as influenza, respiratory syncytial virus, and the 
human rhinovirus may induce immunosuppression. In this review, the current knowledge on 
(mechanisms of) bacterial- and virus-induced immunosuppression and the accompanying 
susceptibility toward various secondary infections is described. In addition, the frequently 
encountered secondary pathogens and their preferred localizations are presented. Finally, 
future perspectives in the context of the development of diagnostic markers and possibilities 
for personalized therapy to improve the diagnosis and treatment of immunocompromised 
patients are discussed.
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INTRODUCTION
Following resolution of the primary infection, sepsis patients are susceptible to secondary 
infections(1). In the past decade, it has become clear that a sepsis-induced immunosuppressive 
state accounts for this increased vulnerability toward secondary infections(2). In light of this 
and due to the failure of clinical trials that have attempted to improve the outcome of sepsis 
patients by blocking pro-inflammatory pathways, the sepsis research field is currently shifting 
its focus toward the detrimental effects of immunosuppression and therapeutic options 
to reverse it(2). In addition, it is increasingly recognized that respiratory viruses can induce 
immunosuppressive mechanisms that may be similar to those observed in “classic” bacterial 
sepsis-induced immunosuppression.
In this review, we present an overview of the current knowledge on immunosuppression 
induced by acute bacterial and viral infections. To the best of our knowledge, there is no 
data on differences between the various bacterial species concerning bacterial sepsis-
induced immunosuppression. Therefore, we have considered bacterial sepsis as a single 
entity. We have included influenza, the most common causative agent for severe respiratory 
viral infections in the intensive care unit (ICU), and also frequently encountered viruses that 
usually cause mild disease, such as the respiratory syncytial virus (RSV) and the human 
rhinovirus (HRV). For each pathogen, we first describe epidemiological data and clinical 
relevance, followed by direct effects on the respiratory tract that predispose to secondary 
infections as well as immunomodulatory mechanisms. Furthermore, we report the most 
common pathogens that induce secondary bacterial/fungal infections and viral reactivation. 
Finally, specific localizations and combinations of pathogens are discussed. Throughout the 
review, we draw parallels between the different pathogens causing immunosuppression.
Bacterial sepsis-induced immunosuppression
Sepsis remains the leading cause of death in ICU patients(1). Pneumonia is the most common 
type of infection(2), and gram-positive bacteria most frequently involved are Staphylococcus 
aureus and Streptococcus pneumoniae, whereas Escherichia coli, Klebsiella pneumoniae, 
and Pseudomonas aeruginosa predominate among gram-negative isolates (Table 1, 
supplementary data file). Bacteria-derived molecules like toxins degrade cell membranes 
resulting in upregulation of receptors targeted by bacteria for adhesion. This facilitates 
bacterial tissue invasion predisposing the host to secondary bacterial infections in a 
direct fashion(3). However, sepsis also renders the host more vulnerable toward secondary 
infections in an indirect fashion, by suppressing the immune system(4). So far, apart from 
antibiotics and supportive care including administration of fluids and vasopressors, no 
adjuvant immunomodulatory therapies have proven successful in sepsis. Although limiting 
the pro-inflammatory immune response could represent a host-protective strategy to reduce 
inflammation-induced tissue damage(1, 2), it may also result in a severely immunosuppressed 
state when the anti-inflammatory response is too pronounced or persistent(4). 
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Sepsis-induced immunosuppression has gained attention due to its contribution to adverse 
clinical outcome(2). Previously it was thought that a phase of hyperinflammation preceded 
the immunosuppressive state, but recent work indicates that hyperinflammation and 
immunosuppression often coexist(2) (Figure 1). This may hamper the possibilities for targeted 
immunomodulatory therapy in these patients.
Figure 1. Overview of the various possible effects of a pathogen on the immune response following the 
primary infection. The green dashed lines represent pro-inflammatory (upper line) and anti-inflammatory 
(bottom line) immune states that return to homeostasis and result in recovery from the infection. The red 
dashed lines indicate that uncontrolled hyperinflammation (upper line) and (persistent) immunosuppression 
(bottom line) cause damage to the host and increase susceptibility toward secondary infections.
Sepsis-induced immunosuppression involves dysfunction of both innate and adaptive 
immunity. This includes functional defects in leukocytes, such as monocytes, neutrophils, 
and dendritic cells (DCs) (Figure 2), causing alterations in antigen-presenting ability and 
cytokine production capacity, the latter skewed toward a more anti-inflammatory profile(1, 4). 
In addition, attenuated expression of immunostimulatory membrane-bound receptors, 
such as human leukocyte antigen-D related (HLA-DR), alongside upregulation of negative 
costimulatory molecules, such as programmed cell death ligand-1 (PD-L1)(5). Not only 
circulating leukocytes, but also tissue-resident immune cells obtained from postmortem 
spleen and lung samples of sepsis patients revealed depletion of splenic CD4+, CD8+, and HLA-
DR cells and increased expression of PD-L1, indicating the extent of immune dysfunction(5). In 
addition, sepsis-induced alterations in count and function of T-lymphocyte subpopulations 
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Figure 2. Overview of mechanisms behind immunosuppression induced by bacterial sepsis, influenza, RSV, 
and HRV infection, all increasing the susceptibility toward various secondary infections of which the most 
frequently encountered in sepsis, influenza, RSV, and HRV are included. Immunosuppressive mechanisms 
are largely similar between bacteria and viruses, except for type I IFNs that only play a role in virus-induced 
immunosuppression: 1, apoptosis and dysfunction of leukocytes; 2, dysregulated cytokine production; 
3, altered expression of costimulatory molecules and/or membrane-bound receptors; 4, dysfunctional 
phagocytosis and bacterial killing; 5, decreased leukocyte recruitment; 6, dysfunction of tissue macrophages; 
7, apoptosis and dysfunction of T-lymphocytes. CMV indicates cytomegalovirus; EBV, epstein barr virus; HRV, 
human rhinovirus; HSV, herpes simplex virus; IFN, interferon; RSV, respiratory syncytial virus.
have been observed(1, 2, 6). It is conceivable that antibody production is also affected due to 
these alterations in T-helper (Th)-lymphocytes; however, this has not been investigated yet.
The pathogens that frequently cause secondary bacterial infections (including Pseudomonas 
spp., Stenotrophomonas spp., Acinetobacter spp., and Enterococcus spp.) confirm the 
presence of immunosuppression in sepsis patients, as these pathogens are weakly virulent 
in immunocompetent patients(2). In addition, secondary fungal infections may occur in sepsis 
patients, with invasive candidiasis being the most frequent, mostly caused by Candida 
albicans. In addition, invasive pulmonary aspergillosis (IPA; mostly Aspergillus Fumigatus) 
has been described in former immunocompetent patients (Table 1, supplementary data file). 
The course of disease varies from chronic or indolent to fulminant, and mortality rates are 
high. It seems conceivable that the type of pathogen and site of the primary infection may 
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influence the susceptibility to a specific type of pathogen causing the secondary infection, 
possibly related to different cytokine profiles evoked by various pathogens.
There are no clinical data on whether sepsis promotes the development of secondary 
viral infections. However, the reactivation of viruses in immunocompromised patients is 
currently gaining increased attention. This phenomenon was previously described for the 
Herpesviridae: cytomegalovirus and herpes simplex virus(2). A recent study showed that 
viremia with multiple viruses (measured with PCR) was detected in more than 40% of sepsis 
patients, including herpes viruses, polyomaviruses, and anelloviruses(6). The clinical relevance 
is illustrated by the fact that patients who became positive for cytomegalovirus were more 
likely to develop a secondary fungal infection and to die(6). The increased viral loads and 
occurrence of viral infections observed were of equal magnitude as those encountered in 
solid-organ transplant patients who receive immunosuppressive medication(6). Owing to 
the high seropositivity for the various detected viruses in the general population, it is likely 
that these increased viral loads represent viral reactivation rather than a new infection. 
Furthermore, murine studies showed that after administration of lipopolysaccharide (LPS) 
(a cell-wall compound of gram-negative bacteria), a subsequent challenge with HRV resulted 
in viral RNA persistence and a deficient HRV-induced cytokine response(7). Possibly, the 
aforementioned T-lymphocyte exhaustion following immunosuppression predisposes to 
viral reactivation and dissemination. However, as these are observational studies, it remains 
unclear whether viral reactivation is merely a marker of immunosuppression or that it actually 
contributes to immunologic impairment in critically ill patients(1, 6).
Influenza virus
The influenza virus causes infections of the upper respiratory tract, and in severe cases of 
the lower respiratory tract(8). Influenza is responsible for 250,000 to 500,000 deaths each 
year in the developed world(9). As with bacterial sepsis, both hyperinflammation and 
immunosuppression seem to coexist(8, 10-12). As a consequence, damaging effects to the host 
as a consequence of an overwhelming immune response to influenza and compromised 
defense against secondary bacterial infection may occur at the same time(9) (Figure 1). 
Seasonal influenza vaccines are used to provide protection against the influenza strains 
that are most likely circulating in the upcoming influenza season. The clinical relevance of 
antiviral drugs, such as oseltamivir, are debated(8). Despite extensive research, no effective 
immunomodulatory therapies for influenza have been developed so far(8).
Influenza infections are frequently complicated by secondary bacterial infections, 
predominantly pneumonia, associated with high mortality rates(13). The clinical relevance of 
this phenomenon is emphasized by the fact that most fatal cases during influenza pandemics 
were due to secondary bacterial pneumonia(13). The influenza-bacterial interaction has 
not been prospectively or experimentally investigated in vivo in humans, but several 
observational studies in patients and experimental animal studies have provided evidence 
for influenza-induced immunosuppression and the resultant increased vulnerability toward 
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secondary bacterial infections. For instance, influenza-infected mice are prone for infection 
with S. pneumoniae, exemplified by decreased clearance of S. pneumoniae and increased 
mortality compared with mice that were not previously infected with influenza(10, 14). 
Furthermore, in chinchillas that were infected with influenza followed by S. pneumoniae, the 
incidence of otitis media (OM) was higher than in animals that were infected with only one of 
these pathogens(15).
Influenza predisposes to secondary infections by direct effects, including the disruption 
of epithelial cell barriers and suppression of the production of antibacterial peptides and 
upregulation of bacterial adhesion molecules(9-11). S. aureus, H. influenzae, and S. pneumoniae 
show enhanced adherence to pharyngeal cells harvested from patients and volunteers with 
natural or experimental influenza infections(14).
Secondary infections are observed following pandemic influenza strains, and also with 
seasonal influenza strains that disrupt epithelial barriers to a lesser extent, suggesting the 
involvement of additional, immunosuppressive mechanisms. The direct effects have been 
extensively reviewed(9-11); therefore, we will focus on the indirect, immunosuppressive 
mechanisms and compare them with bacterial sepsis-induced immunosuppression.
In the acute phase of influenza infection, recruitment of innate immune cells such as 
neutrophils to the influenza-infected lungs is increased upon a subsequent challenge with 
bacterial pathogens(12, 16). In contrast, in the recovery phase, recruitment of neutrophils(11) 
and natural killer (NK)-cells(17) was decreased when a bacterial pathogen was administered, 
although another study reported increased neutrophil recruitment but impaired functionality 
of these cells(18). Moreover, dysfunction of tissue-resident macrophages has also been 
described upon induction of a bacterial coinfection in the recovery phase of influenza, 
marked by suppressed phagocytosis, reduced killing capacity, and impaired antigen 
presenting capacity in the draining lymph nodes(11, 19), a phenomenon that may persist for 
months following influenza infection(11). These functional defects are partly mediated by 
altered expression of costimulatory molecules and cell surface receptors(11, 19). This includes 
desensitization of lung sentinel cells to Toll-like receptor (TLR) ligands(11), leading to reduced 
NF-κB activation and chemokine production, and decreased expression of the macrophage 
receptor MARCO(19), resulting in reduced activation of these cells. Concerning cytokine release, 
both in vitro studies in which influenza-infected alveolar macrophages were stimulated with 
LPS(20) and murine studies that investigated the effects of challenge with a bacterial pathogen 
in the acute phase of influenza infection(10) report increased production of pro-inflammatory 
cytokines, such as tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and IL-8. This might 
explain the aforementioned increased recruitment of immune cells in the acute phase. 
Furthermore, interferon (IFN)-γ production by T-cells was shown to increase one week 
after influenza infection(19, 21), but perhaps counter-intuitively resulted in downregulation of 
MARCO on macrophages and decreased phagocytosis, inhibiting bacterial clearance(19). The 
importance of IFN-γ in the susceptibility toward secondary bacterial infections is underlined by 
the fact that these infections can be prevented by IFN-γ neutralization after influenza infection 
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with an IFN-γ-specific antibody(19). This contrasts the role of IFN-γ in bacterial sepsis, where 
it is currently investigated as immunostimulatory agent to prevent immunosuppression(3). 
During the recovery phase of influenza, again similar as for cellular recruitment, challenge 
with bacterial pathogens results in an immunosuppressive phenotype, demonstrated by 
impaired pro-inflammatory cytokine production(17), whereas production of the archetypal 
anti-inflammatory cytokine IL-10 is increased, resulting in the inability of immune cells to 
kill bacteria(12, 18). The importance of IL-10 is underscored by the finding that neutralization 
of IL-10 improves survival from bacterial pneumonia following influenza infection in mice(18). 
Furthermore, production of IL-17, crucial in the host defense against certain bacteria, is 
suppressed in influenza-infected mice upon a subsequent infection with S. aureus(16).
Influenza also induces thymic atrophy, associated with T-lymphocyte apoptosis and 
decreased T-lymphocyte proliferation(21). This may be the result of influenza-induced 
upregulation of PD-L1, which impairs T-lymphocyte function and induces their apoptosis. 
The chronology of these events is far from understood, probably due to the complex interplay 
between different immune cells.
In general, the influenza-induced immunosuppressive effects preventing virus eradication 
are comparable with those observed in bacterial sepsis. However, during influenza infection, 
various of these processes are mediated by type I IFNs(15), which is not involved in bacterial 
sepsis-induced immunosuppression (Figure 2). This was exemplified by the fact that Ifnar –/– 
mice do not demonstrate immunosuppression and effectively clear a secondary bacterial 
infection after influenza infection, although this was not the case in wild-type mice(14).
The pathogens predominantly involved in influenza-associated secondary 
bacterial infections are S. pneumoniae, S. aureus, H. influenza, and S. pyogenes (Table 1, 
supplementary data file). S. pneumoniae is considered the most common cause of influenza-
associated pneumonia, OM, and sinusitis. In addition, A. fumigatus developed to IPA in 25% 
of the influenza patients who were admitted to the ICU(22), representing an important cause 
of mortality in patients with severe influenza infections(22). Mechanistically, this is in line with 
the aforementioned influenza-induced IL-10 production, which promotes a Th2 response, 
associated with an increased risk for developing IPA.
Similar to bacterial sepsis, influenza is associated with mixed viral infections including 
co-infection with RSV, HRV, and coronavirus (Table 1, supplementary data file). Influenza 
promotes viral reactivation of herpes simplex virus, but underlying mechanisms have not 
been elucidated. In contrast with secondary bacterial infections following influenza, these 
infections are not necessarily associated with a more severe disease course, which might 
be related to the influenza-induced suppressed immune response. Of note, these secondary 
infections are most frequently encountered in patients infected with pandemic influenza, 
possibly because the disruption of the epithelium of the lower respiratory tract is more 
extensive than the seasonal strains.
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RSV
RSV is the most common pathogen of severe respiratory illness during infancy and 
childhood worldwide. RSV is present in more than 90% of the nasal washes of infants less 
than 2 years that suffer from acute bronchiolitis. Apart from children, RSV causes disease 
in immunocompromised, and also in otherwise immunocompetent hosts. No effective 
therapies for severe RSV infections have been developed to date.
Similar to influenza, RSV induces both hyperinflammatory and immunosuppressive 
pathways(23). In addition, RSV predisposes to secondary bacterial infections, of which 
predominantly pneumonia, by both direct and indirect effects. Bacterial adherence to 
epithelial tissues is promoted, thereby enhancing colonization and invasiveness. For 
instance, RSV increases the platelet-activating factor receptor that binds H. influenzae and 
S. pneumoniae, thereby promoting bacterial invasion, whereas simultaneously membrane-
bound receptors that kill these two bacterial pathogens are downregulated(24).
Indirect effects of RSV leading to immunosuppression have been investigated in vitro 
and in animal models as described below. In addition, in observational studies in RSV-
infected patients with severe disease, both local and systemic immunosuppression have 
been demonstrated(23). The development and interpretation of animal models related to 
RSV is more complicated than with influenza models because RSV is highly adapted to the 
human host. Yet, data from murine studies that induce secondary bacterial pathogens to 
RSV-infected mice and studies in natural acquired RSV infections in humans indicate that, 
like influenza, RSV-induced immunosuppression is driven by type I IFNs as well, resulting 
in impaired recruitment and functional defects in leukocytes, such as neutrophils and NK-
cells(23). Furthermore, cytokine profiles are altered, leading to decreased production of pro-
inflammatory cytokines and increased levels of anti-inflammatory cytokines, such as IL-10(23). 
For instance, in previously healthy infants who suffer from a RSV-induced lower respiratory 
tract infection, non-active NK-cells and T-lymphocytes as well as lower plasma levels of 
IFN-γ and TNF-α were observed compared with controls, with the lowest values in the most 
severely infected infants(23). However, opposed to influenza, plasma levels of IL-17 and IL-8, 
and numbers of active NK-cells were increased in these patients(23). The role of IL-17 in RSV 
infection is ambiguous; on the one hand, IL-17 recruits neutrophils and facilitates tertiary 
lymphoid structure development in infected lungs(25), whereas on the other hand IL-17 
promotes the Th2 response(25) and inhibits the ability of CD8+ T-lymphocytes to clear RSV.
Type I IFNs alter the expression of costimulatory molecules and cell surface receptors. 
For instance, PD-L1 is upregulated, resulting in dysfunction of CD8+ lymphocytes, whereas 
TLRs are downregulated(11). Similar to sepsis and influenza, RSV inhibits transcriptional 
activity of macrophages which is critical in linking innate and adaptive immune mechanisms. 
In addition, T-lymphocytes are affected in both number and function and are skewed from a 
Th1 toward an anti-inflammatory Th2 profile(25).
In conclusion, RSV induces similar immunosuppressive mechanisms as sepsis and 
influenza, involving both local and systemic immunosuppression (Figure 2).
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S. pneumoniae, H. influenzae, and S. aureus represent the majority of bacterial infections 
that follow RSV infections (Table 1, supplementary data file). Using PCR techniques, a high 
RSV viral load in combination with S. pneumoniae or H. influenza was associated with an 
increased risk for OM, and S. aureus in the lungs of patients with RSV-induced pneumonia 
was associated with a more severe disease course. In addition, RSV predisposes to IPA, 
although the pathogenesis is unclear.
Finally, RSV is associated with co-infections with influenza, para-influenza, adenovirus, 
and HRV, as well as reactivation of cytomegalovirus (Table 1, supplementary data file). In line 
with influenza, these viral co-infections seem not to be associated with a more severe disease 
course.
HRV
HRVs are the most frequent cause of the common cold, with prevalence estimates as high as 
80% in the adult population. Although HRVs often have a self-limiting nature, the importance 
of HRV infections derives primarily from its high frequency and socioeconomic impact. HRV is 
increasingly recognized in both prevalence and severity, as an important causative agent of 
lower respiratory tract infections in immunocompromised patients and the elderly, and also 
immunocompetent children. Severe disease is associated with exacerbation of underlying 
diseases, seizures, and even death. Furthermore, HRV also predisposes to secondary bacterial 
infections, of which pneumonia and OM are most prevalent (Table 1, supplementary data 
file). HRV was detected in the nasopharynx of more than 50% of the children with a history 
of recurrent OM and was associated with poor bacteriologic outcome for OM compared with 
other respiratory viruses(26).
It is unknown whether transient HRV-induced immunosuppressive mechanisms are 
apparent alongside pro-inflammation. Several studies found that both direct and indirect 
mechanisms are involved. The HRV-induced direct effects are similar as those observed 
during influenza and RSV infections and include increased adhesion of various bacteria to 
airway epithelial cells by disrupting the airway epithelial barrier function and increased 
expression of host cell bacterial adhesion molecules that promote bacterial colonization(27). 
In line with these data, in chronic obstructive pulmonary disease (COPD) patients who have 
damaged respiratory epithelium due to smoking and recurrent respiratory infections, the 
incidence of secondary bacterial infections following HRV is as high as 60%(27).
Indirectly, HRV-induced type I IFNs mediate apoptosis and dysfunction of leukocytes, 
such as DCs(28), but not of NK-cells(29). In addition, HRV downregulates costimulatory 
molecules and cell surface receptors, such as HLA-DR on antigen-presenting cells(28). HRV 
infection also results in dysregulated cytokine responses(28), illustrated by the impaired 
cytokine production in HRV-infected alveolar macrophages when challenged to a second 
bacterial ligand(29). Furthermore, in vivo, we recently found that cytokine levels in nasal wash 
of healthy volunteers who were experimentally infected with HRV were severely attenuated 
when these subjects were pre-exposed to HRV 1 week before, supportive of HRV-induced 
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immunosuppressive effects(30). In addition, proliferation of T-lymphocytes and cytotoxic 
T-lymphocyte responses were attenuated by HRV(31), partly because the most important 
antigen-presenting cells, DCs, are compromised both in number and function(28). HRV also 
induces higher levels of IL-10(28).
The most common secondary infections following HRV are caused by S. pneumoniae. 
However, PCR techniques showed that the presence of H. influenzae and Moraxella 
catarrhalis in the nasopharynx is associated with HRV as well. HRV is also found in more than 
20% of asymptomatic children (Table 1, supplementary data file), indicating that HRV often 
colonizes the nasal mucosa without causing symptoms. However, host and environmental 
determinants influence the pathogenicity of HRV and the subsequent increase in vulnerability 
toward secondary infections.
Fungal infections and viral reactivations are not described in healthy subjects exposed 
to HRV, but reactivation of cytomegalovirus and occurrence of IPA was documented in 
immunocompromised patients following infection with HRV. In both children with acute lower 
respiratory disease as well as asymptomatic children, HRV was present with a concomitant 
virus, such as parainfluenza, RSV, influenza or coronavirus (Table 1, supplementary data file).
In summary, HRV also induces immunosuppression (Figure 2). However, severe HRV infection 
is not as common as with the formerly described pathogens, and possibly related to this, 
HRV-induced immunosuppression is generally limited to localized effects.
Specific localizations and combinations of pathogens
Regarding secondary infections, it seems that specific respiratory tract localizations and 
combinations of pathogens are more common than others (Table 1, supplementary data 
file). In children, influenza, RSV, and HRV predispose to bacterial OM, often caused by S. 
pneumoniae, H. influenzae, or M. catarrhalis, whereas in adults these viruses predispose 
generally to bacterial pneumonia, frequently caused by S. pneumoniae. Synergism between 
pathogens may develop early in life and persist for a long period. For instance, colonization 
with S. pneumoniae or H. influenzae during infancy is associated with a 4-fold increased risk 
to develop repetitive OM(15). In addition, synergism of pathogens may contribute to disease 
severity, illustrated by the devastating effects of influenza combined with S. pneumoniae 
during the influenza pandemic of 1918(9).
As the composition of the normal flora varies at different anatomical sites throughout 
the respiratory tract, creating the optimal environment for certain pathogens at certain 
localizations, it is tempting to speculate that crosstalk between pathogens is localization-
dependent. For example, guinea pigs that were inoculated with influenza intratympanically 
showed decreased ciliary activity in their tubotympani leading to decreased clearance time, 
creating the ideal milieu for bacteria to grow. In addition, RSV facilitates bacterial invasion by 
inducting hyperplasia within the Eustachian tube mucosa, which increases mucus secretion 
into the Eustachian tube of chinchilla(15), thereby promoting retrograde movement of bacteria 
resident within the middle-ear space. At the same time, H. influenza induces necrosis of 
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neutrophils, one of the first cellular lines of defense of the middle ear. Owing to this viral-
bacterial interplay, the ideal environment for bacterial OM is created.
Apart from a common localization, synergism may also be due to common immunological 
signaling cascades. For example, influenza and S. pneumoniae induce similar inflammatory 
pathways. The increase in both pro-inflammatory and anti-inflammatory cytokines in this 
murine model resulted in large numbers of neutrophils and macrophages invading the lung, 
causing inflammatory damage(9). Consequently, this dysregulated immune response during 
sequential infection decreased bacterial clearance.
Although there are some data of synergism between pathogens, much is still unknown 
and especially the underlying mechanisms warrant additional research. It remains elusive 
why in some cases respiratory virus infections result in immunosuppression and associated 
secondary infections, whereas in other cases the virus is successfully eradicated from the 
respiratory tract. Therefore, gaining insight into the course of infection could support the 
development of more personalized therapies. Systems biology approaches represent a 
promising strategy to better understand the pathogenesis of viral and bacterial infections to 
categorize disease severity and determine the immune state (overactive or suppressed). One of 
the first applications of this method was to classify respiratory infections of different etiologies 
in patients, including influenza virus, S. aureus, S. pneumoniae, and E. coli (32). Thereafter, this 
method was used to detect disease early on in adult volunteers experimentally infected with 
influenza through a specific blood gene expression signature, creating the opportunity for 
early intervention(33). Nowadays, the technique is optimized in a way that a mathematical 
prediction algorithm with inclusion of a healthy reference can potentially improve accuracy 
of disease prediction with fewer biomarkers(34). In the future, these diagnostic tools might 
be used in clinical practice to predict disease severity and immunosuppression, facilitating 
targeted therapy and subsequently preventing antibiotic overuse.
CONCLUSIONS
It is becoming evident that not only bacterial sepsis and virulent viruses (such as influenza) 
induce immunosuppression and predispose to secondary infections, but also viruses that 
generally induce mild disease courses (like RSV/HRV) can do so as well.
Secondary infections include opportunistic bacterial and fungal infections and viral 
reactivation, which normally only occur in patients who are immunocompromised by other 
causes than following infection. This supports the theory that, apart from direct effects 
(e.g., disruption of epithelial barriers), immunosuppression plays an important role in the 
pathogenesis and development of secondary infections. It seems that the severity of the 
primary disease is related to the extent of immunosuppression and the risk for secondary 
infections(1, 2, 23).
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Pneumonia is the most common type of secondary infection. Owing to the fact that the 
(upper) respiratory tract is the preferential localization of the primary viral infection, it seems 
plausible that a secondary infection affecting the lower respiratory tract is related to epithelial 
damage. Nevertheless, experimental data illustrate that immunosuppressive effects of the 
primary infection also play an important role.
Reactivation of viruses that normally reside latent in the human body (such as 
Herpesviridae) is also encountered following viral infections. Most likely, mixed viral 
infections and persistence of influenza, RSV, and HRV viral loads are also the result of 
immunosuppression, prolonging the respiratory infection. Remarkably and in contrast to 
secondary bacterial infections, these viral co-infections or reactivations are not associated 
with a more severe disease course.
Although bacterial sepsis and viral respiratory tract infection are very different diseases, 
they all induce immunosuppressive mechanisms that overlap to a great extent. Nevertheless, 
there are also important differences, such as the role of type I IFNs, which are central in virus-, 
but not sepsis-induced immunosuppression. It has become clear that specific localizations 
and combinations of pathogens are more frequently encountered than others, indicating that 
specific pathogen-host interactions may promote certain secondary infections. However, 
the underlying mechanisms are far from understood and require additional investigation. 
Apart from differences between pathogens and individual immune responses, timing is 
a complicating factor in this field as every measurement is only a snapshot of a complex 
cascade.
Nevertheless, as secondary infections are associated with attributable morbidity 
and mortality, further elucidation of general and pathogen-specific mechanisms that are 
responsible for immunosuppression, and the search for markers that identify an overactive 
or suppressed immune response, are highly warranted, as this may enable the development 
and implementation of more personalized therapeutic interventions to control the 
immune response. Gene-expression profiling provides insight in both the direction and the 
timing of the immune response, which may facilitate more personalized therapies in the 
future. Furthermore, we could learn from other diseases in which immunosuppression is 
evident, notably cancer, as it is increasingly recognized that some mechanisms underlying 
immunosuppression in infectious diseases and cancer are similar(35). Therefore, markers or 
novel therapies used in cancer patients may also apply to critically ill patients suffering from 
bacterial sepsis or respiratory viral infections.
Chapter 2
40
REFERENCES
1. Grimaldi D, Llitjos JF, Pene F. Post-infectious immune suppression: a new paradigm of severe 
infections. Medecine et maladies infectieuses. 2014;44(10):455-63.
2. Hotchkiss RS, Monneret G, Payen D. Immunosuppression in sepsis: a novel understanding of the 
disorder and a new therapeutic approach. The Lancet infectious diseases. 2013;13(3):260-8.
3. Schmid-Hempel P. Immune defence, parasite evasion strategies and their relevance for 
‘macroscopic phenomena’ such as virulence. Philosophical transactions of the Royal Society of 
London Series B, Biological sciences. 2009;364(1513):85-98.
4. Leentjens J, Kox M, Hoeven JGvd, Netea MG, Pickkers P. Immunotherapy for the adjunctive 
treatment of sepsis: from immunosuppression to immunostimulation. Time for a paradigm 
change? American Journal of Respiratory and Critical Care Medicine. 2013;vol. 187(iss. 12):1287-93.
5. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, et al. Immunosuppression in 
patients who die of sepsis and multiple organ failure. JAMA. 2011;306(23):2594-605.
6. Walton AH, Muenzer JT, Rasche D, Boomer JS, Sato B, Brownstein BH, et al. Reactivation of multiple 
viruses in patients with sepsis. PLoS One. 2014;9(2):e98819.
7. Sajjan U, Ganesan S, Comstock AT, Shim J, Wang Q, Nagarkar DR, et al. Elastase- and LPS-exposed 
mice display altered responses to rhinovirus infection. Am J Physiol Lung Cell Mol Physiol. 
2009;297(5):L931-44.
8. Lee KY, Rhim JW, Kang JH. Hyperactive immune cells (T cells) may be responsible for acute lung 
injury in influenza virus infections: a need for early immune-modulators for severe cases. Medical 
hypotheses. 2011;76(1):64-9.
9. McCullers JA. Insights into the interaction between influenza virus and pneumococcus. Clinical 
microbiology reviews. 2006;19(3):571-82.
10. Diavatopoulos DA, Short KR, Price JT, Wilksch JJ, Brown LE, Briles DE, et al. Influenza A virus facilitates 
Streptococcus pneumoniae transmission and disease. FASEB journal : official publication of the 
Federation of American Societies for Experimental Biology. 2010;24(6):1789-98.
11. Didierlaurent A, Goulding J, Patel S, Snelgrove R, Low L, Bebien M, et al. Sustained desensitization 
to bacterial Toll-like receptor ligands after resolution of respiratory influenza infection. The Journal 
of experimental medicine. 2008;205(2):323-9.
12. Smith MW, Schmidt JE, Rehg JE, Orihuela CJ, McCullers JA. Induction of pro- and anti-inflammatory 
molecules in a mouse model of pneumococcal pneumonia after influenza. Comparative medicine. 
2007;57(1):82-9.
13. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of 
death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 
2008;198(7):962-70.
14. Shahangian A, Chow EK, Tian X, Kang JR, Ghaffari A, Liu SY, et al. Type I IFNs mediate development 
of postinfluenza bacterial pneumonia in mice. J Clin Invest. 2009;119(7):1910-20.
15. Bakaletz LO. Immunopathogenesis of polymicrobial otitis media. Journal of leukocyte biology. 
2010;87(2):213-22.
Patterns in bacterial- and viral-induced immunosuppression and secondary infections in the ICU
41
2
16. Kudva A, Scheller EV, Robinson KM, Crowe CR, Choi SM, Slight SR, et al. Influenza A inhibits Th17-
mediated host defense against bacterial pneumonia in mice. J Immunol. 2011;186(3):1666-74.
17. Small CL, Shaler CR, McCormick S, Jeyanathan M, Damjanovic D, Brown EG, et al. Influenza 
infection leads to increased susceptibility to subsequent bacterial superinfection by impairing NK 
cell responses in the lung. J Immunol. 2010;184(4):2048-56.
18. van der Sluijs KF, van Elden LJ, Nijhuis M, Schuurman R, Pater JM, Florquin S, et al. IL-10 is an 
important mediator of the enhanced susceptibility to pneumococcal pneumonia after influenza 
infection. J Immunol. 2004;172(12):7603-9.
19. Sun K, Metzger DW. Inhibition of pulmonary antibacterial defense by interferon-gamma during 
recovery from influenza infection. Nature medicine. 2008;14(5):558-64.
20. Lehmann C, Sprenger H, Nain M, Bacher M, Gemsa D. Infection of macrophages by influenza A 
virus: characteristics of tumour necrosis factor-alpha (TNF alpha) gene expression. Research in 
virology. 1996;147(2-3):123-30.
21. Duan X, Lu J, Zhou K, Wang J, Wu J, Gao GF, et al. Natural Killer Cells are involved in Thymic Atrophy 
induced by Influenza A Virus Infection. J Gen Virol. 2015.
22. Wauters J, Baar I, Meersseman P, Meersseman W, Dams K, De Paep R, et al. Invasive pulmonary 
aspergillosis is a frequent complication of critically ill H1N1 patients: a retrospective study. 
Intensive care medicine. 2012;38(11):1761-8.
23. Larranaga CL, Ampuero SL, Luchsinger VF, Carrion FA, Aguilar NV, Morales PR, et al. Impaired 
immune response in severe human lower tract respiratory infection by respiratory syncytial virus. 
Pediatr Infect Dis J. 2009;28(10):867-73.
24. Raza MW, Blackwell CC, Elton RA, Weir DM. Bactericidal activity of a monocytic cell line (THP-1) 
against common respiratory tract bacterial pathogens is depressed after infection with respiratory 
syncytial virus. Journal of medical microbiology. 2000;49(3):227-33.
25. Kallal LE, Hartigan AJ, Hogaboam CM, Schaller MA, Lukacs NW. Inefficient lymph node sensitization 
during respiratory viral infection promotes IL-17-mediated lung pathology. J Immunol. 
2010;185(7):4137-47.
26. Sung BS, Chonmaitree T, Broemeling LD, Owen MJ, Patel JA, Hedgpeth DC, et al. Association of 
rhinovirus infection with poor bacteriologic outcome of bacterial-viral otitis media. Clin Infect Dis. 
1993;17(1):38-42.
27. Mallia P, Footitt J, Sotero R, Jepson A, Contoli M, Trujillo-Torralbo MB, et al. Rhinovirus infection 
induces degradation of antimicrobial peptides and secondary bacterial infection in chronic 
obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(11):1117-24.
28. Kirchberger S, Majdic O, Steinberger P, Bluml S, Pfistershammer K, Zlabinger G, et al. Human 
rhinoviruses inhibit the accessory function of dendritic cells by inducing sialoadhesin and B7-H1 
expression. J Immunol. 2005;175(2):1145-52.
29. Oliver BG, Lim S, Wark P, Laza-Stanca V, King N, Black JL, et al. Rhinovirus exposure impairs immune 
responses to bacterial products in human alveolar macrophages. Thorax. 2008;63(6):519-25.
Chapter 2
42
30. Koch RM, Kox M, van den Kieboom C, Ferwerda G, Gerretsen J, Ten Bruggencate S, et al. Short-term 
repeated HRV-16 exposure results in an attenuated immune response in vivo in humans. PLoS One. 
2018;13(2):e0191937.
31. Gern JE, Joseph B, Galagan DM, Borcherding WR, Dick EC. Rhinovirus inhibits antigen-specific T 
cell proliferation through an intercellular adhesion molecule-1-dependent mechanism. J Infect 
Dis. 1996;174(6):1143-50.
32. Ramilo O, Allman W, Chung W, Mejias A, Ardura M, Glaser C, et al. Gene expression patterns in blood 
leukocytes discriminate patients with acute infections. Blood. 2007;109(5):2066-77.
33. Zaas AK, Chen M, Varkey J, Veldman T, Hero AO, 3rd, Lucas J, et al. Gene expression signatures 
diagnose influenza and other symptomatic respiratory viral infections in humans. Cell host & 
microbe. 2009;6(3):207-17.
34. Liu TY, Burke T, Park LP, Woods CW, Zaas AK, Ginsburg GS, et al. An individualized predictor of health 
and disease using paired reference and target samples. BMC bioinformatics. 2016;17(1):47.
35. Hotchkiss RS, Moldawer LL. Parallels between cancer and infectious disease. N Engl J Med. 
2014;371(4):380-3.
Patterns in bacterial- and viral-induced immunosuppression and secondary infections in the ICU
43
2
Table 1. Secondary infections occurring following sepsis, influenza, RSV and HRV infections. HSV: herpes 
simplex virus, EBV: epstein barr virus, HHV: human herpes virus-6, CMV: cytomegalovirus, VAP: ventilator 
assisted pneumonia. OM: Otitis Media. Very common: >40%. Common: 10-40% Rare: <10%.
BACTERIAL
Primary infection Secondary infection Prevalence
Gram-negative Sepsis
Escherichia coli (1)
Klebsiella species (1)
Pseudomonas aeruginosa (1)
Gram-positive Sepsis
Staphylococcus aureus (2, 3) 
Streptococcus pneumonia (2, 3)
Bacterial
Pseudomonas spp.
Stenotrophomonas spp.
Acinetobacter spp.
Enterococcus spp.
Various(4-6)
Fungal
Candida spp. (C.Albicans) Very common(7, 8)
Aspergillus spp. (A.fumigatus) Common(7, 9-11)
Viral reactivation
Common(4, 12-15)Herpes viridae (CMV, HSV, HHV-6)
EBV Very common(12)
Polyomaviruses (BK and JC) Common(12)
Anelloviruses Very common(12)
Predominant type of primary 
infection: Pulmonary(1)
VIRAL
Primary infection Secondary infection Prevalence
Influenza
Bacterial
Streptococcus pneumonia
Staphylococcus aureus
Haemophilus influenza
Streptococcus pyogenes
Mycoplasma pneumoniae
Very common(6, 16-21)
Very common(6, 16, 18, 20)
Very common(6, 16, 18-20)
Common(6, 16, 20)
Common(16)
Fungal
Aspergillus spp. (A.fumigatus) Common(10)
Viral co-infection
HRV
RSV
Coronavirus
Rare(19, 22-24)
Common(19, 25, 26)
Rare(19, 24)
Viral reactivation
HSV Very common(27)
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RSV
Bacterial
Streptococcus pneumonia
Staphylococcus aureus
Haemophilus influenzae
Streptococcus pyogenes
Moraxella catarrhalis
Common(20, 28, 29)
Common(28-30)
Common(28, 29, 31)
Common(28)
Common(28)
Fungal
Aspergillus fumigatus Unknown(32, 33)
Viral co-infection
Influenza
Parainfluenza
Adenovirus
HRV
Common(19, 25, 26)
Rare(34) 
Rare(35)
Common(22, 26, 36)
Viral reactivation
CMV Rare(35)
HRV
Bacterial
Streptococcus pneumonia
Haemophilus influenzae
Moraxella catarrhalis
Mycoplasma pneumonia
Chlamydophila pneumoniae
Common(21, 37-39)
Common(38)
Common(22, 31, 38, 40)
Rare(22, 41)
Rare(22)
Fungal
Aspergillus fumigatus
Common(42)
Viral co-infection
Influenza
Parainfluenza
RSV
Coronavirus
Rare(19, 22-24)
Rare(36)
Common(22, 26, 36)
Rare(22)
Viral reactivation
CMV Rare(42)
Predominant type of secondary 
infection:  
Pneumonia in adults(29, 37) /  
OM in children(16, 43, 44)
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ABSTRACT
Rationale: Reversal of sepsis-induced immunoparalysis may reduce the incidence of 
secondary infections and improve outcome. Although interferon gamma (IFN-γ) and 
granulocyte-macrophage colony–stimulating factor (GM-CSF) restore immune competence 
of ex vivo stimulated leukocytes of patients with sepsis, effects on immunoparalysis in vivo 
are not known.
Objectives: To investigate the effects of IFN-γ and GM-CSF on immunoparalysis in vivo in 
humans.
Methods: We performed a double-blind, placebo-controlled, randomized study in 18 healthy 
male volunteers that received Escherichia coli endotoxin (LPS; 2 ng/kg, intravenously) on 
days 1 and 7 (visits 1 and 2). On days 2, 4, and 6, subjects received subcutaneous injections of 
IFN-γ (100 μg/day; n=6), GM-CSF (4 μg/kg/day; n=6), or placebo (NaCl 0.9%; n=6).
Measurements and Main Results: In the placebo group, immunoparalysis was illustrated 
by a 60% (48–71%) reduction of LPS-induced tumor necrosis factor (TNF)-α plasma 
concentrations during visit 2 (p=0.03), whereas the anti-inflammatory IL-10 response was 
not significantly attenuated (39% [2–65%]; p=0.15). In contrast, in the IFN-γ group, TNF-α 
concentrations during visit 2 were not significantly attenuated (28% [1–47%]; p=0.09), 
whereas the IL-10 response was significantly lower (reduction of 54% [47–66%]; p=0.03). 
Compared with the placebo group, the reduction in the LPS-induced TNF-α response during 
visit 2 was significantly less pronounced in the IFN-γ group (p=0.01). Moreover, compared 
with placebo, treatment with IFN-γ increased monocyte HLA-DR expression (p=0.02). The 
effects of GM-CSF tended in the same direction as IFN-γ, but were not statistically significant 
compared with placebo.
Conclusions: IFN-γ partially reverses immunoparalysis in vivo in humans. These results 
suggest that IFN-γ is a promising treatment option to reverse sepsis-induced immunoparalysis.
AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
Suppression of the immune system (immunoparalysis) is increasingly recognized as the 
overriding immune dysfunction in patients with sepsis, rendering them vulnerable for 
secondary infections associated with impaired outcome. Trials in patients with sepsis have 
demonstrated that treatment with interferon gamma (IFN-γ) or granulocyte-macrophage 
colony–stimulating factor (GM-CSF) restores the cytokine response of ex vivo stimulated 
leukocytes.
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What This Study Adds to the Field
We report that endotoxin administration in humans results in immunoparalysis reflected 
by attenuated plasma cytokine concentrations after the second endotoxin challenge. 
Treatment with IFN-γ augments endotoxin-induced tumor necrosis factor (TNF)-α and further 
attenuates IL-10 concentrations, indicating partial reversal of immunoparalysis in vivo. The 
effects of GM-CSF tended in the same direction as IFN-γ, but were not statistically significant 
compared with the placebo group. These results implicate that immunoparalysis is relevant 
in vivo in humans and that immunostimulation represents a promising treatment option to 
reverse sepsis-induced immunoparalysis.
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INTRODUCTION
Sepsis is the leading cause of death in the intensive care unit with an estimated 6 million 
victims per year worldwide(1). Although septic shock is traditionally viewed as an excessive 
systemic inflammatory reaction to invasive microbial pathogens, pharmacologic 
interventions aimed at suppression of the immune response in sepsis have proved to be 
unsuccessful(2). An important reason for this might be that most patients with sepsis survive 
the initial pro-inflammatory hit, but die at a later time point from secondary or opportunistic 
infections in a immunosuppressed state(3-5). This so-called sepsis-induced “immunoparalysis” 
is increasingly recognized as the overriding immune dysfunction in patients with sepsis(6), and 
is characterized by impaired innate and adaptive immune responses, including enhanced 
apoptosis and dysfunction of lymphocytes, impaired phagocyte functions, and decreased 
ex vivo cytokine production(7). A widely used marker of immunoparalysis is monocyte HLA-
DR (mHLA-DR) surface expression, reflecting monocyte (de)activation(8). Prolonged down-
regulation of mHLA-DR expression is associated with a higher risk of secondary infections(9) 
and reduced survival in patients with sepsis(9, 10).
In light of the deleterious effects of sepsis-induced immunoparalysis on outcome, the 
sepsis research field is shifting toward novel therapies aimed at restoring immune competence 
in the later phase of sepsis(11). Recent case series and pilot trials indicate that long-lasting 
monocyte deactivation in sepsis can be reversed by treatment with interferon gamma (IFN-γ) 
or granulocyte-macrophage colony–stimulating factor (GM-CSF)(12-16), reflected by restoration 
of tumor necrosis factor (TNF)-α production by ex vivo stimulated leukocytes and increased 
mHLA-DR expression(17, 18). These compounds therefore seem promising candidates to 
reverse sepsis-induced immunoparalysis. However, all studies to date have analyzed the 
immune status of the patients using ex vivo stimulation of leukocytes or flow cytometric 
analysis of HLA-DR expression on circulating monocytes. We have recently demonstrated 
that during systemic inflammation as observed during experimental human endotoxemia 
(LPS administration in healthy volunteers), the response of ex vivo LPS-stimulated leukocytes 
does not correlate with the in vivo LPS-induced inflammatory response in the same subject(19, 
20). These data indicate that the in vivo response to endotoxin is mainly mediated by tissue-
resident cells and that ex vivo measurements do not accurately reflect a subject or patient’s in 
vivo immune status. Hence, it is unknown whether pharmacologic interventions that restore 
the ex vivo immune competence of leukocytes, such as IFN-γ and GM-CSF, are effective in 
restoring immune competence in vivo.
Because experimental human endotoxemia leads to pronounced immunosuppression, 
so-called “endotoxin tolerance,” in vivo and ex vivo(20-23), it can serve as a model for sepsis-
induced immunoparalysis. In the present proof-of-principle study we investigated 
whether treatment with IFN-γ or GM-CSF restores immune competence after experimental 
endotoxemia in humans in vivo.
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METHODS
Subjects
After approval from the local ethics committee of the Radboud University Nijmegen 
Medical Center, 18 healthy, nonsmoking, male volunteers gave written informed consent to 
participate in the experiments. All experiments were in accordance with the declaration of 
Helsinki. Subjects were screened before the start of the experiment and had a normal physical 
examination, electrocardiography, and routine laboratory values (including serology on HIV 
and hepatitis B). Subjects with febrile illness during the 2 weeks before the experiment were 
excluded. Subjects were not allowed to take any prescription drugs and were asked to refrain 
from caffeine and alcohol intake 24 hours before the start of the experiment. Furthermore, 
subjects refrained from food 12 hours before the start of each endotoxemia experiment.
Study Design
We performed a parallel double-blind placebo-controlled randomized study. The study 
design is depicted in Figure 1. Briefly, all subjects received an intravenous injection of LPS 
on two occasions (visits 1 and 2) separated by 6 days. In between, on days 2 (T=24), 4 (T=76), 
and 6 (T=120), subjects were randomized to receive subcutaneous injections of either 100 
μg IFN-γ (Immukine; Boehringer Ingelheim Alkmaar, the Netherlands; n=6), 4 μg/kg GM-CSF 
(Leukine/Sargramostim; Bayer Healthcare Pharmaceuticals, Seattle, WA; n=6), or placebo 
(NaCl 0.9%; n=6), in a double-blind fashion using the sealed envelope method. Endotoxemia 
experiments were conducted as described previously(20). A detailed description is provided 
in the supplementary material. The dosages were based on previous studies in patients 
with sepsis(15, 17). Because GM-CSF and IFN-γ had different administration volumes, a double 
dummy was used to ensure adequate blinding.
Figure 1. Experimental design. GM-CSF = granulocyte-macrophage colony–stimulating factor.
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Cytokine Measurements
For plasma cytokine analysis, ethylenediaminetetraacetic acid anticoagulated blood was 
centrifuged immediately after withdrawal at 2,000 × g at 4°C for 10 minutes, after which 
plasma was stored at −80°C until analysis. Concentrations of TNF-α, IL-6, IL-10, IL-1 receptor 
antagonist (IL-1RA), IFN-γ, and GM-CSF were analyzed batch-wise by a Luminex assay 
according to the manufacturer’s instructions (Milliplex; Millipore, Billerica, MA).
Flow Cytometric Analysis of mHLA-DR Expression and Lymphocyte Subset Counts
Ethylenediaminetetraacetic acid anticoagulated blood was stored at 4°C immediately 
after withdrawal and analyzed by flow cytometry (see supplementary material). mHLA-DR 
expression was determined by calculating %HLA-DR–positive cells within CD14-positive cells 
within the CD45-positive leukocytes and HLA-DR mean fluorescence intensity within these 
CD14-positive cells. Lymphocyte subsets were defined as T-cells (CD45+CD3+); T-helper cells 
(Th, CD45+CD3+CD4+); cytotoxic T-cells (Tc, CD45+CD3+CD8+); B-cells (CD45+CD19+); and 
natural killer (NK) cells (CD45+CD3-CD56+). Subset counts were calculated by multiplying the 
percentage gated cells by the total lymphocyte count.
Calculations and Statistical Analysis
In view of the small sample size, normality of distribution was not assumed. Area under the 
curve (AUC) during visits 1 and 2, representing an integrated measure of the LPS-induced 
responses, was calculated using time points 0–24 hours (cytokines) and 0–8 hours (symptom 
score, heart rate, mean arterial pressure [MAP], and temperature). Comparisons were made 
using Wilcoxon matched pairs (within-group comparisons, two groups) and Mann-Whitney U 
(between-group comparisons, two groups) or Kruskal-Wallis (between-group comparisons, 
three groups) tests as appropriate. A p-value of less than 0.05 was considered statistically 
significant. Data are expressed as median (interquartile range). Calculations and statistical 
analyses were performed using Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA). 
 
RESULTS
Demographic Characteristics
Demographic characteristics of the study population are listed in Table 1. There were no 
significant differences in baseline characteristics among the three study groups. No serious 
adverse events occurred during the trial. During the treatment period (starting just before 
the first IFN-γ/GM-CSF/placebo administration [visit 1, T=24] until visit 2 [T=0]), one subject in 
the placebo group reported mild headaches and muscle pains, whereas five subjects in the 
IFN-γ group and three subjects in the GM-CSF group reported mild complaints ranging from 
headaches and muscle pains to fatigue.
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Table 1. Demographic characteristics obtained during the screening visit. Definition of abbreviations: 
BMI = body mass index; bpm = beats per minute; GM-CSF = granulocyte-macrophage colony–stimulating 
factor; HR = heart rate; MAP = mean arterial blood pressure. Data are presented as median and interquartile 
range.
Placebo 
(n=6)
GM-CSF 
(n=6)
IFN-γ 
(n=6)
Total Group 
(n=18)
p-value 
between 
groups
Age, yr 21 (20–23) 22 (21–23) 20 (20–21) 21 (20–21) 0.15
Height, cm 183 (176–189) 177 (174–193) 188 (171–189) 183 (175–189) 0.97
Weight, kg 81 (89–75) 72 (67–85) 72 (68–80) 74 (70–84) 0.24
BMI, kg/m2 24 (23–26) 23 (22–23) 21 (32–26) 23 (22–24) 0.20
HR, bpm 67 (62–79) 59 (55–71) 65 (58–72) 66 (56–72) 0.50
MAP, mm Hg 96 (82–104) 89 (88–98) 98 (91–99) 95 (88–99) 0.75
Plasma Cytokines
As expected, during visit 1 there was a typical endotoxemia-induced transient increase in all 
measured cytokines, which was similar in the three experimental groups (Figure 2). In the 
LPS-placebo group, the AUC of the LPS-induced plasma concentration of the archetypal 
pro-inflammatory cytokine TNF-α was 60% (48–71%; p=0.03) lower on visit 2 compared with 
visit 1, indicating immunoparalysis. In the IFN-γ and GM-CSF groups, this decrease in LPS-
induced TNF-α release during the second LPS infusion was less pronounced and no longer 
significant (28% [1–47%, p=0.09] and 38% [−2 to 63, p=0.16] lower on visit 2, respectively). 
Furthermore, compared with placebo, the reduction in AUC for TNF-α on visit 2 compared 
with visit 1 was significantly less pronounced in the IFN-γ group (p=0.01). Similarly, in the 
placebo-treated group, plasma IL-6 levels were suppressed (74% [65–83%], p=0.03) after the 
second LPS challenge. Treatment with IFN-γ (62% [42–77%]; p=0.03) or GM-CSF (70% [−27 to 
85%]; p=0.09) did not prevent the attenuated response of IL-6 during repeated endotoxemia. 
In the placebo and GM-CSF groups, no significant attenuation of the plasma concentrations 
of the anti-inflammatory cytokine IL-10 between visits 1 and 2 were observed (39% [2–65%], 
p=0.15, and 48% [−6 to 67], p=0.21, respectively). In contrast, in IFN-γ–treated subjects, the IL-
10 response was significantly attenuated on the second LPS administration (54% [47–66%], 
p=0.03). Finally, in the placebo group, the LPS-induced IL-1RA response was attenuated by 
63% (52–86%; p=0.03), whereas in the IFN-γ and GM-CSF groups, IL-1RA levels were 44% (35–
67%; p=0.03) and 41% (10–76%; p=0.06) lower on visit 2 compared with visit 1, respectively. 
This reduction was not significantly different compared with placebo-treated subjects.
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Figure 2. Left panels show plasma concentration of tumor necrosis factor (TNF)-α, IL-6, IL-10, and IL-1RA 
on the first and second LPS-administration days (visits 1 and 2). Data are expressed as median picogram 
per milliliter (n=6 per group). Right panels show box-and-whisker (Tukey) plots of area under the curve of 
plasma cytokine concentrations during visit 1 (V1) and visit 2 (V2). AU = arbitrary units; GM-CSF = granulocyte-
macrophage colony–stimulating factor.
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mHLA-DR Expression
In the placebo-group, the percentage HLA-DR–positive monocytes (%mHLA-DR+) decreased 
from 73% (68–84%) at t=0 to 61% (54–71%) (p=0.03) during the first LPS challenge (Figure 3). 
A similar reduction was observed in the IFN-γ and GM-CSF groups during visit 1 (before 
the administration of study medication). Throughout the treatment period %mHLA-DR+ 
remained stable in the placebo and GM-CSF groups (from 80% [74–84%] to 76% [72–80%], 
p=0.30 and from 85% [80–92%] to 94% [82–95%], p=0.40, respectively). Conversely, in the 
IFN-γ group, mHLA-DR expression tended to increase during the treatment period, from 
83% [79–92%] to 98% [94–99%] (p=0.06). Histograms of a representative subject from the 
IFN-γ group are shown in Figure E1 in the supplementary material. The effects of IFN-γ on 
%mHLA-DR+ during the treatment period were significantly different compared with placebo 
(p=0.02). Moreover, %mHLA-DR+ in the IFN-γ group remained above 85% in the acute phase 
(8 hours) after the second LPS administration, whereas it dropped to 65–70% in the other 
two experimental groups (see Table E1). Mean fluorescence intensity data showed a similar 
pattern as %mHLA-DR+ (see Table E1).
Figure 3. %HLA-DR positive monocytes (%mHLA-DR+). Data are expressed as median values of six subjects 
per group. GM-CSF = granulocyte-macrophage colony–stimulating factor.
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Hematologic Parameters
After the first LPS administration, total leukocyte counts showed the characteristic biphasic 
pattern in all three experimental groups, a leukopenic phase at t=1 (p<0.01 compared with 
t=0 for all three groups) followed by leukocytosis (p<0.01 compared with t=0 for all three 
groups) (Figure 4). In the placebo group, the total leukocyte count tended to decrease during 
the treatment period (a reduction of 24% [6–31%], p=0.06), whereas in the IFN-γ group, the 
effects were highly variable among subjects (median reduction of 32% [−22 to 54%], p=0.25). 
In the GM-CSF–treated group, there was a clear increase in leukocyte counts during the 
treatment period (increase of 21% [3–36%], p=0.22; p=0.009 compared with placebo). This 
effect was almost completely attributable to an increase of neutrophils (p=0.02 compared 
with placebo). In the placebo and GM-CSF groups, the LPS-induced leucopenia 1 hour 
after the first LPS administration was less pronounced and no longer significant after the 
second LPS administration (p=0.19 and p=0.44, respectively), whereas in the IFN-γ group, no 
attenuation of the LPS-induced effects occurred and again a distinct trend toward leucopenia 
was observed after the second LPS administration (p=0.06). The subsequent leukocytosis was 
similar among the three experimental groups during visit 2, with a comparable distribution 
of leukocyte subpopulations, except for eosinophils, which showed a pronounced rise in the 
GM-CSF–treated group during visit 2 (p=0.03). Lymphocyte subset analysis of T-cell (including 
T-helper and cytotoxic T-cells), B-cell, and NK-cell counts by flow cytometry revealed no 
differences among groups (see Table E2 and Figure E2).
Figure 4. Leukocyte count and differentiation. Data are expressed as median values of six subjects per group. 
GM-CSF = granulocyte-macrophage colony–stimulating factor.
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Clinical Parameters
The first LPS administration expectedly elicited transient flulike symptoms, which were 
comparable among all three experimental groups (Figure 5, upper panel). Symptoms 
were significantly less pronounced in the placebo and GM-CSF groups after the second 
LPS administration (reduction in AUC symptom score of 72% [48–87%], p=0.03, and 50% 
[29–75%], p=0.03, respectively). In the IFN-γ group, however, the symptom score did not 
significantly differ between visits 1 and 2 (reduction AUC of 9% [−21 to 49%, p=0.48]), an effect 
that was significantly different compared with the placebo group (p=0.02). In the placebo 
and GM-CSF groups, the LPS-induced increase in heart rate was significantly attenuated after 
the second LPS administration (reduction in AUC heart rate of 10% [7–14%], p=0.03, and 4% 
[1–13%], p=0.03, respectively) (Figure 5, lower panel). In the IFN-γ group, heart rate response 
was not significantly attenuated during the second LPS challenge (7% [−1 to 11%, p=0.15]). 
In all three groups, there was a significant LPS-induced rise in temperature and a decrease 
in MAP during both visits (p<0.01 in all three groups for visits 1 and 2, data not shown). No 
differences in temperature and MAP (based on AUC) between visits 1 and 2 were observed in 
any of the experimental groups.
Figure 5. Left panels show symptom score and heart rate after LPS administration during visits 1 and 2. Data 
are expressed as median values of six subjects per group. Right panels show box-and-whisker (Tukey) plots of 
AUC of symptom score and heart rate after LPS administration during visit 1 (V1) and visit 2 (V2). AU = arbitrary 
units; GM-CSF = granulocyte-macrophage colony–stimulating factor.
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DISCUSSION
Immunoparalysis is increasingly recognized as the overriding immune response observed in 
patients with sepsis, and the interest in pharmacologic interventions aimed at the prevention 
and treatment of immunoparalysis is growing. This is the first study showing that IFN-γ 
partially restores in vivo production of the pro-inflammatory cytokine TNF-α, whereas this is 
accompanied by further dampening of the anti-inflammatory IL-10 response after a second 
LPS administration. The more pro-inflammatory spectrum during the second LPS challenge 
indicates that IFN-γ partially reverses LPS-induced immunoparalysis in vivo in humans. In 
accordance, IFN-γ prevented the reduction in symptom score and heart rate response to 
a second LPS administration and significantly increased mHLA-DR cell-surface expression, 
reflecting monocyte function improvement. The effects of GM-CSF tended in the same 
direction as IFN-γ, but were not statistically significant compared with the placebo group.
In patients with sepsis, the term “immunoparalysis” is commonly used to indicate 
reduced responsiveness of leukocytes on ex vivo stimulation with LPS. Data on the immune 
status of tissue-resident cells, which play a more important role in host defense compared 
with leukocytes, are limited because of the lack of access to these cells or tissues in patients. 
However, there is a strong relation between ex vivo responsiveness and susceptibility toward 
secondary infections and outcome in patients with sepsis(24, 25). Furthermore, a very recent 
study demonstrated that immunosuppression was also found in splenocytes and lung 
tissue of patients with sepsis(5). We(20-22), and others(26, 27) have demonstrated that endotoxin 
administration in healthy volunteers leads to a profound suppression of cytokine production, 
in ex vivo LPS-stimulated leukocytes and in vivo. This indicates that the human endotoxemia 
model and the associated development of endotoxin tolerance(20, 21) represent a suitable 
model for sepsis-induced immunoparalysis. To the best of our knowledge, we are the first 
to investigate reversal of immunoparalysis in vivo, and the result of this study suggests that 
repeated LPS administration with an interval of one week is a suitable model to investigate 
possible interventions to reverse sepsis-induced immunoparalysis.
IFN-γ is a well-known activator of monocytes. It increases monocyte antigen-presenting 
capacity by up-regulating costimulatory and HLA molecules(28). Furthermore, previous 
studies have demonstrated that IFN-γ reverses LPS tolerance; it restores inflammatory 
cytokine production in vitro, and in vivo in mice(29-31). In contrast, IFN-γ failed to restore TNF-α 
production by ex vivo LPS-stimulated leukocytes obtained 4 hours after LPS administration in 
vivo, possibly related to the short IFN-γ incubation time(32). Interestingly, a case series report 
revealed that, when administered to patients with sepsis with low mHLA-DR expression, 
IFN-γ treatment resulted in restoration of mHLA-DR expression and ex vivo LPS-induced 
TNF-α production by monocytes. Moreover, the recovery of monocyte function resulted 
in resolution of sepsis in eight of nine patients(17). More recently, two case reports showed 
similar results(9). It is clear that more studies are needed to confirm these observations. Our 
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data expand on these studies by showing for the first time that IFN-γ can indeed restore 
immune competence in vivo.
We found differential effects of IFN-γ on the various cytokines studied. In agreement with 
our results, earlier work has demonstrated that IFN-γ enhances TNF-α production(31, 33, 34) and 
suppresses IL-10 release by primary human monocytes in vitro(33). In contrast to our data, it 
was recently shown that IFN-γ prevents LPS-induced tolerization for IL-6 in primary human 
monocytes in vitro(31). We do not have a clear explanation for the lack of an effect of IFN-γ 
on IL-6 in our study, although in vitro/in vivo differences may play a role. It should be noted, 
however, that the absence of restoration of the IL-6 response does not necessarily reflect 
a less pro-inflammatory spectrum in IFN-γ–treated subjects, because IL-6 has been shown 
to possess pro-inflammatory and anti-inflammatory properties(35, 36). No effects of IFN-γ on 
IL-1RA levels were observed in our study. Reports regarding the direct effects of IFN-γ on 
IL-1RA production are conflicting(37-39). Moreover, although generally regarded as an anti-
inflammatory cytokine, IL-1RA production is induced by TNF-α and IL-6(40, 41). Therefore, the 
lack of an effect of IFN-γ on IL-6 levels in our study might have diluted its effects on IL-1RA 
production through enhanced TNF-α release. In this respect, it is of note that we did observe 
a trend toward restoration of IL-1RA.
Similar to IFN-γ, GM-CSF is known for its potent immunostimulatory effects. In a recent 
meta-analysis of four placebo-controlled randomized controlled trials in patients with sepsis 
(total n=195), treatment with GM-CSF was associated with a significantly increased rate of 
reversal from infection(16). Not surprisingly, no beneficial effect of GM-CSF on 28-day mortality 
could be demonstrated because of limited power. Recently, a double-blind, randomized, 
placebo-controlled trial used mHLA-DR expression to guide treatment of patients with sepsis 
with GM-CSF(15). In a selected patient population with very low mHLA-DR expression, GM-CSF 
restored mHLA-DR expression and TNF-α production of ex vivo LPS-stimulated monocytes. 
Moreover, the results suggested that GM-CSF may shorten the time on mechanical ventilation 
and hospital and intensive care unit length of stay. In our study, GM-CSF tended to increase 
mHLA-DR expression, although to a much lesser extent than IFN-γ. Furthermore, GM-CSF 
prevented the attenuation in TNF-α, IL-6, and IL-1RA plasma levels after the second LPS 
administration observed in the placebo group, but, unlike IFN-γ, this difference was not 
statistically significant compared with the placebo group for any of the studied cytokines. 
The small sample size in our study is a possible explanation for this lack of significance. An 
alternative explanation is that the immunoparalysis evoked by repeated LPS administrations 
is relatively mild, thereby limiting possible beneficial effects of GM-CSF. This is illustrated by 
the fact that in the aforementioned studies in patients with sepsis, treatment was started 
when mHLA-DR expression was less than 50%(15) or even 30%(17), whereas mHLA-DR expression 
in our subjects never dropped below 61%.
The promising results of IFN-γ in this study and previous case series warrant a larger 
trial in patients with sepsis. However, care should be taken with regard to the timing of this 
intervention in the clinical setting. The more pronounced pro-inflammatory response in the 
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early phase of sepsis might be amplified by IFN-γ, thereby possibly enhancing shock and 
tissue damage(42). Although no evidence of detrimental effects of IFN-γ is available, there is a 
clear need for suitable biomarkers to identify a patient’s immune status. Currently, mHLA-DR 
expression and the production of cytokines by ex vivo stimulated leukocytes, two parameters 
that are highly correlated(15, 17), are used to this end. Decreased expression of mHLA-DR has 
been reported to be associated with reduced survival in patients with sepsis by some(10, 
43-46), but not all(47, 48). Recent studies indicate that, instead of a single value at a given time 
point, the slope of recovery of mHLA-DR may better reflect susceptibility toward secondary 
infections and therefore may more accurately predict outcome(9, 49, 50). Likewise, attenuated 
TNF-α production by ex vivo LPS-stimulated monocytes is associated with a higher incidence 
of clinical infection(24). Moreover, in a recent study in trauma patients suffering from sepsis, 
attenuated TNF-α production by ex vivo LPS-stimulated monocytes was shown to be an 
earlier predictor of clinical outcome than mHLA-DR expression(25). However, the potential 
value of mHLA-DR expression or ex vivo cytokine production as predictors of a patient’s 
immune status remains questionable because they only reflect the status of the blood-
leukocyte compartment. Recent studies of our group indicate that this compartment barely 
contributes to the in vivo immune response to LPS(19, 20). In accordance, in the present study 
HLA-DR expression of circulating monocytes returned to normal levels within 24 hours, 
whereas the in vivo immune response was still severely blunted 6 days later. These results 
indicate that tissue-resident immune cells, such as macrophages, are the predominant 
mediators of the in vivo immune response. In this respect, the slow turnover rate of tissue-
resident macrophages, as opposed to that of circulating cells, is a plausible explanation 
for the lengthy in vivo refractory state toward a second LPS challenge. The fact that the 
function of tissue-resident immune cells, like their counterparts in the blood compartment, 
is severely compromised in patients with sepsis was recently confirmed(5). It was shown that 
postmortem obtained tissue-resident cells of patients who die of sepsis exhibit a distinct 
immunosuppressed phenotype compared with cells obtained from patients who die of 
etiologies not related to sepsis. Taken together, novel markers to assess a patient’s in vivo 
immune status are highly warranted, but their identification and applicability is hampered 
by the lack of access to tissue-resident immune cells. In the meantime and with regard to the 
timing of immunostimulatory therapy, the use of surrogate markers to determine whether 
a patient is out of the initial overwhelming pro-inflammatory phase, such as recovery of 
hemodynamic stability indicated by decreased inotropic requirements, might be considered.
Our study has several limitations. First, because of the small sample size, some of the 
trends described did not reach statistical significance, likely because of a type 2 error. Despite 
the small sample size, the significant primary end points of our study illustrate the extent of 
the effects of IFN-γ. Second, experimental human endotoxemia remains a model of sepsis-
induced immunoparalysis, rather than completely mimicking the complex pathologic clinical 
condition of sepsis, and our study population is distinctively different from intensive care unit 
patients suffering from sepsis. Furthermore, inherent to the administration of purified LPS, 
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this model is limited to activation of the immune system by the Toll-like receptor 4 pathway, 
whereas in the pathophysiology of sepsis, a combination of recognition pathways can be 
engaged by a large variety of microorganisms.
CONCLUSIONS
In conclusion, we demonstrate that IFN-γ partially reverses immunoparalysis in vivo in 
humans. These results implicate that IFN-γ–mediated immunostimulation could represent 
a promising treatment option to reverse sepsis-induced immunoparalysis in critically ill 
patients.
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SUPPLEMENTARY MATERIAL
METHODS
Endotoxemia experiments
After admission to the research intensive care unit of the Radboud University Nijmegen 
Medical Center, purified LPS (US Standard Reference Endotoxin Escherichia Coli O:113) 
obtained from the Pharmaceutical Development Section of the National Institutes of Health 
(Bethesda, MD) was administered at a dose of 2 ng/kg body weight. In all subjects, heart 
rate (5-lead electrocardiogram) and blood pressure (20-gauge radial artery catheter) were 
monitored starting 2 hours before administration of LPS until discharge 8 hours after LPS 
administration. A cannula was placed in an antecubital vein to permit infusion of prehydration 
fluid (1.5 L 2.5% glucose/0.45% saline 1 hour before LPS administration), endotoxin, and 
continuous infusion of 2.5% glucose/0.45% saline (150 mL/hour during 8 hours after LPS 
administration) to ensure optimal hydration status. Body temperature was measured using 
an infrared tympanic thermometer (FirstTemp Genius, Sherwood Medical, Crawley/Sussex, 
UK). The course of endotoxin-induced flu-like symptoms (headache, nausea, shivering, and 
muscle and back pain) was scored every 30 minutes on a 6-point Likert scale (0=no symptoms, 
5=very severe symptoms), resulting in a total score of 0 to 25.
Analysis of mHLA-DR expression
Analysis was performed within 24 hours because pilot studies showed that mHLA-DR 
expression remained unaltered after 24 hours at 4°C. 100 μl blood was incubated with the 
following fluorochrome-conjugated monoclonal antibodies, for 15 minutes protected from 
light at 4°C. After erythrocyte lysis (NH4CL: 180 mL + 20 mL lysis stock dilution [BD Pharm-
Lyse, BectonDickinson]), cells were washed three times in PBS and the mHLA-DR expression 
was determined using flow cytometry (NAVIOS flow cytometer, Beckman Coulter, Miami). 
Monocytes were identified by forward and side scatter and by cell-specific binding. The 
following monoclonal antibodies were used, HLA-DR-PE (Immu-357), 10 μl; CD14-ECD 
(RMO52), 10 μl; CD45-KO (J33), 10 µl (all from Beckman Coulter, Marseille). 
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Supplementary Table 1: monocyte HLA-DR expression. % indicates % HLA-DR-positive monocytes, MFI 
indicates monocyte HLA-DR mean fluorescent intensity. Values are presented as median [interquartile range] 
of 6 subjects per group.
Placebo IFNγ GM-CSF
% MFI % MFI % MFI
Visit 1 t=0 73 [68-84] 7.6 [6.5-10.2] 79 [67-88] 9.6 [6.3-11.2] 85 [77-91] 9.4 [7.0-11.0]
Visit 1 t=4 61 [57-78] 5.2 [4.4-7.6] 74 [50-78] 5.3 [4.1-7.3] 72 [66-76] 6.0 [4.7-7.4]
Visit 1 t=8 68 [63-78] 6.6[5.8-8.4] 58 [58-82] 6.6 [5.5-7.0] 68 [58-89] 6.0 [5.0-13.7]
Visit 1 t=24 80 [74-84] 13.0[10.0-15.1] 83 [79-92] 12.3 [11.5-14.4] 85 [80-92] 11.8 [9.6-26.8]
t=72 80 [74-83] 9.4[7.1-10.5] 83 [77-93] 9.7 [7.4-10.7] 81 [65-85] 9.1[5.9-10.5]
t=120 80 [79-85] 7.4[6.4-10.3] 85 [80-91] 12.0 [9.6-13.2] 83 [71-87] 8.1 [7.5-8.9]
Visit 2 t=0 76 [72-80] 6.5[5.7-7.8] 98 [95-100] 13.1 [10.6-17.4] 94 [82-95] 12.2 [10.2-14.5]
Visit 2 t=4 62 [51-66] 4.7[3.5-5.3] 91 [74-92] 7.8 [5.1-9.4] 71 [46-94] 7.5 [5.4-12.9]
Visit 2 t=8 71 [67-81] 7.3[6.5-8.7] 87 [81-93] 10.0 [8.8-11.8] 70 [65-79] 8.5 [6.7-12.4]
Visit 2 t=24 84 [81-87] 12.4[10.9-13.6] 82 [77-96] 14.5 [13.1-24.0] 73 [66-88] 12.9 [8.2-17.8]
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Supplementary Figure 1: mHLA-DR expression histograms of a representative subject from the IFN-γ group.
T=148
T=152
T=168
T=144
Supplementary Figure 1: mHLA-DR expression histograms of a representative subject from 
the IFN-Ȗ group. 
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Supplementary Figure 2: lymphocyte subset counts determined by flow cytometry. T-cells 
(CD45+CD3+); T-helper cells (Th, CD45+CD3+CD4+); cytotoxic T-cells (Tc, 
CD45+CD3+CD8+); B-cells (CD45+CD19+); NK-cells (CD45+CD3-CD56+). Values are 
presented as median of 6 subjects per group. 
 
Supplementary Figure 1: mHLA-DR expression histograms of a representative subject from the IFN-γ group.
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Chapter 4
Development of endotoxin tolerance does 
not influence the response to a challenge 
with the mucosal live-attenuated influenza 
vaccine in humans in vivo.
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ABSTRACT
Introduction: The effects of bacterial infections on the response to subsequent viral 
infections are largely unknown. This is important to elucidate to increase insight into the 
pathophysiology of bacterial and viral co-infections, and to assess whether bacterial 
infections may influence the course of viral infections.
Methods: Healthy male subjects received either bacterial endotoxin [Escherichia coli-
derived lipopolysaccharide (LPS), 2 ng/kg, n=15] or placebo (n=15) intravenously, followed 
by intranasal Fluenz (live-attenuated influenza vaccine) one week later.
Results: LPS administration resulted in increased plasma cytokine levels and development 
of endotoxin tolerance in vivo and ex vivo, illustrated by attenuated cytokine production 
upon rechallenge with LPS. Following Fluenz administration, infectivity for the Fluenz A/B 
strains was similar between the LPS–Fluenz and placebo–Fluenz groups (13/15 subjects in 
both groups). Also, the Fluenz-induced increase in temperature and IL-6, G-CSF and IP-10 
concentrations in nasal wash were similar between both groups.
Conclusion: While endotoxemia profoundly attenuates the immune response upon a 
second LPS challenge, it does not influence the Fluenz-induced immune response. These 
results suggest immunosuppression after bacterial infection does not alter the response to a 
subsequent viral infection.
DEVELOPMENT OF ENDOTOXIN TOLERANCE DOES NOT INFLUENCE THE RESPONSE 
TO A CHALLENGE WITH THE MUCOSAL LIVE-ATTENUATED INFLUENZA VACCINE IN HUMANS IN VIVO.
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INTRODUCTION
Secondary infections with a pathogen other than that which caused the primary infection 
are generally associated with an unfavorable prognosis compared with de novo infections(1). 
It may be rational to hypothesize that this is the consequence of immunological interplay 
between pathogen-specific pathways. Concerning the innate immune response, two 
phenomena have been described for these interactions. First, the primary challenge can 
induce immunosuppression or “tolerance.” This phenotype is increasingly recognized as 
the overriding immune dysfunction in bacterial sepsis, where it is known as sepsis-induced 
immunoparalysis, rendering patients unable to clear their primary infection and rendering 
them more susceptible toward secondary infections(2). We have previously demonstrated 
that human endotoxemia [intravenous challenge with bacterial lipopolysaccharide (LPS) 
in healthy volunteers] results in the development of endotoxin tolerance, exemplified by a 
severely blunted immune response upon a second LPS challenge(3, 4). Second, the primary 
challenge can induce “priming”(5) or “training”(6), resulting in a more pronounced response 
following the secondary infection. As an example for that, bacille Calmette–Guerin vaccination 
results in enhanced immunological responses by cells of the innate immune system upon a 
subsequent challenge with a different pathogen(7).
Viral–bacterial interactions are well characterized in animal models, mainly using 
influenza infection followed by a challenge with live bacteria or LPS. These studies have 
demonstrated an initial influenza-induced hyperinflammatory state (priming)(8, 9), followed 
by an immunosuppressive state, which predisposes to secondary bacterial infections(10-12). 
By contrast, bacterial–viral immunological interactions are much less well studied, and 
no human data exist to date. The few in vitro studies that investigated this interplay have 
employed co-infection models, in which pretreatment with LPS takes place ≤24 hours before 
influenza infection(13-15). In these studies, LPS pretreatment was shown to induce a primed 
response upon influenza challenge, characterized by the initiation of an enhanced type I 
immune response and decreased viral transcription(13–15). Furthermore, it was shown recently 
that commensal bacteria producing LPS significantly reduce the thermal stability of IAV in vitro, 
that LPS decreases stability of human and avian viral strains at physiological temperatures, 
and that LPS binds to and affects the morphology of influenza virions(16). In accordance with 
these in vitro data, intramuscular LPS injection in chicken followed by an intranasal influenza 
challenge 24 hours later resulted in reduced influenza viral shedding 4 and 7 days later, 
compared with animals that did not receive LPS pretreatment. This was accompanied by 
pulmonary upregulation of interferon (IFN)-α and IFN-γ genes(17). IFNs are known for their 
antiviral functions, such as inhibition of viral replication and activation of immune cells. 
However, their upregulation has also been associated with immunosuppression and the 
increased incidence of secondary infections(18).
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In this study, we investigated the bacterial–viral interplay in humans in vivo in a unique two-
hit model: human endotoxemia followed by a challenge with the mucosal live-attenuated 
influenza vaccine Fluenz. We used this approach as a model to assess the effects of a bacterial-
induced immune response and development of endotoxin tolerance on the response to a 
subsequent infection with influenza, which is administered in another body compartment: 
the respiratory mucosa.
MATERIALS AND METHODS
Subjects
This randomized placebo-controlled study was registered at ClinicalTrials.gov (NCT02642237). 
After approval by the local medical ethics committee (CMO 2015/2058), 30 healthy, non-
smoking male subjects aged 18–35 years gave written informed consent to participate in the 
study. All study procedures were in accordance with the declaration of Helsinki, including 
the latest revisions. Subjects were screened before the start of the study and had a normal 
physical examination, electrocardiography, and routine laboratory values. Subjects were 
excluded if they had a preexistent (lung) disease, a suspicion of influenza infection in the 
preceding year or a (febrile) illness within 4 weeks before the LPS/placebo challenge. 
Subjects were not allowed to take (prescription) drugs and to have received a vaccination 
in the previous months. Subjects were asked to refrain from caffeine and alcohol intake 24 
hours, and from food 12 hours before the LPS/placebo challenge.
To illustrate the development of in vivo endotoxin tolerance, we used cytokine data 
from our previously published double-blind placebo-controlled randomized study (March–
April 2012) in which the same inclusion criteria were used, healthy male subjects were 
administered endotoxin twice with an interval of one week [NCT01374711 (3)]. Only data 
from the six subjects that received placebo beside the endotoxin challenges were used. The 
human endotoxemia procedures employed in this study are identical to that of our previous 
study(3).
Study Design
The study design is depicted in Figure 1. The study was performed from the 11th of January 
until the 26th of February 2016. Subjects were randomized by an independent nurse to 
receive an intravenous bolus administration of LPS (2 ng/kg; n=15) or placebo (0.9% saline; 
n=15) on day 0. The procedures on day 0 were carried out according to our standard human 
endotoxemia protocol(3). Seven days later (day 7), all 30 subjects underwent intranasal 
vaccination with the live-attenuated quadrivalent influenza vaccine (LAIV) Fluenz Tetra 
(0.1 mL/nostril). Subjects remained in the recumbent position for 1 minutes after Fluenz 
administration.
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Figure 1. Experimental design.
Lipopolysaccharide (US Standard Reference Endotoxin Escherichia coli O:113), obtained from 
the Pharmaceutical Development Section of the National Institutes of Health (Bethesda, 
MD, USA), supplied as a lyophilized powder, was reconstituted in 5 mL saline 0.9% for 
injection and vortex-mixed for 20 minutes after reconstitution. Fluenz Tetra (Medimmune 
LLC, Nijmegen, The Netherlands), complied with the WHO recommendation (Northern 
Hemisphere) and EU decision for the 2015/2016 season and contained the following strains: 
A/California/7/2009 (H1N1)pdm09-like, A/Switzerland/9715293/2013 (H3N2)-like strain, B/
Brisbane/60/2008 (Victoria lineage)-like strain, B/Phuket/3073/2013 (Yamagata lineage)-like 
strain, all at 107.0±0.5 FFU*** per 0.2 mL dose.
Fluenz infectivity was defined as positive viral load (measured by real time PCR) in nasal 
washings for at least one of the influenza strains from day 9 onward and/or seroconversion 
[defined as ≥4-fold increase in IgG-antibody titer for at least one of the four influenza strains 
present in the vaccine at 4 weeks postvaccination (day 35) compared with the day of 
vaccination (day 7)]. For viral load, we assessed Fluenz infectivity from day 9 onward, because 
Fluenz detected in nasal wash on the first day after vaccination (day 8) most likely originated 
from the vaccination and does not indicate actual viral replication.
Nasal Wash
Nasal washings for viral RNA, flow cytometric determinations, leukocyte counts, and cytokine 
quantification were collected as described previously(19). Nasal wash from two nostrils was 
pooled and directly analyzed or centrifuged (2,000 g, 4°C, 10 minutes), and stored at −80°C 
until further analysis.
CHAPTER 4
80
Viral Load
Viral load was semi-quantitatively measured for the Influenza A (with subtype analysis for 
H1N1 and H3N2) and influenza B strains. Viral load was determined from nasal wash using the 
MagNA Pure 96 (MagNA Pure 96 DNA and Viral NA Small Volume Kit), and PCRs were performed 
on the LightCycler 480 with Probes Master Mix (Roche Diagnostics, Almere, The Netherlands) 
using commercial validated primer and probe mixes (Tib-Molbiol GmbH, Berlin, Germany). 
Cycling conditions were 95°C for 5 minutes, followed by 40 cycles of 95°C (15 s), 55°C (15 s), 
and 72°C (20 s). The relative virus amount was determined based on the difference in cycle 
threshold value (Ct value) compared with baseline (day 7), at which virus was undetectable 
(Ct > 40, so Ct was set at 40) in all subjects included for analysis, and expressed as fold change 
using the formula 2 ΔC t  2ΔCt, where ΔCt equals 40 − (Ct value on day x). The real time PCR for 
Fluenz was performed at the clinical laboratory of microbiology at the Radboud University 
Medical Center. This laboratory is ISO certified and participates regularly with QCMD quality 
controls. The influenza strains measured included: influenza A, influenza B, and influenza A 
subtypes: influenza A/California/7/2009 (H1N1) and A/Switzerland/9715293/2013 (H3N2). 
The PCR assay for influenza A and influenza B was more sensitive than the PCR for the 
influenza A subtypes (H1N1/H3N2), leading to lower Ct values for influenza A and influenza B. 
We only measured the influenza A and influenza B strains that were present in the vaccine and 
no wild-type influenza types, because detection of influenza A and B strains by PCR cannot 
differentiate between vaccine and wild-type influenza subtypes. We excluded subjects in 
which Ct values of a particular influenza strain increased again after a period of absence of 
detectable influenza for this strain, or when the PCR was negative in the first 2 days after 
vaccination (days 8–9) but became positive in follow-up samples. The latter was the case in 
one subject (Figure 2, subject with co-infection). Subjects were also excluded when fever or 
clinical symptoms appeared for a second time or appeared very late after inoculation with 
Fluenz. This was also the case in the excluded subject mentioned earlier.
Serology
Hemagglutination inhibition (HI) assays were performed for the detection of influenza virus 
specific antibodies. Serum samples were tested for the presence of antibodies to influenza 
viruses using the HI assay that was performed in duplicate according to standard methods(20, 21). 
All sera were treated with a filtrate of Vibrio cholerae as a source of receptor destroying 
enzyme and heat inactivated at 56°C. Twofold serial dilutions of the serum samples, starting 
at 1:20, were incubated with four hemagglutinating units of virus propagated in 11-day-
old embryonated chicken eggs for 30 minutes at 37°C. Subsequently turkey erythrocytes 
were added, incubated for 1 hour at 4°C, and hemagglutination patterns were recorded. 
For this purpose, vaccine strains NIB-88 [A/Switzerland/9715293/13-like (H3N2)], X-181 [A/
California/7/09-like (H1N1)pdm09], B/Phuket/3073/13, or B/Brisbane/060/08 were used. 
Ferret sera raised against the test antigens were used as positive controls. The paired serum 
samples of each individual study subject were tested simultaneously. For statistical analysis, 
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a titer of 5 was arbitrarily assigned to sera with a titer <10. Titers were transformed to a 
logarithmic scale, and geometric means were used for further calculations.
Figure 2. Flowchart based on infectivity, defined as positive viral load for at least one of the influenza strains 
>day 7 and/or seroconversion (≥4-fold increase in antibody titer for at least one of the influenza strains at 
day 28 postvaccination compared with baseline). One subject in the placebo–Fluenz group became positive 
again for one of the influenza strains and was therefore considered to have a co-infection with influenza virus. 
This subject was excluded for further analyses.
Hemodynamic Parameters, Symptoms, and Temperature
On day 0, heart rate (3-lead electrocardiogram) and intra-arterial blood pressure data were 
recorded from a Philips MP50 patient monitor (Philips, Eindhoven, The Netherlands) every 30 
seconds by a custom in-house developed data recording system. On the same day, the LPS-
induced rise in temperature and flu-like symptoms (headache, nausea, shivering, muscle 
pain, and back pain) were scored every 30 minutes on a 6-point scale (0 = no symptoms, 
5 = worst ever experienced), resulting in a total score of 0–25. To assess Fluenz-induced local, 
lower respiratory tract and systemic symptoms, all subjects filled out an online symptom 
diary (LimeSurvey Project Hamburg, Germany), using the validated Jackson score [summing 
the following symptoms: sneezing, nasal discharge, nasal obstruction, sore throat, cough, 
headache, malaise, and chilliness(22)]. Symptoms were assessed before Fluenz vaccination 
and then daily until day 28. The severity of each symptom was rated on a 4-point scale. Body 
temperature was measured using an infrared tympanic thermometer (FirstTemp Genius 2, 
Sherwood Medical, Crawley/Sussex, UK).
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Peak Expiratory Flow (PEF)
Peak expiratory flow was measured using a peak flow meter PFM20 (Omron Healthcare 
Europe B.V., Hoofddorp, The Netherlands). PEF was determined twice during each visit and 
the highest value was used. An affected lower respiratory tract was defined as >20% decrease 
in PEF compared with the predicted values of subjects’ corresponding age, gender, and 
stature(23).
Leukocyte Counts
Analysis of leukocyte counts and differentiation from EDTA anticoagulated blood and nasal 
wash were measured using routine analysis methods also used for patient samples (flow 
cytometric analysis on a Sysmex XE-5000).
Ex Vivo Monocyte Stimulation
Primary monocytes were isolated and stimulated as described previously(24). The mononuclear 
cell fraction was isolated by density centrifugation of EDTA anticoagulated blood, diluted 1:1 
in pyrogen-free saline over Ficoll-Paque (GE Healthcare, UK). Isolated cells were washed twice 
in PBS, and monocyte isolation was subsequently performed using CD14 positive magnetic 
beads (MACS Miltenyi). MACS isolation was performed according to the manufacturer’s 
protocol. Monocytes were resuspended in culture medium (RPMI, Invitrogen, Carlsbad, CA, 
USA) supplemented with 10 µg/mL gentamicin, 10 mM glutamax, and 10 mM pyruvate. Cell 
counts were performed using a Coulter counter (Coulter Electronics). 1 × 105 monocytes in 
a 100 µL volume were plated in 96-well flat-bottom plates (Corning, NY, USA) and stimulated 
for 24 hours at 37°C in 5% CO2 with 100 µl of RPMI, LPS (10 ng/mL, serotype 055:B5, Sigma-
Aldrich), heat-killed Candida albicans (1 × 106/mL, strain UC820), and Staphylococcus aureus 
(1 × 106/mL, clinical isolate). Supernatants were stored at −20°C until cytokine analysis.
Cytokine Analysis
For plasma cytokine concentrations, EDTA anticoagulated blood was centrifuged (2,000 g, 
4°C, 10 minutes) and stored at −80°C until analysis. Concentrations of cytokines in plasma, 
nasal wash, and supernatants of stimulated monocyte cultures were determined by 
simultaneous Luminex assay (R&D Systems; Abingdon Science Park, UK) and enzyme-linked 
immunosorbent assays (ELISAs) (R&D Systems, Minneapolis, MN, USA). TNF-α, IL-6, and IL-10 
were measured in plasma samples collected on day 0 using a simultaneous Luminex assay 
(R&D Systems; Abingdon Science Park, UK). In samples obtained from day 7 onward, G-CSF, 
IL-6, IL-8, IL-10, and IFN-γ in nasal wash were measured using a Luminex assay from R&D 
Systems (Minneapolis, MN, USA), and IFN-α and IFN-β were measured by a Luminex assay 
from eBioscience (Vienna, Austria). IP-10 concentrations in nasal wash and plasma were 
measured using an ELISA (R&D Systems, Minneapolis, MN, USA). Lower detection limits in 
plasma were 1.2 pg/mL for TNF-α, IL-6, and IL-10, and 156 pg/mL for IP-10. In nasal wash, 
lower detection limits were 309 pg/mL for IP-10, 0.49 for IFN-α and IFN-β, and 1.4 pg/mL 
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for the remaining analytes. Cytokines in supernatants of ex vivo stimulated monocytes were 
measured using ELISA (IL-1β and IL-13: R&D Systems, Minneapolis, MN, USA, IL-6 and IL-10: 
Sanquin, Amsterdam, The Netherlands) following the protocols of the manufacturers.
Statistical Analysis
Data are presented as mean ± SEM, median [IQR] or geometric mean (95% CI). Between-
group comparisons were made using Mann–Whitney U tests, Kruskal–Wallis tests, 
Wilcoxon matched-pairs tests, or repeated measures two-way ANOVAs (interaction term) as 
appropriate, the latter after log transformation if data were not normally distributed (based 
on the Shapiro–Wilk test). Categorical data were analyzed using Fisher exact tests. Spearman 
correlation was used. For reasons of clarity, in case of multiple lines in one graph and a 
logarithmic y-axis, only upper or lower bounds of the 95% CI are shown. Statistical analyses 
were performed using GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA, USA). 
p-values < 0.05 were considered statistically significant.
RESULTS
Demographic Characteristics
Demographic characteristics of the study population are listed in Table 1. We also included 
the six subjects from our previous study, in which subjects received LPS twice. There were no 
differences in baseline characteristics between the groups.
Table 1. Demographic characteristics of the 30 subjects who participated in the study, including the 6 subjects 
from our previous study, in which subjects received lipopolysaccharide (LPS) twice.
LPS-LPS  
(n = 6)    
Placebo-
Fluenz 
(n = 15)      
LPS-
Fluenz 
(n = 15)   
Total group 
(n = 30)   
p-value 
between 
groups 
Age, years 21 [20-23] 21 [20-23] 22 [19-23] 21 [22-24] 0.83
Height, cm   183 [176-189]   180 [178-188]   186 [178-190]   182 [178-189] 0.36
Weight, kg 81 [75-89] 75 [70-84] 79 [71-87] 78 [69-85] 0.52
BMI, kg/m2 24 [23-26] 23 [20-26] 23 [22-25] 23 [21-25] 0.64
LPS/Placebo Challenge
LPS-Induced Immune Response In Vivo
As expected, plasma levels of TNF-α, IL-6, and IL-10 increased profoundly in the LPS group, 
but not in the placebo group (Figure 3). This cytokine response was accompanied by a 
transient monocytopenia, lymphocytopenia, and neutrophilia in the LPS group (Figure 4). 
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In both groups, blood pressure decreased during the experimental day, and this was more 
pronounced in the LPS than in the placebo group (Figure 5). Only subjects in the LPS group 
showed an increase in heart rate (Figure 5). LPS-induced symptoms typically started 1 
hour following LPS administration and peaked at 90 minutes after LPS administration, 
accompanied by an increase in body temperature to 38.2 ± 0.1°C (Figure 5).
Figure 3. Plasma levels of the cytokines TNF-α, IL-6, and IL-10 in 30 subjects who received an intravenous 
administration of lipopolysaccharide (LPS) (n=15) or placebo (n=15) at T=0. Data are represented as median 
[IQR].
Figure 4. Circulating leukocyte numbers in 30 subjects who received an intravenous administration of 
lipopolysaccharide (LPS) (n=15) or placebo (n=15) at T=0. Data are represented as mean ± SEM.
To illustrate the blunted in vivo immune response toward a second LPS challenge one week 
after the first LPS administration, we used data from a previous study in which subjects 
received LPS twice (with an interval of one week) using the exact same endotoxemia protocol 
as used in this study (3). Upon the second LPS administration, peak plasma levels of the 
cytokines such as TNF-α, IL-6, and IL-1RA were reduced by a median [IQR] of 74% [61–83], 79% 
[66–88], and 53% [47–88], respectively, illustrative of profound in vivo endotoxin tolerance 
(Figure 6).
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Figure 5. Hemodynamic and clinical parameters in 30 subjects who received an intravenous administration 
of lipopolysaccharide (LPS) (n=15) or placebo (n=15) at T=0. Data are represented as mean ± SEM.
Figure 6. Peak plasma levels of TNF-α, IL-6, and IL-1RA in six subjects who were challenged with 
lipopolysaccharide (LPS) twice, separated by one week. Data are represented as Box and Whisker (Min 
to Max) plots of individual peak levels of plasma cytokine concentrations during the first and second 
lipopolysaccharide (LPS) challenge. Data previously published(3).
Ex Vivo Cytokine Responses
Ex vivo stimulation of monocytes with LPS, Candida albicans, or Staphylococcus aureus 
demonstrates clear immunosuppression at 4 h after LPS administration, illustrated by 
significant attenuation of IL-1β and IL-6 production following endotoxemia, compared with 
the placebo group (Figure 7).
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Figure 7. Production of IL-6 and IL-1β measured in supernatants of ex vivo stimulated monocytes of 30 
subjects who received lipopolysaccharide (LPS) (n=15) or placebo (n=15) at T=0. Monocytes were stimulated 
with LPS, Candida albicans, and Staphylococcus aureus. Cytokine production was measured at T=0 (baseline) 
and 4 hours after administration of LPS/placebo. Data are represented as mean ± SEM.
Fluenz Challenge
Viral Load and Antibody Responses
A flowchart of the study based on Fluenz infectivity is depicted in Figure 2. In 26 of the 30 
subjects (87%), Fluenz inoculation resulted in infectivity, with identical rates in the LPS-
Fluenz and placebo-Fluenz groups (13 out of 15 subjects in both groups). Three subjects 
showed no increase in viral load after Fluenz inoculation and one subject in the placebo–
Fluenz group showed a second increase in viral load, suggestive for co-infection with a 
wild-type influenza strain. These subjects were excluded from further analysis (Figure 2). 
Changes in viral load are depicted in Figure 8. Influenza A viral load peaked 1 day after Fluenz 
vaccination to 26 (20–83) and 16 (10–27) fold change in the LPS–Fluenz and placebo–Fluenz 
group, respectively (p=0.54). Viral load of the influenza B strain peaked to 14 (11–40) and 29 
(20–64) fold change in the LPS–Fluenz and placebo–Fluenz group, respectively (p=0.45). 
Subtyping of the influenza A strain showed only a slight and short-lived increase for the H1N1 
strain and a more substantial and sustained increase for the H3N2 strain, with no differences 
between groups (Figure 8). Viral load gradually returned to baseline levels in the following 
weeks, with no differences between the LPS and placebo pretreatment groups. Antibody 
responses over time against the four strains present in the vaccine were also mainly driven 
by the H3N2 response and comparable between groups (Figure 9). Likewise, the proportion 
of subjects that displayed seroconversion was similar between groups [10 out of 13 (77%) in 
the LPS–Fluenz group and all 13 subjects in the placebo–Fluenz group, p=0.22]. Detailed data 
concerning the antibody responses per strain are listed in Table 2.
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Figure 8. Viral load of the influenza A and B strains as well as the influenza A subtypes H1N1 and H3N2 in nasal 
wash of the 26 subjects who were challenged with lipopolysaccharide (LPS) (n=13) or placebo (n=13) on day 0 
and displayed infectivity after inoculation with Fluenz on day 7. Data are presented as geometric means with 
95% CI of fold changes in viral load compared with baseline, where viral load was undetectable (Ct > 40, so Ct 
was set at 40). The italic numbers placed under the time points indicate how many subjects were PCR positive 
for the respective strain in each group.
Figure 9. IgG titers for the different influenza strains in 26 subjects who were challenged with lipopolysaccharide 
(LPS) (n=13) or placebo (n=13) on day 0 and displayed infectivity after inoculation with Fluenz on day 7. Data 
are represented as geometric mean with 95% CI.
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Table 2. Results of the hemagglutination inhibition (HI) assay for the various influenza strains present in the 
vaccine in the 26 subjects who were challenged with lipopolysaccharide (LPS) (n=13) or placebo (n=13) on day 
0 and were inoculated with Fluenz on day 7.
Placebo-Fluenz LPS-Fluenz
Total % seroconversion 13/15 (87%) 10/15 (77%)
A (H1N1)
Baseline HI titer >1:20 (seropositives) 12/15 (80%) 14/15 (93%)
Seroconversion (day 35) 4/15 (27%) 1/15 (7%)
A (H3N2)
Baseline HI titer >1:20 (seropositives) 6/15 (40%) 7/15 (47%)
Seroconversion (day 35) 11/15 (73%) 10/15 (67%)
B (Phuket)
Baseline HI titer >1:20 (seropositives) 6/15 (40%) 7/15 (47%)
Seroconversion (day 35) 0/0 (0%) 0/0 (0%)
B (Brisbane)
Baseline HI titer >1:20 (seropositives) 6/15 (40%) 5/15 (33%)
Seroconversion (day 35) 2/15 (13%) 0/0 (0%)
GMT H1N1 at baseline  69 (26-184) 82 (43-158)
GMT H1N1 at day 35 158 (83-303) 66 (40-108)
GMT H3N2 at baseline      14 (6-33) 10 (5-21)
GMT H3N2 at day 35 128 (60-275) 115 (46-286)
GMT B (Phuket) at baseline   11 (5-24) 12 (6-24)
GMT B (Phuket) at day 35   10 (5-17) 10 (6-18)
GMT B (Brisbane) at baseline   11 (6-20) 10 (5-22)
GMT B (Brisbane) at day 35   12 (5-26) 9 (5-16)
Cytokines and Leukocytes in Nasal Wash
In both study groups, nasal wash levels of the cytokines IL-6 and G-CSF, and the chemokine 
IP-10 increased after Fluenz vaccination to a similar extent (Figure 10). The cytokines/
chemokines IL-8, IL-10, IFN-α, IFN-β, and IFN-γ were below detection limits in virtually 
all subjects at all time points, and no clear differences between placebo and LPS groups 
were observed following Fluenz vaccination. Neither total leukocyte counts nor numbers of 
mononuclear cells and neutrophils in nasal wash were affected by Fluenz vaccination, and 
no differences between groups were observed (Figure 11).
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Figure 11. Total leukocyte counts, numbers of mononuclear cells, and neutrophils in nasal wash in the 26 
subjects who were challenged with lipopolysaccharide (LPS) (n=13) or placebo (n=13) on day 0 and displayed 
infectivity after inoculation with Fluenz on day 7. Data are represented as geometric mean with 95% CI.
Local and Systemic Symptoms, Temperature, and PEF
Symptoms indicative for local inflammation of the nasal mucosa in the upper respiratory 
tract (such as sneezing, nasal discharge, nasal obstruction, sore throat, and cough) did not 
show a clear increase after Fluenz vaccination and were similar in both groups (maximum 
levels of 2 [0–5.5] vs. 3 [2–5.5] symptom points in the LPS–Fluenz and placebo–Fluenz groups, 
respectively, p=0.42). Systemic symptoms (headache, malaise, and chilliness) were not 
encountered in any of the subjects. Body temperature increased to peak levels of 37.0 [36.9-
37.2]°C and 37.2 [36.9-37.3]°C in the LPS-Fluenz and placebo-Fluenz groups, respectively, 
p=0.52 (Figure 12). Finally, Fluenz vaccination did not affect PEF, as all subjects produced 
values >80% of their individual predicted values at all time points (Figure 12).
Figure 12. Temperature and peak expiratory flow (PEF) in the 26 subjects who were challenged with 
lipopolysaccharide (LPS) (n=13) or placebo (n=13) on day 0 and displayed infectivity after inoculation with 
Fluenz on day 7. Data are represented as geometric mean with 95% CI.
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Plasma IP-10 Levels and Circulating Leukocytes
Plasma levels of the chemokine IP-10 did not increase following Fluenz vaccination and no 
differences in circulating leukocyte counts or differentiation were observed (data not shown).
DISCUSSION
This study demonstrates that a challenge with LPS and the resulting development of 
profound tolerance to a subsequent challenge with the same agent does not influence the 
immune response induced by a subsequent viral challenge with the mucosal LAIV Fluenz.
In bacterial sepsis, a tolerant state called “sepsis-induced immunoparalysis” renders the 
host unable to clear the primary infection and increases the susceptibility toward secondary 
infections(1). These secondary infections include bacterial and fungal infections, while 
reactivation of viruses that reside latently in the human host is also frequently encountered(25). 
However, it was unknown to what extent the development of an endotoxin-tolerant 
phenotype following bacterial infection influences the innate host response toward a viral 
challenge. Herein, we employed a unique two-hit model in humans in vivo, consisting of a 
challenge with LPS followed by a Fluenz challenge. This study, as well as previous studies(3, 
4, 26-28) show that LPS administration results in the development of endotoxin tolerance 
in vivo and ex vivo, illustrated by a profound attenuation of the cytokine response upon a 
subsequent LPS challenge. As such, human endotoxemia can serve as a model for bacterial 
sepsis and the associated development of immunoparalysis, and has already been used to 
investigate potential therapies to reverse sepsis-induced immunoparalysis(3).
The live-attenuated, quadrivalent influenza vaccine “Fluenz Tetra” contains four different 
influenza strains recommended by international public health agencies as most likely to 
provide protection against seasonal influenza in any given year(29). Fluenz is a vaccine applied 
to the nasal mucosa; the natural entrance of respiratory viruses. Therefore, Fluenz vaccination 
can be used to model influenza infection in humans in vivo, albeit a very mild infection, as the 
response to LAIVs is much less pronounced than to live pathogenic influenza(30). Nevertheless, 
we believe that LAIVs such as Fluenz are the closest to live pathogenic influenza virus that can 
be safely used in healthy volunteers.
Our data show that a preceding LPS challenge neither influenced infectivity and innate 
immune parameters (illustrated by identical cytokine responses in nasal wash) nor impacted 
measures of adaptive immunity (such as antibody levels and rate of seroconversion), 
following Fluenz vaccination. These results do not correspond with previous in vitro and in 
vivo findings, where immunological priming was observed(13–15, 17). Furthermore, our findings 
are different than those from to earlier ex vivo work, where it was shown that leukocytes 
from healthy volunteers undergoing human endotoxemia demonstrated a profound tolerant 
phenotype upon ex vivo stimulation with the viral ligands poly(I:C) and S-27609(28). There are 
several possible explanations for these seemingly discrepant results.
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First, the timing of LPS and influenza challenges may be crucial; in the abovementioned 
studies, a time interval of 24 hours or less between LPS and influenza/viral ligands was 
employed, whereas we employed an interval of 7 days to ensure that the acute LPS-induced 
immune response had subsided but endotoxin tolerance was profound. This explanation 
is supported by two murine studies that showed protection against influenza infection in 
terms of mortality when LPS was administered 12 and 24 hours as well as 3 days before 
influenza infection, but not when an interval of 7 days was employed(31, 32). These findings in 
mice strongly suggest that there were no major alterations in the immune response using 
this interval.
A second possible explanation for the absence of a reduced immune response toward 
Fluenz after LPS administration is represented by compartment-specific effects. Although 
in vivo endotoxin tolerance is likely due to reprogramming of tissue-resident macrophages, 
which are assumed to be the main cytokine producers in response to LPS administration 
in vivo(4), it is unknown which tissues are actually affected and to what extent. It can be 
speculated that the mucosal compartment, in which Fluenz is administered and the initial 
antiviral immune response mounted, is not tolerized by a preceding LPS administration. 
To the best of our knowledge, there are no other studies that investigated the effects of a 
systemic bacterial challenge on a subsequent mucosal challenge. Nevertheless, there are 
data that show compartment-specific effects concerning endotoxin tolerance. For instance, 
a study in which murine peritoneal and alveolar macrophages were ex vivo restimulated with 
LPS after a systemic LPS challenge showed a marked discrepancy between these two cell 
types from different compartments: alveolar macrophages were not displaying endotoxin 
tolerance, while peritoneal macrophages did(33). The attenuated susceptibility of pulmonary 
macrophages to develop endotoxin tolerance is supported by other work in mice that were 
intrapulmonary challenged with 1 µg LPS for four consecutive days, followed by a pulmonary 
LPS challenge with 10 µg 24 hours later. Although TNF-α levels were attenuated in chronic 
LPS-exposed mice upon the final LPS challenge compared with PBS-pretreated mice, IL-6 
levels were increased, accompanied by unrestricted neutrophil recruitment to the alveolar 
space(34). It was speculated that this represents a mechanism by which the lungs protect 
themselves against pulmonary bacterial infections(34). In addition, chronic pulmonary LPS 
exposure did not confer cross-tolerance to the TLR2 ligand Pam3Cys(34). Taken together, similar 
to the lung, the nasal mucosa might be less sensitive to tolerance. This compartmentalization 
could also explain why primary virus infections entering the body through the nasal mucosa 
have not been reported following sepsis-induced immunosuppression, while latent 
viruses that are already present in the systemic compartment may induce infection in the 
immunocompromised host through reactivation.
Third, one may argue that the absence of an effect of preceding LPS administration 
on antiviral responses in our study might be that the human endotoxemia model and the 
resulting immunosuppressive effect is too mild to affect antiviral immunity. However, the 
profound (>70%) suppression of the response to a subsequent LPS challenge, also one week 
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after the first LPS challenge, indicates that this model is able to induce clinically relevant 
tolerance in case of rechallenge with LPS.
Finally, the pathophysiology induced by the use of the LAIV Fluenz may not be 
comparable with the actual pathogenic influenza virus, because it is an attenuated virus that 
may not show same infectivity, tissue tropism and virus dissemination as actual influenza. 
Furthermore, the immune evasion strategies/other specific immune parameters of live virus 
in the host cells might not be shown by the LAIV, as discussed elsewhere(35, 36). Nevertheless, 
aforementioned work in mice using a pathogenic influenza strain(31, 32) corroborates our 
findings that an interval of 7 days does not result in an altered response upon challenge 
with influenza. As alluded before, we believe that using LAIVs such as Fluenz is the most 
accurate way to model an actual influenza infection in humans in vivo in a safe manner. Use 
of a primate model(37-39) could definitively exclude that the lack of effects by LPS pretreatment 
is not due to differences between LAIVs and pathogenic influenza virus.
The lack of an in vivo interaction found in this study might explain why no adverse 
effects of the live-attenuated influenza vaccine have been reported in immunocompromised 
patients, including the elderly and young children(40-43), while immunogenicity of the vaccine 
is unaltered(40, 43). This is demonstrated by the absence of an exaggerated immune response 
or excessive viral replication, and seroconversion rates similar to those observed in healthy 
young adults. Nevertheless, the vaccine is not recommended for immunocompromised 
patients(29).
The Fluenz-induced immunological effects observed in this study are in accordance with 
previous work(29, 44-48). The proportion of subjects that displayed detectable influenza virus in 
nasal washings after Fluenz vaccination(47), as well as the increased production of cytokines 
in nasal wash(45) is in line with previous findings. Moreover, Fluenz-induced robust serum 
antibody responses(46), especially for the H3N2 strain(29). The overall high seroconversion rate 
in our study could be explained by our study population, which are young, healthy males 
with competent immune systems, efficient in eliminating Fluenz.
A limitation to our study is the fact that we performed the study during the winter season 
could have influenced the results. Although we tested for the presence of various influenza 
strains, other respiratory viruses are prevalent in the winter period as well, such as the human 
rhinovirus (HRV) and respiratory syncytial virus (RSV), and it has been demonstrated that viral 
co-infections may alter the disease course(49-51). Also, the reactivation of latent viruses, such 
as herpes simplex virus, CMV, and epstein barr virus (EBV) are common in this season, which 
could have affected the immune response as well(52, 53).
In conclusion, challenge with the bacterial ligand LPS does not affect the mediated 
response toward a subsequent viral challenge consisting of the live-attenuated influenza 
vaccine Fluenz. Our results suggest that immunosuppression after bacterial infection does 
not alter the response to a subsequent viral infection.
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Chapter 5
Short-term repeated HRV-16 exposure 
results in an attenuated immune 
response in vivo in humans.
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ABSTRACT
 
Introduction: Naturally, development of adaptive immunity following human rhinovirus 
(HRV) infection affects the immune response. However, it is currently unclear whether or 
not HRV re-exposure within a short time frame leads to an altered innate immune response. 
The "experimental cold model" is used to investigate the pathogenesis of HRV infection and 
allows us to investigate the effects of repeated exposure on both local and systemic innate 
immunity.
Methods: 40 healthy male and female (1:1) subjects were nasally inoculated with HRV-16 or 
placebo. One week later, all subjects received HRV-16. Baseline seronegative subjects (n=18) 
were included for further analysis.
Results: Infection rate was 82%. Primary HRV infection induced a marked increase in viral 
load and IP-10 levels in nasal wash, while a similar trend was observed for IL-6 and IL-10. 
Apart from an increase in IP-10 plasma levels, HRV infection did not induce systemic immune 
effects nor lower respiratory tract inflammation. With similar viral load present during the 
second HRV challenge, IP-10 and IL-6 in nasal wash showed no increase, but gradually 
declined, with a similar trend for IL-10.
Conclusion: Upon a second HRV challenge one week after the first, a less pronounced 
response for several innate immune parameters is observed. This could be the result of 
immunological tolerance and possibly increases vulnerability toward secondary infections.
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INTRODUCTION
In the recent decade, it has become clear that bacterial sepsis may induce an 
immunosuppressed state called “sepsis-induced immunoparalysis”(1, 2), a form of 
immunological tolerance which renders the host unable to clear primary infections leading 
to increased vulnerability toward secondary infections(3). This immunologically tolerant state 
is characterized by both innate as well as adaptive immunodysfunction, such as functional 
defects in leukocytes, downregulation of cytokines and immunostimulatory membrane-
bound receptors, accompanied by the upregulation of negative costimulatory molecules(3, 
4). A similar phenomenon is observed with virulent respiratory virus infections, such as 
influenza, which predispose to secondary bacterial or fungal infections(5, 6).
Human rhinoviruses (HRVs) are the most frequent cause of the common cold(7, 8) with 
prevalence estimates as high as 80% of the adult population(9). HRV infection results in the 
production of inflammatory cytokines and chemokines(10-14), and subsequent recruitment 
of immune cells into the nasopharyngeal(15) and bronchial mucosa, and secretions(11–14). In 
addition, HRV-specific neutralizing antibodies are produced, resulting in seroconversion 
approximately 28 days later(11, 16). HRVs consist of three species, HRV-A, HRV-B and the more 
recently discovered HRV-C(7). Due to its high virulence, HRV-C can cause systemic and severe 
respiratory infections in previously healthy subjects(7). This has mainly been reported for 
children, although several adult cases have also been described(7, 17). Although HRV-A and 
HRV-B may cause severe infections in young children, immunocompromised patients, and/
or patients with pre-existing respiratory diseases(18-21), it is unknown to what extent these 
species induce systemic immunological effects or lower respiratory tract disease in healthy 
adult subjects. Furthermore, although in vitro studies indicate that HRV can also induce 
immunosuppressive or tolerance mechanisms(22, 23), this has never been investigated in 
humans in vivo.
In the present study, we investigated the local respiratory tract and systemic immune 
response following challenge with HRV-16 (a HRV-A species) using the so-called “experimental 
cold model”. This model is widely used to investigate the pathogenesis of HRV infection, 
including the effects on pulmonary function(24), allergies(10), chronic obstructive pulmonary 
disease (COPD)(25), and asthma exacerbations(24, 26). Subjects were re-challenged with the 
same virus one week after the first challenge, to investigate whether the primary HRV 
infection modulates the innate immune response against the second HRV exposure. A one-
week interval was chosen, as at this time point the innate immune response induced by the 
first infection is expected to be largely resolved and specific antibodies have not yet been 
produced to a large extent(16, 27, 28). We recently demonstrated that seropositivity for HRV is 
associated with a virtually nullified immune response upon HRV challenge(29). Therefore, we 
only analyzed data from seronegative subjects in the current study.
Our data indicate that, despite similar viral loads upon both challenges, a second HRV 
challenge one week after the first results in less pronounced response of several innate 
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immune parameters. This could be the result of immunological tolerance and may be 
associated with increased vulnerability toward secondary infections.
MATERIALS AND METHODS
Subjects
This randomized, placebo-controlled study was part of a larger trial also investigating effects 
of serostatus and gender on the HRV-induced immune response[29]. This study is registered 
at ClinicalTrials.gov (NCT01823640, participant recruitment and follow-up: March-May 2013). 
The authors confirm that all ongoing and related trials for this intervention are registered. 
As this was a pilot study, no power calculation was performed. After approval by the local 
medical ethics committee CMO Arnhem-Nijmegen (NL42503.091.12; CMO 2012/476), 40 
healthy, non-smoking, male and female subjects (ratio 1:1), aged 18–35 years gave written 
informed consent to participate in the study. All study procedures were in accordance with 
the declaration of Helsinki. Subjects were screened and excluded if they had a (febrile) illness 
within four weeks before the HRV-challenge, a pre-existent lung disease, or a history of 
allergic rhinitis. Subjects were not allowed to take (prescription) drugs throughout the study.
Study design
A flowchart of the study, based on infection rate (further detailed in ‘antibody titer analysis’ 
section) is depicted in Figure 1 and the study design is depicted in Figure 2. Stratification 
was based on sex and serostatus as follows: Subjects with the same sex were grouped in two 
groups of 10 subjects (2x n=10 males; 2x n=10 females; in total n=40) subjects. Each group 
of 10 subjects consisted of roughly 50% seronegatives and 50% seropositives, based on the 
baseline antibody titers to HRV-16, measured at the screening visit (assay and cutoff value 
detailed in “antibody titer analysis” section below). Subsequently, one group of the same sex 
(n=10) was randomized to the placebo-HRV group, while the other (n=10) was randomized 
to the HRV-HRV group. Randomization was carried out by an independent nurse using the 
sealed envelope method. Subjects were inoculated by an independent nurse with either 
HRV-16 by instillation of 102 TCID50 (Tissue Culture Infectious Dose in 50% of subjects, based 
on previous studies(30)) units of HRV-16, diluted in 0.5 mL 0.9% saline, (n=20; 10 males; 10 
females), or placebo (0.9% saline; n=20; 10 males; 10 females) into each nostril. Subjects 
remained in the recumbent position for two minutes after instillation and refrained from 
touching their nose for 30 minutes. Seven days later, all 40 subjects underwent challenge 
with HRV-16. For the analyses described in this manuscript, only seronegative subjects were 
included, as serostatus was shown to exert profound effects on the HRV-induced immune 
response, which was virtually absent in seropositive subjects(29). Furthermore, we did not 
stratify our analyses for gender, as we found no differences in any parameters between males 
and females(29).
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Figure 1. Flowchart of the study. S+ indicates seropositive at baseline; S- indicates seronegative at baseline.
Figure 2. Experimental design of the study.
HRV-16 virus
Safety-tested Good Manufacturing Practice (GMP+) grade inoculum pools of HRV-16 were 
supplied by Respivert Ltd. (MM#400472 Lot#R2011038, London, UK). Each cryovial contained 
0.2 mL of HRV-16 at a dose of 2*102 TCID50 units/mL and was diluted in Hartmann’s solution 
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to a concentration of 102 TCID50 units/mL and stored at -80°C. Per infection day, one aliquot 
of HRV-16 was cultured in fourfold on a MRC-5 cell monolayer in 10-fold dilutions of samples, 
positive and negative controls in order to assess infectivity. Cell plates were placed at 33°C 
with 5% CO2 for seven days and observed for the development of cytopathic effects (CPE). 
The Reed-Muench formula was used to calculate the viral titer(31). Viral titers were all in the 
expected infectivity range (101−102 TCID50 units/mL) and positive and negative control wells 
positive and negative for CPE, respectively.
Antibody titer analysis
A standard end-point neutralization assay for HRV-16 was used to quantify levels of HRV-
neutralizing antibodies in the serum of every subject at baseline (virus neutralization titer 
[VNT] <1:4) and seropositive subjects (VNT ≥1:4) to exclude subjects who were seropositive 
to HRV-16 for the analyzes described in this manuscript, to assess seroconversion (≥fourfold 
increase in antibody titer at day 28 post-challenge; day 28 in the HRV-HRV group and day 35 
in the placebo-HRV group; Figure 1). The assay was performed on HEL cells at 37°C and 5% 
CO2. Two-step serum dilutions starting at 1:4 were incubated with 102 TCID50 HRV-16 for 1 
hour at 37°C before inoculation on HEL cells. Serum controls were included on each plate to 
test for toxicity, and a positive control of anti-HRV-16 antiserum was added to each test plate. 
The formation of CPE was examined daily and after 7 days the cultures were scored for CPE. 
The Reed-Muench formula was used to calculate the antibody titer[31]. Cells with >50% CPE/
well were scored antibody negative and ≤50% CPE as antibody positive. HRV-infection was 
defined as positive viral load and/or seroconversion (≥fourfold increase in antibody titer at 
day 28 post-inoculation) compared with baseline[24].
Nasal wash
Nasal washings for viral load and cytokine quantification were collected daily from subjects 
according to the method described by Naclerio(32). Nasal wash from two nostrils was pooled, 
centrifuged (6000 rpm, 4°C, 20 minutes), and stored at -80°C until analysis.
Viral load
Non-specific HRV viral load was determined from nasal wash as described previously(33) 
and performed at the laboratory of medical microbiology at the Radboudumc according to 
QCMD regulations. Briefly, nucleic acids were extracted from each sample using the MagNA 
Pure LC (with Total Nucleic Acid Isolation Kit) and PCRs were performed on the LightCycler 
480 with Probes Master Mix (Roche Diagnostics, Almere, The Netherlands) using commercial 
validated primer and probe-mixes (Diagenode, Liège, Belgium; Table B in S1 File). Cycling 
conditions were 95°C for five minutes, followed by 40 cycles of 95°C (15 seconds), 55°C (15 
seconds) and 72°C (20 seconds). Virus amount was recorded semi-quantitatively based on 
the cycle threshold value (Ct value). All samples in which virus was detected (Ct<40) were 
considered as having a positive viral load. For samples in which no virus was detected, the Ct 
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value was set as 40 to allow fold change calculations. Fold change from baseline (Ct=40) was 
calculated using the formula 2∆Ct.
Symptoms
We previously showed that the HRV-16 batch used in this study does not result in significant 
induction of cold symptoms(29). Therefore, we focused on lower respiratory tract and systemic 
symptoms in the current study. To assess these, all subjects filled out an online symptom 
diary (LimeSurvey Project Hamburg, Germany), using questions from the validated Wisconsin 
Upper Respiratory Symptom Survey-24 (WURSS-24)(34), indicative for a lower respiratory tract/
systemic respiratory infection (headache, sinusitis, cough, chest tightness, dyspnoea, fever, 
shivering, body ache and malaise). Symptoms were assessed prior to viral/placebo challenge 
and then twice daily, to take into account circadian variations, until day 28. The severity of 
each symptom was rated on a six-point scale.
Peak Expiratory Flow
To evaluate whether HRV influenced pulmonary function (lower respiratory tract effects), Peak 
Expiratory Flow (PEF) was measured during each visit using a peak flow meter (PFM20, Omron 
Healthcare Europe B.V., Hoofddorp, The Netherlands). PEF was determined twice during each 
visit and the highest value was used. An affected lower respiratory tract was defined as a >20% 
decrease in PEF of the predicted values of their corresponding age, gender, and stature(35). 
Cytokine analysis
Nasal wash and ethylenediaminetetraacetic acid (EDTA) anticoagulated blood samples were 
collected at various time points (Figure 1) centrifuged (6000 rpm, 4°C, 20 minutes) and stored 
at -80°C until analysis. Concentrations of interferon gamma (IFN-γ), tumor necrosis factor 
(TNF)-α, interleukin (IL)-1β, IL-6, IL-8, IL-10 were measured using a simultaneous Luminex 
assay (Milliplex; Millipore, Billerica, MA, USA). IFN-γ-induced protein (IP-10) was measured 
using ELISA (R&D Systems, Minneapolis, MN, USA). Lower detection limits were 3.2 pg/mL for 
IFN-γ, TNF-α, IL-1β, IL-6, IL-8, IL-10, and 156 pg/mL for IP-10.
Statistical analysis
According to the Kolmogov-Smirnov test, all data were non-normally distributed. Therefore, 
demographic data are presented as medians [interquartile range] and between-group 
comparisons were made using Mann-Whitney U tests. All other data are presented as 
geometric mean and 95% CI. Because there was an interindividual variation in the peak of 
acute infection ranging from day 1–4 after HRV inoculation, differences were analyzed on 
log-transformed peak levels in the first four days post-challenge using paired and unpaired 
Student’s t-tests. Statistical analyses were performed using Graphpad Prism version 5.0 
(Graphpad Software, San Diego, CA, USA). Two-sided p-values <0.05 were considered 
statistically significant.
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RESULTS
Baseline subject characteristics
Baseline characteristics of the entire study population (n=40, before exclusion of subject 
as detailed below) are listed in Table A in S1 File). There were no significant differences in 
baseline characteristics between the groups. No adverse events occurred during the trial.
Infection rate
A flowchart based on infection rate is depicted in Figure 1. Seven subjects displayed a 
positive viral load in nasal wash before challenge with HRV, hence they were excluded from 
all subsequent analyses. In 27 of the remaining 33 subjects (82%), HRV challenge resulted in 
infection (positive viral load and/or seroconversion; antibody titers of all subject provided 
in Table C in S1 File). The six subjects who showed neither positive viral load at any of the 
time-points post-challenge, nor seroconversion were categorized ‘not infected’ and were 
also excluded from all subsequent analyses. Furthermore, as explained in the introduction 
and materials and methods section, 9 subjects who were HRV-seropositive at baseline were 
excluded from the subsequent analyses. Characteristics of the 18 remaining baseline HRV-
seronegative infected subjects who were included for the final analysis showed no significant 
differences between groups (Table 1).
Table 1. Demographic characteristics of the 18 seronegative subjects who displayed positive infection that 
were included in the final analysis. Parameters were assessed during the screening visit. M: male, F: female. 
BMI: body mass index. Data are presented as medians [interquartile range].
Placebo-HRV  
(n = 7)
M (n = 3)
F (n = 4)    
HRV-HRV
(n = 11) 
M (n = 6)
F (n = 5)     
Total group 
(n = 18)   
p-value 
between 
groups 
Age, years 22 [21-26] 22 [22-25] 22 [21-25] 0.51
Height, cm   175 [166-182]   175 [168-184]   175 [168-183] 0.82
Weight, kg 73 [66-88] 71 [64-78] 72 [66-79] 0.56
BMI, kg/m2 23 [22-25] 23 [21-24] 23 [22-25] 0.41
Viral load
Viral load in nasal wash increased following HRV infection (Figure 3). At day 7, viral load was 
still increased, and remained at a similar level upon a second challenge with the same virus 
(Figure 3).
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5Figure 3. Viral load levels in nasal wash following placebo inoculation and HRV challenge (panel A) and following two HRV challenges separated by one week time (panel B). Panel C shows the peak levels in the 
first four days post-challenge in the group that received placebo, followed by a HRV challenge (bars 1 and 2), 
and in the group that were challenged with HRV twice (bars 3 and 4). Data are represented as geometric mean 
and 95% CI. 
Figure 4. Cytokine levels in nasal wash following placebo inoculation and HRV challenge (panels A, D, and G) 
and following two HRV challenges separated by one week time (panels B, E, and H). Panels C, F, and I 
show the peak levels in the first four days post-challenge in the group that received placebo, followed by 
a HRV challenge (bar 1 and 2), and in the group that were challenged with HRV twice (bar 3 and 4). Data are 
represented as geometric mean and 95% CI. Lower detection limits were 3.2 pg/mL for IL-6 and IL-10, and 
156 pg/mL for IP-10.
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Cytokines in nasal wash
HRV infection did not increase the production of IFN-γ, TNF-α, IL-1β and IL-8. However, a 
transient increase in levels of IP-10 in nasal wash, and a similar trend for IL-6 and IL-10 was 
observed (Figure 4). In subjects who were challenged with HRV twice, the first HRV inoculation 
resulted in an identical immune response compared with subjects who received HRV once 
(Figure 4).
However, following the second HRV challenge, levels of IP-10 and IL-6 in nasal wash showed 
no further increase, but decreased significantly. A similar trend was observed for IL-10 (Figure 4). 
IFN-γ, IL-1β, and TNF-α levels in nasal wash were below the detection limit in virtually all 
subjects, and no clear profiles were observed following HRV infection.
Systemic and lower respiratory tract responses
Plasma levels of IFN-γ, TNF-α, IL-1β, IL-6, IL-8, and IL-10 were below the detection limit in 
virtually all subjects at all time points. In the few subjects who displayed detectable levels 
of these cytokines, values were very low (approximately 10 pg/mL), in most cases already 
present as baseline, and did not increase following HRV infection. IP-10 levels were detectable 
in plasma already at baseline, but HRV infection after placebo inoculation did not result in 
significantly increased plasma levels (Figure 5). In subjects who were challenged with HRV 
twice, a more pronounced increase was observed after the first inoculation, although this 
response was not significantly different compared with that observed in subjects who 
received HRV once. Upon the second HRV challenge however, a significant decrease was 
observed compared with the first (Figure 5).
Figure 5. Plasma IP-10 levels following placebo inoculation and HRV challenge (panel A) and following two 
HRV challenges separated by one week time (panel B). Panel C shows the peak levels in the first four days 
post-challenge in the group that received placebo, followed by a HRV challenge (bar 1 and 2) and in the group 
that were challenged with HRV twice (bar 3 and 4). Data are represented as geometric mean and 95% CI. 
Lower detection limit was 156 pg/mL.
HRV infection resulted neither in systemic symptoms, nor in symptoms indicating a 
descending respiratory tract infection (Figure A in S1 File). Furthermore, HRV infection did 
not affect PEF, as all subjects produced values >80% of their individual predicted values at all 
time-points, and PEF did not change after HRV challenge (Figure B in S1 File).
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DISCUSSION
In the present study, we show that the response of several innate immune parameters is less 
pronounced upon a second HRV challenge seven days after the first challenge.
We chose to investigate the influence of two consecutive HRV challenges within a 
short time frame. As a consequence, the observed attenuated response of several innate 
immune parameters to the second HRV exposure may be the result of tolerance. These 
results indicate that viruses causing relatively mild illness also induce attenuation of innate 
immune responses and may lead to increased vulnerability toward secondary fungal / 
bacterial infections, or reactivation of viruses that reside latent in the human host(4). This 
could have consequences for vulnerable patient groups, such as the elderly, and might 
influence vaccination strategies. This finding is supported by in vitro studies that have 
shown that HRV can induce immunosuppressive mechanisms(22, 23). The effects observed 
in the present study are reminiscent of “endotoxin tolerance”, observed after challenging 
healthy volunteers with bacterial lipopolysaccharide(36, 37), and might resemble some aspects 
of the severely immunosuppressed state observed in patients with sepsis(3) and influenza 
infections(5). As such, it is tempting to speculate that previous infection with relatively mild 
viruses such as HRV renders patients increased vulnerable toward secondary bacterial and/
or viral infections. However, additional studies are warranted to assess the clinical relevance 
of our observations. The tolerance effect observed could be due to desensitization effects 
on local immune cells or a type I interferon induced CD8+ T-cell mediated anti-viral state 
where no replication occurs(38). For instance, it was shown that HRV can survive in alveolar 
macrophages and impair the cytokine responses to a second challenge with bacterial 
ligands(23). Along these lines, for influenza and respiratory syncytial virus (RSV), previous work 
has demonstrated a post-viral desensitization of alveolar macrophages to Toll-like receptor 
(TLR) ligands, associated with reduced NF-kappaB activation and chemokine production(5).
In our study, we only included seronegative subjects, because previous work has 
demonstrated that serostatus alters both HRV-induced symptom scores(16, 39) as well as the 
HRV-induced immune response, which we showed to be virtually nullified in seropositive 
subjects[29]. As such, next to the pathophysiological consequences, our results indicate that a 
crossover design is neither feasible using a short interval, due to a suppressed innate immune 
response, nor using a longer interval, due to antibody formation that starts approximately 
one week after HRV infection[16] and severely impacts the immune response(29).
The mucosal immune response observed in the present study, reflected by the increase 
in cytokines in nasal wash, is in line with various previous in vitro and in vivo studies(11-13, 40). 
In response to HRV infection, IP-10 was in contrast to other cytokines, produced in nasal 
wash of all subjects following infection. As such, our results are in accordance with previous 
studies that have demonstrated that IP-10 is a sensitive marker for HRV infection(12, 41, 42). IP-10 
plasma levels did not significantly increase upon a single HRV challenge although a trend 
was apparent, especially following the first HRV inoculation in subjects who were challenged 
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with HRV twice. In addition, more subjects that were challenged twice demonstrated positive 
infection (11 in the HRV-HRV group vs. 7 in the placebo-HRV group; Figure 2). Apparently in this 
short time frame, the host is not yet capable to induce an effective innate immune response 
to eliminate HRV, supportive of the immunological tolerance theory. The mild increase of IP-
10 plasma levels is in line with studies in asthmatic and COPD patients(41, 42). In the absence 
of alterations of all other systemic markers measured, this relatively minor increase might 
suggest spillover from the nasopharynx to the circulation, although production by cells 
outside the nasopharynx cannot be excluded.
Apart from the increase in IP-10, neither systemic symptoms or immune effects were found 
after HRV infection, nor effects on the lower respiratory tract were observed. These findings 
suggest that, unlike what has been described for vulnerable groups such as young children, 
immunocompromised patients, and/or patients with pre-existing airway diseases(18–21), HRV-16 
does not exert these effects in healthy subjects.
This study has several limitations. First, we included a relatively low number of subjects, 
which probably explains that several differences did not reach statistical significance.
Second, we only studied healthy subjects, therefore the observed effects could be 
different in a diseased population, such as those suffering from sepsis, which might display 
dysregulated cytokine responses(37).
Third, we did not store the nasal wash cellular fraction and therefore could not assess 
cellular markers such as induction of antiviral genes such as type I or III interferons, which 
play important roles in respiratory viral infections(43).
Finally, we chose to perform the second HRV challenge one week after the first, as at 
this time point the innate immune response induced by the first infection is expected to be 
largely resolved, but apparently, viral load and levels of the cytokines in nasal wash had not 
returned to baseline yet. However, one would expect a further increase in these parameters 
after a second HRV challenge in case of a normal immune response, while a similar viral load 
and further decrease in cytokines was apparent. In addition, although tolerance is a plausible 
explanation for the attenuated immune response, one could speculate about the possibility 
that, albeit in relatively little quantities, anti-HRV specific antibodies are already present at 
this time, which could also lead to attenuation of the immune response upon the second 
HRV-16 challenge. However, studies that investigated kinetics of HRV-induced neutralizing 
antibodies make this theory less likely(44, 45). These studies demonstrate that HRV-neutralizing 
antibodies in both nasal wash and serum are low seven days after HRV inoculation, and their 
titers begin to rise at approximately two weeks after inoculation(44), although it should be 
mentioned that the conventional detection tests used in these studies might be less sensitive 
in detecting HRV-specific antibodies than the tests that are used nowadays. Nonetheless, our 
data also show that viral load remained elevated until day 28, when the majority of subjects 
displayed seroconversion. Therefore, it appears not to be possible to find a suitable time-
window to investigate the effects of consecutive HRV challenges without taking into account 
the possibly confounding effects of the development of an adaptive immune response, 
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leading to the production of anti-HRV specific antibodies. Using a different HRV strain for the 
second HRV challenge would eliminate the possible influence of HRV-16-specific antibodies 
on the immune response.
In conclusion, we report that a second HRV challenge one week after the first results in 
a less pronounced response of several innate immune parameters. This could indicate that 
relatively mild viruses can also induce immunosuppression, possibly leading to increased 
vulnerability toward secondary infections.
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SUPPLEMENTARY MATERIAL
S1 File. Supporting Tables and Figures
Supplementary tables
Table A. Demographic characteristics of all 40 subjects. Parameters were assessed during the screening visit. 
M:male, F:female. BMI: body mass index. S-: seronegative for HRV-16, S+: seropositive for HRV-16. Data are 
presented as medians [interquartile range].
Placebo-
HRV 
M (n=10)      
Placebo-
HRV 
F (n=10)      
HRV-
HRV 
M (n=10)   
HRV-
HRV 
F (n=10)   
Total 
group 
(n=40)
p-value 
between 
groups 
Age, years 23[21-25] 24[20-26] 22[21-25] 23[22-24] 22[21-25] 1.00
Height, cm 187[191-190] 168[164-173] 185[178-190] 173[168-176] 178[168-186] 0.45 (M)
0.17 (F)
Weight, kg 78[77-89] 67[62-72] 77[72-84] 66[57-68] 73[66-80] 0.20 (M)
0.62 (F)
BMI, kg/m2 23[22-25] 23[22-24] 23[22-24] 21[20-24] 23[22-24] 0.73 (M)
0.14 (F)
Serostatus S- (n=5)
S+ (n=5)
S- (n=6)
S+ (n=4)
S- (n=6)
S+ (n=4)
S- (n=5)
S+ (n=5)
S- (n=22)
S+ (n=18)
Table B. Validated primer and probe-mixes for HRV used in the multiplex assay. The stem structure of the 
molecular beacon is italicised. Reporter dye: carboxy-fluorescein (FAM); Quencher: black hole quencher 1 
(BHQ1). Probe: Taqman probe (TQ).
Target Primer Sequence and label PCR product size 
(bp)
HRV 235HRVs GACARGGTGTGAAGSYC 142
236HRVas CAAAGTAGTYGGTCCCATCC
522HRV-TQ-FAM FAM-TCCTCCGGCCCCTGAATGYGGCTAA-BHQ-1
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Table C. HRV-16 pre-, and post-infection antibody titers of all 40 subjects. S-: seronegative for HRV-16, S+: 
seropositive for HRV-16.
Group of subjects Antibody titer 
Pre-infection 
Antibody titer 
Post-infection 
Seroconversion
yes / no 
Males placebo-HRV   
S- n=5
S+ n=5
<4
<4
<4
<4
<4
8
4
4
8
45
4
4
388
4
32
16
91
16
8
152
no
no
yes
no
yes
no
yes
yes
no
yes
Females placebo-HRV 
S- n=6
S+ n=4
<4
<4
<4
4
4
4
8
128
4
8
64
4
4
54
23
64
8
128
8
16
yes
no
no
yes
yes
yes
no
no
no
no
Males HRV-HRV      
S- n=6
S+ n=4
<4
<4
<4
<4
<4
<4
64
16
4
45
4
8
16
16
256
64
64
19
32
128
no
no
yes
yes
yes
yes
no
no
yes
yes
Females HRV-HRV    
S- n=5
S+ n=5
<4
<4
<4
<4
4
8
16
16
64
27
4
4
1024
64
32
609
609
128
64
256
no
no
yes
yes
yes
yes
yes
yes
no
yes
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Supplementary figures
Fig A. Systemic symptom score (points) following placebo inoculation and HRV challenge (panel A) and 
following two HRV challenges separated by one week time (panel B). Panel C shows the peak levels in the 
first four days post-challenge in the group that received placebo, followed by a HRV challenge (bars 1 and 2), 
and in the group that were challenged with HRV twice (bars 3 and 4). Data are represented as geometric mean 
and 95% CI. 
Fig B. Peak Expiratory Flow (PEF) values (% pred.) following placebo inoculation and HRV challenge (panel 
A) and following two HRV challenges separated by one week time (panel B). Panel C shows the peak levels in 
the first four days post-challenge in the group that received placebo, followed by a HRV challenge (bars 1 and 
2), and in the group that were challenged with HRV twice (bars 3 and 4). Data are represented as geometric 
mean and 95% CI. 
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Chapter 6
The endotoxin-induced pulmonary 
inflammatory response is enhanced during 
the acute phase of influenza infection 
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ABSTRACT
Introduction: Influenza infections are often complicated by secondary infections, which 
are associated with high morbidity and mortality, suggesting that influenza profoundly 
influences the immune response toward a subsequent pathogenic challenge. However, data 
on the immunological interplay between influenza and secondary infections are equivocal, 
with some studies reporting influenza-induced augmentation of the immune response, 
whereas others demonstrate that influenza suppresses the immune response toward a 
subsequent challenge. These contrasting results may be due to the use of various types of 
live bacteria as secondary challenges, which impedes clear interpretation of causal relations, 
and to differences in timing of the secondary challenge relative to influenza infection. Herein, 
we investigated whether influenza infection results in an enhanced or suppressed innate 
immune response upon a secondary challenge with bacterial lipopolysaccharide (LPS) in 
either the acute or the recovery phase of infection.
Methods: Male C57BL/6J mice were intranasally inoculated with 5x103 PFU influenza virus 
(pH1N1, strain A/Netherlands/602/2009) or mock treated. After 4 (acute phase) or 10 (recovery 
phase) days, 5 mg/kg LPS or saline was administered intravenously, and mice were sacrificed 
90 minutes later. Cytokine levels in plasma and lung tissue, and lung myeloperoxidase (MPO) 
content were determined.
Results: LPS administration four days after influenza infection resulted in a synergistic 
increase in TNF-α, IL-1β, and IL-6 concentrations in lung tissue, but not in plasma. This effect 
was also observed 10 days after influenza infection, albeit to a lesser extent. LPS-induced 
plasma levels of the anti-inflammatory cytokine IL-10 were enhanced four days after influenza 
infection, whereas a trend toward increased pulmonary IL-10 concentrations was found. LPS-
induced increases in pulmonary MPO content tended to be enhanced as well, but only at four 
days post-infection. 
Conclusions: An LPS challenge in the acute phase of influenza infection results in an 
enhanced pulmonary pro-inflammatory innate immune response. These data increase our 
insight on influenza-bacterial interplay. Combing data of the present study with previous 
findings, it appears that this enhanced response is not beneficial in terms of protection 
against secondary infections, but rather damaging by increasing immunopathology. 
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INTRODUCTION
Patients with influenza infection often suffer from severe secondary bacterial infections, 
which are associated with high morbidity and mortality rates(1, 2). A striking example of this 
relationship was provided by bacteriological and histopathological analysis of infected 
lung tissue obtained from people who died of influenza during the 1918-1919 “Spanish flu” 
pandemic, in whom bacterial pneumonia was found to be the predominant cause of death(1). 
These data suggest that an influenza infection profoundly influences the immune response 
upon a secondary bacterial infection. 
Several studies have evaluated immunological interactions between influenza and 
bacterial infections, including infections with Gram-negative bacteria(3). In vitro studies 
in which influenza-infected alveolar macrophages were subsequently stimulated with 
bacterial lipopolysaccharide (LPS), a bacterial compound that induces a profound innate 
immune response, revealed increased levels of pro-inflammatory cytokines Tumor Necrosis 
Factor (TNF)α, interleukin (IL)-1β and IL-6(4-8), indicative of a priming effect on these cells by 
influenza. Data from in vivo animal studies are ambiguous. Similar to the in vitro data, some 
report enhanced responses. For instance, influenza infection in mice was shown to enhance 
the inflammatory response and neuropathogenicity resulting from LPS administration 
on days three and four after influenza inoculation(9). Likewise, murine influenza infection 
resulted in increased levels of pro-inflammatory cytokines in both plasma and lungs, and 
enhanced pulmonary neutrophil influx upon pneumococcal infection seven days later(10). 
Similar results were observed in mice 14 days after influenza infection(11). However, two 
otherwise largely comparable studies demonstrated reduced pulmonary pro-inflammatory 
cytokine concentrations upon Streptococcus pneumoniae and Staphylococcus aureus 
infections in mice infected with influenza seven days before, indicative of influenza-induced 
immunosuppression(12, 13). These equivocal results may be due to differences in the severity 
or kinetics of the influenza infection or the use of different bacteria as secondary challenges, 
thereby targeting various complex multi-receptor signaling pathways. Also, the use of live 
bacteria could have contributed to these ambiguous results. For instance, if influenza would 
induce immunosuppression and thereby facilitate outgrowth of bacteria upon a secondary 
live infectious challenge, the increased bacterial burden can eventually result in fulminant 
inflammation, which would wrongfully suggest influenza-induced augmentation of the 
immune response. 
In the present study, we investigated whether influenza infection results in an enhanced 
or suppressed innate immune response upon a secondary challenge with LPS. Furthermore, 
we assessed the kinetics of these influenza-induced effects by performing the LPS challenges 
in either the acute or the recovery phase of influenza infection.
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METHODS
Ethics and animals
All procedures described were in accordance with the requirements of the Dutch Experiments 
on Animals Act, the EC Directive 86/609, and approved by the Animal Ethics Committee of the 
Radboud University Nijmegen Medical Center (RU-DEC 2013-029). 48 male C57BL/6J mice 
(Charles River, Sutzfield, Germany) aged 10–12 weeks and weighing 23–29 grams were used. 
Mice were housed in individually ventilated cages, with five mice per cage at the central 
animal facility of the Radboud University. 
Study design
At day 0, six groups of 8 mice (total n=48) were anesthetized by isoflurane and intranasally 
inoculated with a sublethal dose of influenza virus (pH1N1, strain A/Netherlands/602/2009, 
5x103 PFU) or mock treated (NaCl 0.9%) in a volume of 50 μL. Following infection, all 
mice were monitored and weighed daily. The temperature was recorded with an infrared 
thermometer on the skin and physical condition was scored using a scoring and weight sheet 
(weight, body temperature, ruffled coat, hunched back, reduced mobility, and moribund). 
At either day 4 (acute phase) or day 10 (recovery phase), mice were placed in a temperature 
controlled chamber to receive LPS (E coli, serotype 0111:B4, 5 mg/kg) or NaCl 0.9% by 
intravenous injection in the tail vein. 90 minutes after LPS or NaCl administration, mice were 
deeply anesthetized with isoflurane and exsanguinated through orbital extraction, followed 
by cervical dislocation after which organs were collected. 
Blood and tissue collection 
Ethylenediaminetetraacetic acid (EDTA)-anticoagulated blood was centrifuged at 13000 
x g for 2 min at room temperature after which plasma was stored at −80  °C until analysis. 
Subsequently, perfusion of the lungs was performed by intracardiac injection with 
phosphate-buffered saline (PBS), after which lung lobes were harvested and snap frozen in 
liquid nitrogen and stored at −80 °C until homogenization. Lung tissue was placed in 1 mL lysis 
buffer containing PBS, 0.5% triton X-100, and a protease inhibitor cocktail (complete EDTA-
free tablets, Roche, Woerden, the Netherlands, 1 tablet per 50 mL lysis buffer). Subsequently, 
lung lobes were homogenized at 50 Hz, using a polytron homogenizer and subjected to 
two rapid freeze-thaw cycles using liquid nitrogen. Finally, homogenates were centrifuged 
(10 minutes, 14000 x g, 4°C), and the supernatant was stored at −80°C until cytokine analysis.
Cytokine analysis
Concentrations of TNF-α, IL-1β, IL-6, IL-10 in plasma and lung homogenates were measured 
using a Luminex assay (Milliplex, Millipore, Billerica, MA) according to the manufacturer’s 
instructions. The lower detection limit of the assay was 32 pg/mL for all cytokines. Plasma IL-
1β levels were below the detection limit in the majority of animals. Lung homogenate cytokine 
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concentrations were normalized to total protein content determined by bicinchoninic acid 
assay (BCA Protein Assay; Thermo Fisher Scientific). 
Myeloperoxidase content
Myeloperoxidase (MPO) content was measured in lung homogenates using an enzyme-
linked immunosorbent assay (Hycult biotech, Uden, the Netherlands) according to the 
manufacturer’s instructions. Concentrations were normalized to total protein content as 
described above.
Statistical analysis
All data were normally distributed according to the Shapiro-Wilk test. The Grubbs test 
(extreme studentized deviate method) was used to exclude significant outliers from analysis 
(maximum of one exclusion per dataset). To determine the number of animals required per 
group, we performed a power calculation based on a minimal detectable difference of 50% 
in LPS-induced plasma TNF-α levels between influenza-infected and non-influenza-infected 
mice. Mean ± SD (533 ± 163 pg/mL) TNF-α plasma levels were obtained from previous work 
from our group, in which male C57BL/6J mice were also injected intravenously with 5 mg/
kg LPS and sacrificed 90 minutes later(14). Using a two-sided α of 0.05, and a power of 80% 
(β of 0.2) in an unpaired t-test design, 6 animals per group were required. To account for 
potential loss of animals due to influenza infection, 8 animals per group were used. The effect 
size was based on previous work(9), in which influenza infection modulated the plasma 
cytokine response to LPS administration by at least 50%. Comparisons were analyzed using 
unpaired Student’s t-tests and repeated measures one-way analysis of variance (ANOVA) as 
indicated in the figure legends. Statistical analyses were performed in GraphPad Prism 5.03 
for Windows (GraphPad Software, San Diego, CA). Two-tailed p-values <0.05 were considered 
statistically significant. 
RESULTS
Clinical signs of influenza infection
All influenza-inoculated mice showed clinical signs of infection, including weight loss, 
lethargy, and pyrexia. Four influenza-infected mice were prematurely taken out of the 
experiment because of signs of severe infection. Body weight decreased in all influenza-
infected mice in the acute phase of infection, whereas it remained stable in mock-inoculated 
mice (Figure 1). From day 7 onwards, body weight started to increase, marking the recovery 
phase of influenza infection (Figure 1).
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Figure 1. Body weight of influenza- or mock-inoculated mice. Data are presented as mean with SEM. † 
indicates the two time-points at which mice in the respective groups were sacrificed.
Cytokines in plasma and lung homogenates
Influenza infection by itself did not result in increased plasma levels of any of the cytokines 
measured at both four and 10 days post-infection (Figure 2). 
Figure 2. Plasma levels of TNF-α, IL-6, and IL-10 in mice that received influenza/mock followed by LPS/NaCl 
four or ten days later. Data are presented as scatter-dot plots with horizontal lines indicating the mean value. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001 (calculated by unpaired Student’s t-tests).
Expectedly, LPS administration led to profoundly increased plasma concentrations of TNF-α, 
IL-6, and IL-10. Although TNF-α and IL-6 plasma levels appeared to be somewhat higher in 
mice challenged with LPS four days after influenza infection compared with mock-inoculated 
mice, this did not reach statistical significance (p=0.12 and p=0.86, respectively). Plasma 
concentrations of the anti-inflammatory cytokine IL-10 were however significantly enhanced 
in mice challenged with LPS four days after influenza infection. No differences in any of the 
plasma cytokine levels were measured between influenza-infected and mock-inoculated 
mice at 10 days. 
In lung homogenates, influenza by itself caused mildly elevated levels of TNF-α, IL-1β, 
IL-6, and IL-10 at four days post-infection, and to a lesser extent at 10 days after infection 
(Figure 3). 
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Figure 3. Levels of TNF-α, IL-1β, IL-6 and IL-10 in lung homogenates of mice that received influenza/mock followed 
by LPS/NaCl four or ten days later. Data are presented as scatter-dot plots with horizontal lines indicating the mean 
value. * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, # indicates p=0.05-0.10 (calculated by unpaired 
Student’s t-tests).
Figure 4. MPO content in lung homogenates of mice that received mock/influenza followed by NaCl/LPS 
four or ten days later. Data are presented as scatter-dot plots with horizontal lines indicating the mean value. 
* indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001, # indicates p=0.05-0.10 (calculated by unpaired 
Student’s t-tests).
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Similar to what was found in plasma, LPS challenge also led to increased concentrations of 
all measured cytokines in lung tissue. A synergistic increase of all pro-inflammatory cytokines 
in the lungs was found in influenza-infected mice challenged with LPS four days later, and, 
to a lesser extent, in mice challenged with LPS 10 days post-influenza infection. For IL-10, 
the potentiating effect was additive rather than synergistic, only observed at four days post-
influenza infection, and reached a trend toward statistical significance.
Pulmonary MPO content
In accordance with pulmonary cytokine levels, influenza infection by itself led to increased 
MPO content in the lungs four days after infection, and tended to result in increased MPO 
content 10 days post-infection (Figure 4). 
Again, LPS administration also resulted in increased MPO levels in lung tissue and there 
was a trend toward enhanced MPO content in influenza-infected mice challenged with LPS 
four days after infection. 
DISCUSSION
In the present study, we demonstrate that a systemic LPS challenge in the acute phase 
of influenza infection (four days post-infection) results in an enhanced pulmonary, but 
not systemic pro-inflammatory cytokine response. This effect was synergistic rather than 
additive, indicating that influenza infection actually modulates the immune response to a 
subsequent challenge with LPS. Furthermore, this effect remained present, although less 
pronounced, in the recovery phase of influenza infection (10 days post-infection). The LPS-
induced increase in MPO content in lung homogenates, reflecting pulmonary neutrophil 
influx or sequestration, tended to be enhanced in the acute phase of influenza infection as 
well. These results suggest that influenza infection, especially in the acute phase, may cause 
a more pronounced pulmonary pro-inflammatory immune response upon a secondary 
bacterial infection.
Our results are in accordance with in vitro data reporting a cellular priming effect of 
influenza observed upon secondary stimulation with LPS(4-8), as well as with other murine 
in vivo studies that report increased inflammation and pulmonary neutrophil influx or 
sequestration upon a secondary bacterial infection or LPS challenge in the acute phase of 
influenza infection(9, 10). For example, a preceding influenza infection in mice gravely enhanced 
lung injury induced by a secondary infection with Streptococcus pneumoniae seven days later, 
resulting in a severe necrotic pneumonia accompanied by increased mortality(10). Also, the 
increased MPO content observed in our study is an important hallmark of acute respiratory 
distress syndrome (ARDS)(15, 16), a severe complication of influenza infection caused by 
excessive pulmonary inflammation. These and our study reveal that the enhancing effect 
on the pro-inflammatory innate immune response is most evident in the lungs, probably 
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because the influenza-induced damage and consequent inflammatory effects are most 
pronounced at this site. In this context, our data are in line with the recommendation to 
use corticosteroids in patients with severe influenza infections in the Intensive Care Unit to 
counteract the pulmonary hyperinflammatory response causing ARDS. Several underlying 
mechanisms may contribute to the observed effects. At the cellular level, studies have 
shown that influenza and certain bacterial pathogens, such as Haemophilus influenzae and 
Streptococcus pneumoniae, utilize similar immunological pathways, and that the overlap 
in the inflammatory mediators produced thereby creates augmentation of the immune 
response during sequential infection, in turn causing immunopathology(17, 18). Furthermore, it 
has been hypothesized that influenza stimulates TNF-α gene transcription activators or may 
interfere with labile transcription repressor proteins and stabilizes TNF-α mRNA by delaying 
its degradation(8). Alternatively, the increased lung MPO levels observed do not necessarily 
reflect PMN infiltration into the lungs, but may (also) result from PMNs trapped in the 
vasculature, as circulating activated neutrophils become rigid and can be trapped within the 
small capillaries of the lung(19). As such, increased entrapment of leukocytes in the pulmonary 
vasculature during influenza infection could also contribute to the enhanced inflammatory 
cytokine levels upon LPS challenge. We can only speculate on this, because no histological 
data are available, which represents a limitation of this work.
It may be argued that the enhanced pro-inflammatory immune response induced by 
influenza serves as a means to efficiently eliminate the primary pathogen and to enhance 
host defense toward a secondary infection. For instance, pro-inflammatory cytokines are 
induced in influenza-infected cells to limit viral replication, and to initiate downstream 
immune responses(20). However, this is not supported by previous work, where an increased 
bacterial burden was observed irrespective of a enhanced or suppressed response(11-13). 
Several explanations for this observation may be put forward. First, next to potentiating 
pro-inflammatory cytokine responses, the present study and work by others(11) has shown 
that influenza infection also potentiates production of the key anti-inflammatory cytokine 
IL-10, which was demonstrated to be crucial in facilitating bacterial outgrowth upon 
secondary challenge with Streptococcus pneumoniae(11). Second, influenza may on the 
one hand prime for production of innate cytokines produced by myeloid cells, but impair 
T-cell-derived cytokines that are instrumental for the adaptive immune response. This was 
elegantly demonstrated by Kudva et al., who showed that, in line with our results, infection 
with Staphylococcus aureus six days after influenza resulted in increased pulmonary levels 
of innate cytokines such as IL-6 and MCP-1, and increased neutrophil influx to the lungs, but 
decreased concentrations of T-cell-derived IL-17 and IL-22, which were demonstrated to play 
a pivotal role in fending off the staphylococcal infection(21). 
Whereas the enhancing effects of influenza on pro-inflammatory innate immune 
parameters were less pronounced at 10 days post-infection, a suppressed response was neither 
evident. This could be partly biased by the exclusion of two mice in both recovery groups due 
to severe influenza infection. However, it might also be argued that 10 days post-infection is 
CHAPTER 6
128
too soon for these effects to manifest. For example, profound desensitization toward LPS 
and flagellin, another Toll-like receptor (TLR) ligand, was observed in alveolar macrophages 
obtained from mice up to six weeks after influenza infection(22). Furthermore, the direction 
of the response upon a secondary challenge is probably highly dependent on the pathogen 
or stimulus used, each using distinct intracellular signaling pathways. With regard to this, it 
is well-known that influenza virus particularly predisposes to Aspergillus fumigatus, which is 
present in 25% of all influenza patients(23, 24), causing infections such as invasive pulmonary 
aspergillosis that are associated with very high mortality rates. As different mechanisms 
may be important in host defense toward various pathogens, the specific response toward 
Aspergillus fumigatus could be suppressed by a preceding influenza infection. The use 
of corticosteroids may be another important factor in the observed vulnerability toward 
particular secondary infections, as steroid use was shown to be independently associated 
with the presence of Aspergillus fumigatus in sputum of cystic fibrosis patients(25) and with 
a substantially increased risk of community-acquired Staphylococcus aureus bacteremia(26). 
Furthermore, a meta-analysis revealed that the use of corticosteroids to be significantly 
associated with nosocomial infections(27). To the best of our knowledge, these putative 
detrimental effects of corticosteroid treatment during influenza on secondary infections have 
yet to be studied systematically in animal models. In any case, it remains to be determined 
whether the overall effects of corticosteroid treatment are beneficial or not, as they may 
lead to increased susceptibility in a subset of influenza virus-infected patients but may also 
provide health benefits in another subset of influenza virus-infected patients.
CONCLUSIONS 
An LPS challenge in the acute phase of influenza infection results in an enhanced pulmonary 
pro-inflammatory innate immune response. These data increases our insight concerning 
viral-bacterial interplay. Combined with previous findings, it appears that this enhanced pro-
inflammatory response does not lead to protection against secondary infections, but rather 
causes immunopathology leading to damage, and thereby to organ failure. 
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ABSTRACT
Introduction: While most influenza patients have a self-limited respiratory illness, 5–10% 
of hospitalized patients develop severe disease requiring ICU admission. The aim of this 
study was to identify influenza-specific factors associated with ICU admission and mortality. 
Furthermore, influenza-specific pulmonary bacterial, fungal and viral co-infections were 
investigated. 
Methods: 199 influenza patients, admitted to two academic hospitals in the Netherlands 
between 01-10-2015 and 01-04-2016 were investigated of which 45/199 were admitted to the 
ICU. 
Results: A history of Obstructive/Central Sleep Apnea Syndrome, myocardial infarction, 
dyspnea, influenza type A, BMI > 30 kg/m2, the development of renal failure and bacterial and 
fungal co-infections, were observed more frequently in patients who were admitted to the 
ICU, compared with patients at the normal ward. Co-infections were evident in 55.6% of ICU-
admitted patients, compared with 20.1% of patients at the normal ward, mainly caused by 
Staphylococcus aureus, Streptococcus pneumoniae, and Aspergillus fumigatus. Non-survivors 
suffered from diabetes mellitus and (pre-existent) renal failure more often. 
Conclusions: The current study indicates that a history of OSAS/CSAS, myocardial infarction 
and BMI > 30 kg/m2 might be related to ICU admission in influenza patients. Second, ICU 
patients develop more pulmonary co-infections. Last, (pre-existent) renal failure and 
diabetes mellitus are more often observed in non-survivors.
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INTRODUCTION
Influenza virus infection is an important cause of mortality worldwide, leading to 250.000–
500.000 deaths each year in the developed world(1). While most influenza patients have a 
self-limited respiratory illness, 5–10% of hospitalized patients may develop severe dyspnea 
or respiratory distress requiring ICU admission(2). Mortality is caused by the primary viral 
infection which can have a fulminant disease course(3), but also by influenza-associated 
pulmonary co-infections(4, 5). It is increasingly recognized that similar to sepsis, influenza 
can initiate immunosuppressive mechanisms(5, 6), creating an ideal environment for 
opportunistic pathogens to grow out and induce co-infections. Pulmonary bacterial co-
infections are predominantly caused by Streptococcus pneumoniae, Staphylococcus aureus 
and Haemophilus influenzae(5). Also, invasive pulmonary aspergillosis (IPA) caused by the 
fungal Aspergillus fumigatus is recently recognized as a co-infection occurring in 20–25% 
of influenza patients who are admitted to the intensive care unit (ICU)(7, 8). Both bacterial as 
well as fungal pulmonary co-infections are associated with increased mortality rates(7, 9-11). 
In addition, viral co-infections(12) and reactivation of viruses that reside latent in the host, 
such as cytomegalovirus (CMV), epstein barr virus (EBV) and herpes simplex virus (HSV) 
are frequently encountered in influenza patients as well(4, 13). Whether these infections are 
associated with increased mortality or merely reflect a manifestation of immunosuppression 
is not elucidated yet.
Influenza patients represent a heterogeneous patient population, presenting various 
age categories, comorbidities and are often treated with a diverse range of medical therapies, 
such as antibiotics, antiviral and immunosuppressive drugs. Due to this heterogeneity, it 
is not fully clarified which factors are protective and which factors are on the other hand 
associated with increased mortality in these patients.
Although the impact of seasonal influenza varies depending on the type of virus, timing of 
the season, vaccine coverage and effectiveness of the vaccine, the rate of influenza-associated 
hospitalization places a substantial burden on health care resources. More importantly, 
early recognition of certain factors that influence the disease course of influenza-infected 
patients may improve current therapy strategies. In the present study, we investigated a 
cohort of influenza patients (2015–2016 season) admitted to two university hospitals in the 
Netherlands, to identify factors that are related to ICU admission and mortality. In addition, 
we investigated the incidence of influenza-associated pulmonary co-infections, their 
causative pathogens and their relationship with ICU admission and mortality.
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METHODS
Patient population
Data was collected from influenza patients who were admitted to the Radboud university 
medical center (Radboudumc) or Maastricht university medical center (MUMC), both located 
in the Netherlands. The local institutional review boards approved the protocol (METC 
16–4-195 and CMO 2016–2777). The influenza epidemic of 2015–2016 started on November 
1st 2015 and ended on May 1st 2016 according to the National Institute for Health and the 
Environment (RIVM Rapport 2016–0071). Patients who were admitted to the participating 
hospitals between October 1st 015 and April 1st 2016 were checked for eligibility for the study. 
Cases were identified using a database of the microbiology departments at both medical 
centers. Patients who were admitted to the hospital with clinical symptoms due to an acute 
infection with Influenza A or B were included. Virus samples were obtained from nose/throat 
swabs, sputum or bronchoalveolar lavage (BAL). The laboratory of microbiology of both 
hospitals confirmed a novel influenza infection by positive polymerase chain reaction (PCR; 
Diagenode, Belgium) for either influenza A (H1N1 / H2N3) or influenza B(14). No distinction was 
made between self-referral, scheduled admission or emergency hospital admission. Patients 
who were initially admitted to regional hospitals before admittance to one of the university 
medical centers were included if they met the case definition and had not received antibiotic 
or antiviral treatments before admission. Patients with a positive influenza PCR who were 
already admitted to the hospital were excluded from the study if the sample was collected as 
part of a routine screening and no prior symptoms of infection were observed. The initial day 
of hospital admission was defined as day 0.
Data collection and study design
Detailed information was collected on demographics, comorbid medical conditions, use of 
immunosuppressive medication before hospitalization or chemotherapy, self-reported date 
of onset of illness, clinical signs and symptoms at presentation, need for treatment at the 
ICU, occurrence of organ failure, development of bacterial, fungal or viral co-infections, use 
of neuraminidase inhibitors (oseltamivir), need for antimicrobial therapy and final outcome.
BMI was subdivided in underweight (<18 kg/m2), normal weight (18 to 25 kg/m2), 
overweight (25 to 30 kg/m2) and obese (>30 kg/m2). Pregnancy was defined as any 
gestational age confirmed by ultrasonography. Ex-smokers who stopped smoking within the 
last 6 months were considered to be active smokers. Occasional alcohol consumption was 
defined as <21 international units (IU)/week and regular alcohol consumption was defined 
as >21 IU/week. Use of medication or chemotherapy was defined as current use or the use 
in the former 3 months. Comorbid medical conditions included: OSAS, defined as an apnea-
hypopnea index (AHI) ≥ 5 with associated symptoms (eg, excessive daytime sleepiness, 
fatigue, or impaired cognition) or an AHI of 15 or greater, regardless of associated symptoms, 
CSAS defined as: AHI > 5 with >50% of the respiratory events occurring without any respiratory 
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effort and associated with symptoms of either excessive sleepiness or disrupted sleep(1), 
asthma, Chronic Obstructive Pulmonary Disease (COPD) and other pulmonary diseases, 
hypertension, myocardial infarction, heart failure and other cardiovascular diseases, hepatic 
diseases, renal diseases, stroke and other neurological or neurodegenerative diseases, 
diabetes mellitus and other endocrine diseases, autoimmune diseases and malignancies. 
Comorbidities were considered present if they were mentioned in the patient's medical file 
or by the use of typical medication for a particular condition (e.g. insulin therapy for diabetes 
mellitus). Comorbidities were considered absent if the medical file stated that the patient 
has previously been healthy.
Patient delay was defined as the number of days from the onset of illness to hospital 
admission. Length of stay (for either hospital or ICU) was defined as the number of days 
from admission to discharge or death. Re-admission <7 days after discharge was considered 
as a continuous stay. ICU admission criteria included a quick deteriorating disease course 
with potential need for vasopressive therapy and/or mechanical ventilation. Organ failure 
was defined when ≥3 points on the SOFA scale were scored for a particular organ system(15). 
Circulatory failure was defined as a mean arterial pressure (MAP) <65 mmHg, a decrease 
in MAP >20 mmHg relative to baseline, the need for vasopressive therapies or intravenous 
fluids (>40 mL/kg) for ≥24 hours. Respiratory failure was defined as the need for any form 
of respiratory support, hepatic failure as a total bilirubin level > 20 μmol/L, central nerve 
system (CNS) failure as a Glasgow Coma Scale (GCS) <14 in the absence of sedatives, opioids 
or delirium. Hematological failure was defined as leukopenia, thrombocytopenia and/
or anemia. Renal failure was defined as a twofold rise in serum creatinine level relative to 
baseline, 50% reduction of glomerular filtration rate (GFR) or a urine production <0.5 mL/
kg/hr for >12 hours. Disease severity scores SAPS 2 and APACHE III were calculated in all ICU 
patients.
Pulmonary bacterial co-infection was defined as a positive bacterial culture of either 
endotracheal or endobronchial secretions or a positive urine pneumococcal antigen test 
in combination with the start of antimicrobial therapy. Pulmonary fungal infections were 
detected by fungal culture of endotracheal or endobronchial secretions or a galactomannan 
optical index in BAL (>1) / in serum (>0.5) within three weeks of influenza diagnosis(16). Viral 
infections and Pneumocystis jirovecii infections were detected by PCR. Based on recent work 
from van de Veerdonk et al., critically ill influenza patients with positive fungal cultures from 
deep pulmonary material (endotracheal or endobronchial secretions) were considered to be 
positive for pulmonary fungal infections(8).
Oseltamivir was started according to the local hospital protocol. Consequently at the 
Radboudumc, it was started in all influenza patients who suffered from clinical symptoms 
<5 days at admission. At the MUMC, oseltamivir was started in all influenza patients who 
had symptoms up to 48 hours at admission. Exceptions included immunocompromised 
patients or patients with an interstitial or secondary bacterial pneumonia. In these patients, 
oseltamivir was started even after 48 hours.
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All data were abstracted from the patients' records and included: admission history, daily 
doctor's report, discharge letter, physical measurements, laboratory information system and 
information from ICU surveillance systems.
Statistical analysis
Categorical data were analyzed using Fisher exact tests. Continuous variables were analyzed 
using binary logistic regression. P-values were two-sided and values of <0.05 were considered 
statistically significant. Statistical analyses were performed using SPSS Statistics for Windows, 
Version 22.0 (IBM Corp., Armonk, NY, USA). An univariate descriptive analysis was performed 
to identify risk factors for ICU admission in patients admitted to the hospital for influenza 
virus infection. Chi-square tests and one-sided Fisher exact tests were used for dichotomous 
variables, unpaired t-tests for normally distributed continuous variables, and Mann-Whitney 
U tests for non-normally distributed continuous data. All results were verified with a logistic 
regression model. Next, a multivariate logistic regression was used to identify independent 
risk factors. Variables with a significance level of p < 0.05 were selected and those with the 
greatest odds ratio were included for the number of cases in the ICU-group. All individual 
variables in the multivariate model were tested on interaction. Odds ratios (OR) and 95% 
confidence intervals (CI) were calculated for each individual risk factor.
RESULTS
Demographic characteristics
A total of 200 cases were identified. Data of one patient missed a lot of values and was excluded 
from further analysis. Demographic characteristics of the remaining 199 patients are listed in 
Table 1. The median age of the entire patient population was 56[30–67] years, including 31 
children (<18 years; 16%) and 52 elderly patients (>65 years; 26%). 76/199 patients (38%) had 
a history of pulmonary disease, of which predominantly COPD. Pre-existing hypertension 
was reported in 101/199 patients (51%). Pre-existing neurological, renal and hepatic disease 
was documented in 65/199 (33%), 39/199 (20%) and 12/199 (6%) patients at admission. 
119/199 (60%) patients were considered immunocompromised, when the systemic use 
of steroids and other immunosuppressive drugs was evident before hospitalization. The 
median duration of hospitalization was 5 [[2], [3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13]] 
days. The overall mortality rate was 18/199 (9%).
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Table 1. Characteristics of patients with influenza virus infection admitted to the hospital 
Demographic data (n=199)
Gender [Male/Female] 109/90 (55%)
Age group (in years)
< 18 31/199 (16%)
18-65 116/199 (58%)
>65 52/199 (26%)
BMI1, 2 (kg/m2)
<18 11/167 (7%)
18 - <25 85/167 (51%)
25 - <30 40/167 (24%)
≥30 31/167 (19%)
Pregnancy 3/90 (3%)
Smoking habit3 53/134 (40%)
Ex-smoker 19/134 (14%)
Active smoking 34/134 (25%)
Alcohol consumption4 39/117 (33%)
Pulmonary disease (any) 76/199 (38%)
Asthma 17/199 (9%)
COPD 25/199 (13%)
OSAS 9/199 (5%)
Other 41/199 (21%)
Cardiovascular disease (any) 101/199 (51%)
Myocardial infarction 18/199 (9%)
Hypertension 66/199 (33%)
Heart failure 12/199 (6%)
Other 83/199 (42%)
Hepatic disease 12/199 (6%)
Renal insufficiency 39/199 (20%)
Neurological disease (any) 65/199 (33%)
Stroke 10/199 (5%)
CNS tumor 6/199 (3%)
Other 56/199 (28%)
Immunocompromised state (any) 119/199 (60%)
Diabetes 23/199 (12%)
Use of systemic steroids 67/199 (34%)
Use of immunosuppressants 47/199 (24%)
1 Children (≤ 6 years) were excluded
2 Data of 12 patients were missing
3 Data of 65 patients were missing 
4 Data of 65 patients were missing 
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Clinical characteristics
The majority of patients suffered from Influenza type A (141/199; 71%) (Table S1, 
supplementary material). Influenza subtyping was performed in 75/141 (53%) patients 
with type A influenza and showed that 74/75 (99%) suffered from subtype H1N1. Cough 
(161/197; 82%), fever (146/197; 74%), dyspnea, defined as the subjective feeling of shortness 
of breath (107/197; 54%) and general discomfort (100/197; 51%) were the most common 
reported symptoms at admission. Oseltamivir was administered during admission in 
92/199 (46%) patients. 53/199 patients (27%) already received antibiotic treatment before 
hospital admission, 89/199 patients (45%) were administered antibiotic treatment upon 
hospital admission and 17/199 (9%) patients received antibiotics at later time points 
during hospitalization. Empirical treatment at the ICU for community-acquired pneumonia 
consisted of ceftriaxone 2000 mg mg 2 times a day and of piperacillin-tazobactam 4500 mg 3 
times a day for hospital-acquired pneumonia, according to the Dutch national guideline for 
community-acquired pneumonia in adults (SWAB)(17, 18). Antibiotic regimes were de-escalated 
when bacterial sputum cultures became positive for a specific bacterial pathogen. 45/199 
(23%) of the influenza patients were admitted to the ICU, at a median of 4 [[2], [3], [4], [5], [6], 
[7]] days after development of the first symptoms.
Factors related to ICU admission
45/199 (23%) patients were admitted to the ICU, with a mean age of 53[±22] years. Respiratory 
failure was the main cause of ICU admission: 39/45 (87%) patients received invasive 
mechanical ventilation (IMV), 4/45 (9%) patients received only non-invasive ventilation, and 
a non-rebreathing mask was applied in one (2%) patient. The median duration of IMV was 12 
[[3], [4], [5], [6], [7], [8], [9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], 
[24], [25], [26], [27], [28], [29], [30], [31], [32], [33]] days. Nitric oxide (NO) inhalation was used 
in 2/45 patients (4%), and epoprostenol inhalation in 4/45 patients (9%). One patient did not 
receive pulmonary supportive therapy (2%).
Factors related to ICU admission are shown in Table 2. OSAS/CSAS (11% vs. 3%; p=0.03), 
a history of myocardial infarction (20% vs. 6%; p=0.007) and BMI >30 kg/m2 (30% vs. 15%; 
p=0.04) were more often observed in patients admitted to the ICU. No relation was found 
between age and ICU admission (p=0.13). Influenza A infection occurred more often in the 
ICU population compared with influenza B (34 vs. 13%, p=0.007). In addition, patients who 
were admitted to the ICU developed renal failure (47% vs. 5%; p <0.001), secondary bacterial 
(36% vs. 7%; p <0.001) and fungal pulmonary infections (29% vs. 1%; p <0.001) more often 
during their hospital stay, compared with influenza patients who were not admitted to the 
ICU. Oseltamivir was administered more frequently in these patients (84% vs. 35%; p <0.001). 
After multivariate analysis, age between 50 and 65 years., OSAS/CSAS, a history of myocardial 
infarction, dyspnea and influenza type A were identified as independent factors related to 
ICU admission in influenza patients (Table 3).
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Table 2. Factors related to ICU admission, univariate analysis
Characteristic No ICU 
admission
(n = 154)
ICU 
admission
(n = 45)
OR 95% CI p- 
value
Male sex 88/154 (57.1%) 21/45 (46.7%) 1.524 [0.782-2.969] 0.236
Age group (years) [mean] 46.82 53.02 0.126
<18 24/154 (15.6%) 7/45 (15.6%) 0.998 [0.073-0.636] 0.002
18-50 48/154 (24.0%) 4/45 (8.9%) 0.215 [0.073-0.636] 0.002
50-65 37/154 (62.7%) 22/45 (48.9%) 3.025 [1.515-6.040] 0.003
>65 45/154 (29.2%) 12/45 (26.7%) 0.881 [0.418-1.858] 0.852
BMI kg/m2 [mean]1,2 24.80 27.01 0.058
>30 19/127 (15.0%) 12/40 (30.0%) 2.436 [1.058-5.607] 0.039
Active smoking3 22/104 (21.2%) 12/30 (40.0%) 2.485 [1.042-5.925] 0.055
Alcohol consumption4 29/97 (29.9%) 10/20 (50.0%) 2.345 [0.881-6.238] 0.117
New renal failure 7/154 (4.5%) 21/45 (46.7%) 18.375 [7.049-47.897] <0.001
Pulmonary disease (any) 52/154 (77.4%) 24/45 (53.3%) 2.242 [1.142-4.399] 0.023
OSAS/CSAS 4/154 (2.6%) 5/45 (11.1%) 4.688 [1.203-18.268] 0.029
Cardiovascular disease (any) 73/154 (47.4%) 28/45 (62.2%) 1.828 [0.925-3.610] 0.092
Myocardial infarction 9/154 (5.8%) 9/45 (20.0%) 4.028 [1.492-10.877] 0.007
Immunocompromised state 
(any)
91/154 (59.1%) 28/45 (62.2%) 1.140 [0.576-2.257] 0.733
Symptoms5
Fever 121/154 (78.6%) 25/43 (58.1%) 0.379 [0.185-0.776] 0.010
Dyspnea 74/154 (48.1%) 33/43 (76.7%) 3.568 [1.644-7.743] 0.001
Duration6 (days) [mean] 3.56 2.39 0.474
Influenza type A (vs. B) 102/154 (66.2%) 39/45 (86.7%) 0.302 [0.120-0.759] 0.009
Pulmonary bacterial co-
infection
10/154 (6.5%) 16/45 (35.6%) 7.945 [3.279-19.252] <0.001
Pulmonary fungal co-infection 2/154 (1.3%) 13/45 (28.9%) 30.875 [6.641-143.459] <0.001
First antibiotic treatment
Before admission 39/154 (25.3%) 14/45 (31.1%) 1.332 [0.643-2.758] 0.448
At admission 68/154 (44.2%) 21/45 (46.7%) 1.107 [0.568-2.155] 0.865
Use of oseltamivir 54/154 (35.1%) 38/45 (84.4%) 10.053 [4.206-24.030] <0.001
1 Children (≤ 6 years) were excluded
2 Data of 12 patients were missing
3 Data of 65 patients were missing 
4 Data of 65 patients were missing 
5 Data of 2 patients were missing
6 Duration first symptoms until hospital admission 
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Table 3. Independent factors related to ICU admission, multivariate logistic regression analysis. 
Characteristic OR 95% CI p-value
Age 50-65 years 3.85 [1.62-9.19] 0.002
Obesity¹ 0.95 [0.32-2.80] 0.924
OSAS 9.73 [1.30-73.06] 0.027
Myocardial infarction 4.58 [1.36-15.44] 0.014
Dyspnea 3.26 [1.26-8.47] 0.015
Influenza type A 3.66 [1.06-12.69] 0.041
OR; odds ratio, CI; confidence interval, OSA; obstructive sleep apnea, MI; myocardial infarction.
¹ Defined as a Body Mass Index >30 kg/m2.
Influenza-associated ICU mortality
A total of 45 patients were admitted to the ICU. The ICU mortality of influenza patients was 
17/45 (38%). Median SAPS2 and APACHE III scores were 46[39–55] and 99[86–116] respectively. 
Respiratory failure was the main indication for ICU admission: 40 patients received invasive 
mechanical ventilation (IMV), 4 patients non-invasive ventilation and a non-rebreathing 
mask was applied in one patient. The median duration of IMV was 12 [[4], [5], [6], [7], [8], 
[9], [10], [11], [12], [13], [14], [15], [16], [17], [18], [19], [20], [21], [22], [23], [24], [25], [26], [27], 
[28], [29], [30]] days. 9/45 (20%) patients were treated with continuous muscle relaxation for 
a median of 5 [[4], [5], [6], [7]] days. 3/9 (33%) patients who were treated with continuous 
muscle relaxation therapy deceased (p=1.00). Nitric oxide inhalation was used in 2/45 
patients (4.4%), and epoprostenol inhalation in 4/45 patients (8.9%). 17/45 (38%) patients 
were ventilated in prone position, of which 8/17 (47%) did not survive (p=0.36). Lung rescue 
therapies were used in 5 patients: 2/45 (4%) received extra-corporal CO2 removal; 3/45 (7%) 
were treated with extracorporal membrane oxygenation (ECMO).
ICU survivors were compared with non-survivors (Table 4). Patients who died suffered 
more often from diabetes mellitus (OR 7.09, CI 95% 1.23–40.75; p=0.04). Renal failure was a risk 
factor for mortality both present before or during ICU admission (OR 6.815, CI 95% 1.47–31.61; 
p=0.01 and OR 8.13, CI 95% 2.03–32.57; p=0.002 respectively). The use of immunosuppressive 
drugs (systemic steroids and non-steroids) before hospitalization showed a trend toward 
increased ICU mortality (OR 3.57, CI 95% 1.01–12.68; p=0.06 and OR 4.54, CI 95% 0.96–21.56; 
p=0.06).
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Table 4. Mortality rates of influenza patients at the ICU, univariate analysis
Characteristic Death  
(n = 17)
No death       
(n = 28)
OR  95% CI p-value
Male sex 7 (41.2%) 14 (50.0%) 1.429 [0.423-4.826] 0.759
Comorbidity
Pulmonary disease (any) 8/17 (47.1%) 16/28 (57.1%) 0.667 [0.199-2.239] 0.552
Cardiovascular disease (any) 12/17 (70.6%) 16/28 (57.1%) 1.800 [0.498-6.500] 0.528
Neurological disease (any) 9/17 (52.9%) 9/28 (32.1%) 2.375 [0.688-8.202] 0.216
Diabetes mellitus 6 (35.3%) 2 (7.1%) 7.091 [1.234-40.752] 0.039
Renal insufficiency 3 (17.6%) 3 (10.7%) 1.786 [0.317-10.061] 0.658
Immunocompromised state 
(any)
13/17 (76.5%) 15/28 (53.6%) 2.817 [0.734-10.805] 0.205
Systemic steroids 10 (58.8%) 8 (28.6%) 3.571 [1.006-12.679] 0.063
Non-steroids 6 (35.3%) 3 (10.7%) 4.545 [0.958-21.562] 0.063
Renal failure 
 Before ICU admission1 8/17 (47.1%) 3/26 (11.5%) 6.815 [1.469-31.612] 0.014
 During ICU admission
 Dialysis 
13 (76.5%) 
7 (41.2%)
8 (28.6%)
7 (25.0%)
8.125
2.100
[2.027-32.574]
[0.578-7.630]
0.002
0.326
Oseltamivir during ICU stay 15 (88.2%) 23 (82.1%) 1.630 [0.279-9.516] 0.693
Pulmonary co-infections 10 (58.8%) 15 (53.6%) 1.238 [0.366-4.187] 0.767
Bacterial 4 (23.5%) 12 (42.9%) 0.410 [0.107-1.579] 0.219
Fungal 6 (35.3%) 7 (25.0%) 1.636 [0.441-6.076] 0.511
Viral 3 (17.6%) 1 (3.6%) 5.786 [0.550-60.875] 0.144
OR; odds ratio, CI; confidence interval, OSA; obstructive sleep apnea, MI; myocardial infarction.
¹ Regarding to renal failure before ICU admission, data of 2 patients were missing
Influenza-associated pulmonary co-infections
Influenza-associated pulmonary co-infections and their causative pathogens are listed 
in Table 5. During the course of their admission, 40/199 (20.1%) of the hospitalized 
patients developed a pulmonary co-infection of either bacterial, fungal or viral origin or a 
combination of pathogens. The proportion of co-infections in ICU-admitted patients was 
significantly higher compared with patients at the normal ward (25/45, 55.6%, P <0.0001). 
This was evident for bacterial, fungal and viral pathogens (p=0.0008, p=0.0003 and p=0.02 
respectively). The most common bacterial pathogens included Staphylococcus aureus 
(11%) and Streptococcus pneumoniae (7%). Aspergillus fumigatus was most common 
among the fungal pathogens (18%), followed by Pneumocystis jirovecii (7%). Patients with 
a pulmonary co-infection received oseltamivir more often (OR 0.65, CI 95% 0.47–0.90, 
p=0.002). No association was observed between the use of immunosuppressive drugs before 
hospitalization and the development of pulmonary co-infections. Also, no relationship was 
found between the development of a pulmonary co-infection and ICU mortality (OR 1.24, CI 
95% 0.37–4.19; p=0.76).
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Table 5. Influenza-associated pulmonary co-infections 
Total number of patients with a pulmonary 
co-infection 
40/199 (20.1%) 25/45 (55.6%) p<0.0001
Bacterial infections – no. (%) 26/199 (13.1%) 16/45 (35.6%) 0.0008
Staphylococcus aureus 5/199 (2.5%) 5/45 (11.1%)
Streptococcus pneumoniae 7/199 (3.5%) 3/45 (6.7%)
Haemophilus influenzae 3/199 (1.5%) 1/45 (2.2%)
Streptococcus pyogenus1 2/199 (1.0%) 1/45 (2.2%)
Bordetella bronchoseptica 1/199 (0.5%) 1/45 (2.2%)
Enterobacter cloacae 1/199 (0.5%) 1/45 (2.2%)
Escherichia coli 1/199 (0.5%) 0/45 (0%)
Haemophilus + Enterobacter spp 1/199 (0.5%) 1/45 (2.2%)
Moraxella catarrhalis 1/199 (0.5%) 0/45 (0%)
Pseudomonas spp 1/199 (0.5%) 1/45 (2.2%)
Stenotrophomonas spp 1/199 (0.5%) 1/45 (2.2%)
Unknown pathogen 2/199 (1.0%) 1/45 (2.2%)
Fungal infections – no. (%) 15/199 (7.5%) 13/45 (28.9%) 0.0003
Aspergillus fumigatus 8/199 (4.0%) 8/45 (17.8%)
Pneumocystis jirovecii 4/199 (2.0%) 3/45 (6.7%)
Candida albicans 2/199 (1.0%) 1/45 (2.2%)
Unknown pathogen 1/199 (0.5%) 1/45 (2.2%)
Viral infections – no. (%) 8/199 (4.0%) 4/45 (8.9%) 0.0233
adenovirus + coronavirus 1/199 (0.5%) 0/45 (0%)
cytomegalovirus (CMV) 1/199 (0.5%) 1/45 (2.2%)
human metapneumovirus 1/199 (0.5%) 0/45 (0%)
parainfluenza 2/199 (0.5%) 0/45 (0%)
parainfluenza + herpes simplex virus (HSV) 1/199 (0.5%) 0/45 (0%)
respiratory syncytial virus (RSV) 1/199 (0.5%) 1/45 (2.2%)
Unknown pathogen 1/199 (0.5%) 0/45 (0%)
¹ Haemolytic streptococcus group A.
 
DISCUSSION
The present study supports the high morbidity and mortality rates of influenza patients 
admitted to the ICU described in previous work(1, 19). Independent factors related to ICU 
admission in the 2015–2016 seasonal influenza outbreak were influenza type A, dyspnea, a 
history of myocardial infarction and OSAS/CSAS. Co-infections with bacterial, fungal and viral 
pathogens developed more often in patients who were admitted to the ICU.
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Similar to previous seasons, our data indicate that pre-existing respiratory disease is 
associated with ICU admission in the 2015–2016 influenza season(20). From our database, 
dyspnea appeared to be the most determinative clinical sign for influenza-associated ICU 
admission. Also, OSAS/CSAS could be a new independent factor related to ICU admission, 
although the total numbers of patients in this group was only 9. Possibly, a decreased 
breathing quality weakens pulmonary function in OSAS/CSAS patients and thereby increases 
the risk for ICU admission. Other mechanisms may influence pulmonary function as well, 
such as activation of the sympathetic nervous system, vascular endothelial dysfunction, 
inflammation and oxidative stress as described as OSAS/CSAS-related (cardiovascular) 
complications(21).
The number of patients in our cohort with influenza A virus infections was substantially 
higher than the number of patients with influenza B virus infections, which is usually the 
case in influenza epidemics(22). H1N1 was most prevalent in our study cohort, which is 
representative for the global prevalence of this subtype in the community during the 2015–
2016 influenza season(22). In our study, patients with influenza type A were admitted more 
often to the ICU than patients with subtype B, probably due to H1N1 being the most prevalent 
circulating subtype during this season. In addition, H1N1 is associated with a more severe 
disease course and higher mortality rates, compared with influenza B and other influenza A 
subtypes like H3N2, being less virulent(22).
In the current study, 23% of hospitalized influenza patients were admitted to the ICU, 
which is more than the 5–10% described in literature(2). This could be due to selection of the 
patients, composed from a database of two tertiary centers in the Netherlands which overall 
represent the most severely ill and therefore logically associated with an increased number of 
ICU admissions. The ICU population was treated more often with oseltamivir in comparison 
with patients at the normal ward. Oseltamivir is a neuraminidase inhibitor that blocks the viral 
neuraminidase, an enzyme that is essential for the release of newly formed virions from the 
host cells. A Cochrane analysis concluded that oseltamivir reduced the time to first alleviation 
of symptoms by 16.8 hours, but had no effect on hospitalization risk(23). Oseltamivir had no 
effects on mortality among patients with type A/H1N1 influenza during the 2009 pandemic(24). 
In our study, oseltamivir was administered to every influenza patient upon admission, except 
when clinical symptoms were prevalent >5 days, most likely reflecting a less severe influenza 
disease course in these patients. The increased use of oseltamivir in patients admitted to the 
ICU is therefore more likely due to selection bias, and not a true risk factor for ICU admission. 
Also, an increasing trend for ICU mortality was observed for the systemic use of steroids 
and non-steroid immunosuppressive drugs before hospitalization. The latter suggests that 
an immunosuppressive state, caused by (pre-existent) immunomodulatory therapy or as 
a direct result of influenza infection leading to increased susceptibility toward secondary 
infections, might influence the disease course and prognosis of influenza infection. Further 
research is needed to identify risk factors for a complicated disease course.
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Co-infections were more often observed in patients admitted to the ICU, which could 
probably be the result of an influenza-induced immunosuppressed state, which hampers the 
initiation of an adequate immune response to eradicate invading pathogens. As expected, 
Staphylococcus aureus and Streptococcus pneumonia were the most common bacterial 
pathogens determined, prevalent in respectively 11% and 7% of influenza patients at the 
ICU, causing a transition from normal colonization of the upper respiratory tract to infectious 
disease(5, 25). Influenza predisposes to secondary infections by direct effects, including the 
disruption of epithelial cell barriers and suppression of the production of antibacterial 
peptides and upregulation of bacterial adhesion molecules(1, 26, 27), but also by indirect 
immunomodulatory effects, such as impairing antigen presenting capacity in the draining 
lymph nodes(27, 28) and altered expression of costimulatory molecules and cell surface 
receptors(5, 27, 28). The high incidence of fungal co-infections in the subgroup of ICU patients, 
in particular caused by Aspergillus fumigatus (18%) is in line with previous reports, showing 
that the pathogen Aspergillus fumigatus is observed in 20–25% of influenza patients(7, 29-34). 
The high incidence of co-infections caused by Streptococcus pneumonia, Staphylococcus 
aureus and Aspergillus fumigatus indicates that a specific immune defect could be present 
in influenza patients, increasing the susceptibility toward these pathogens, which is currently 
under investigation(35). Our data indicates that although pulmonary co-infections are more 
often observed in ICU patients, compared with patients at the normal ward, this is not 
necessarily associated with increased mortality. The majority of previous studies illustrate 
increased mortality resulting from infections with Staphylococcus aureus, Pseudomonas 
aeruginosa and Aspergillus spp. following influenza infection(4, 36, 37). Possibly, the increased 
mortality could not be demonstrated due to the low number of patients in the current study. 
Of note, we cannot exclude that the high incidence of pulmonary fungal and bacterial co-
infections in the current study is related to selection bias, because both selected hospitals 
for this study are tertiary hospitals, generally receiving the most severely ill influenza patients.
In our population, in-hospital mortality was 9% and ICU mortality reached 38%. The 
majority of patients died from therapy-resistant respiratory failure and multi-organ failure. 
These relatively high mortality rates may be attributed to the influenza virus itself. However, 
the 2015–2016 seasonal influenza epidemic in the Netherlands did not result in increased 
mortality compared with previous seasonal outbreaks (RIVM, Rapport 2016–0071). More 
likely, this high in-hospital and ICU-associated mortality is a reflection of the referral function 
of a tertiary center.
Other limitations to our study include the large spreading of some data and relatively 
small sample size of the study cohort, arising from one seasonal outbreak and subsequently 
limited events in the regression models. Also, the method of analyses could have influenced 
the data. In the current study, we used the Frequentist interpretation that views probability 
as the limit of the relative frequency of an event after a large number of trials. This instead 
of for example the Bayesian approach in which the conditional probability of an event 
based on data as well as prior information about the event or conditions related to the 
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event is taken into account. All factors above have influenced the scientific impact of the 
data. However, even with the limited number of study subjects, independent risk factors 
and several statistical significant relationships were identified using a multivariate logistic 
regression analysis. However, complications logically occur in the most severely ill and one 
could suggest that these factors would therefore merely reflect disease severity than being 
true risk factors. Nevertheless, despite the limited validity due to large spreading and small 
sample sizes, the identified factors may contribute to a complicated disease course and 
could represent a tool for early recognition of the influenza patients at risk for a complicated 
disease course.
CONCLUSIONS
The current study indicates that a history of OSAS/CSAS, myocardial infarction, dyspnea, 
influenza type A, BMI > 30 kg/m2, the development of renal failure and bacterial and fungal 
co-infections, were observed more frequently in influenza patients who were admitted to 
the ICU, compared with patients at the normal ward. Also, pulmonary co-infections were 
observed more often in ICU patients, mainly caused by Staphylococcus aureus, Streptococcus 
pneumoniae, and Aspergillus fumigatus. Last, non-survivors suffered from diabetes mellitus 
and (pre-existent) renal failure more often.
AVAILABILITY OF DATA AND MATERIAL
The datasets used and analyzed in the current study are available at the corresponding 
author on reasonable request. All data generated or analyzed during this study are included 
in this published article.
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patients is not explained by systemic 
immunoparalysis 
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ABSTRACT
 
Introduction: Aspergillosis occurs in 20-25% of influenza patients at the ICU, suggesting that 
an immune defect may account for this increased susceptibility to Aspergillus fumigatus. In 
bacterial sepsis, systemic immunosuppression called “immunoparalysis” often develops, 
which is associated with the development of secondary infections. 
Methods: In the current study, we studied various aspects of the immune response in 
patients with severe influenza infections that were admitted to the ICU to elucidate whether 
influenza induces systemic immunoparalyis that could explain the increased susceptibility 
to Aspergillus fumigatus infections. We compared these patients with patients suffering from 
bacterial pneumonia, isolated neurotrauma, healthy individuals, and healthy volunteers 
who were intranasally challenged with the live-attenuated influenza vaccine Fluenz.
Results: Circulating cytokine responses, cytokine production upon ex vivo stimulation of 
PBMCs with various ligands and populations of IFNγ-, IL-17A-, and IL-22-producing T-cells 
were not altered in influenza patients, compared with the control groups. Also, in healthy 
volunteers challenged with Fluenz, no effects on ex vivo cytokine production were observed.
Conclusions: Severe influenza infection does not result in systemic immunosuppression 
that may explain the increased susceptibility to Aspergillus fumigatus. Additional studies are 
crucial to elucidate the factors underlying influenza-induced aspergillosis. 
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INTRODUCTION
Influenza infection is generally a self-limiting disease without major complications. However, 
it may result in an uncontrolled detrimental hyperinflammatory immune state(1). Intriguingly, 
patients may also exhibit hallmarks of profound immunosuppression(2), associated with 
an increased incidence of secondary infections. Bacterial co-infections caused by, e.g., 
Staphylococcus aureus or Streptococcus pneumoniae are frequently observed in influenza 
patients(3), but also infections caused by the opportunistic pathogenic fungus Aspergillus 
fumigatus have recently been recognized as a significant complication of influenza infection(4, 
5). Approximately 20-25% of influenza patients who require admission to the intensive care 
develop invasive pulmonary aspergillosis (IPA), which is associated with high mortality rates(4, 
6-11). This high incidence of influenza-associated aspergillosis may suggest that a severe 
influenza infection causes a systemic immune defect that may account for the increased 
susceptibility toward this particular fungal infection. The characterization of inflammatory 
responses against Aspergillus fumigatus and other immunogenic stimuli by circulating 
immune cells of patients may demonstrate such an underlying immune defect.
Following bacterial sepsis, systemic immunosuppression called “immunoparalysis” may 
develop, which is associated with the development of secondary infections. Immunoparalyis 
is characterized by functional defects in circulating leukocytes, causing alterations in antigen-
presenting ability and cytokine production capacity(12, 13), but also in tissue-resident cells 
obtained from postmortem organ samples of sepsis patients, which show depletion of splenic 
CD4+, CD8+, and HLA-DR+ cells, and increased expression of PD-L1 on various immune cells(14, 15). 
          In influenza patients, it is not clarified what mechanisms may contribute to the increased 
susceptibility to secondary infections. Several murine models demonstrate an influenza-
induced hyperinflammatory state upon subsequent LPS administration(16). Murine influenza 
infection also results in augmented systemic and pulmonary inflammation, which is associated 
with enhanced pulmonary neutrophil influx, upon a secondary bacterial infection(17, 18). 
However, other studies in influenza-infected mice show local immunosuppression upon 
bacterial co-infection, demonstrated by attenuated pulmonary pro-inflammatory cytokine 
levels(19, 20), less recruitment and/or impaired functionality of neutrophils, natural killer (NK)-
cells and tissue-resident macrophages(18, 20, 21), leading to impaired phagocytosis, attenuated 
microbial killing, and impaired antigen presentation. However, whether influenza infection 
causes systemic immunoparalyis, as observed during bacterial sepsis, remains unknown. 
We studied various aspects of the immune response in patients with severe influenza 
infections who were admitted to the ICU, to elucidate whether or not influenza induces systemic 
immunoparalyis that could explain the increased susceptibility to Aspergillus fumigatus 
infections. We compared these patients with other patients admitted to the ICU without 
influenza, such as patients suffering from bacterial pneumonia or isolated neurotrauma, 
healthy individuals, and volunteers who were intranasally challenged with Fluenz, a live-
attenuated influenza vaccine (LAIV), used as a model for an actual influenza infection. 
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METHODS
Study design
The study was carried out in the Netherlands in accordance with the applicable rules 
concerning the review of research ethics committees and informed consent. All legal 
representatives were informed about the study details. All procedures complied with the 
Declaration of Helsinki including current revisions and the Good Clinical Practice guidelines. A 
total of 7 adult influenza patients who were admitted to the intensive care department of the 
Radboud University Medical Center in Nijmegen during the influenza seasons of 2012-2016, 
were included. In this period, only patients with influenza A (H1N1>H3N2), by far the most 
common influenza type, were included. Influenza infection was diagnosed by strong clinical 
suspicion and/or positive Polymerase Chain Reaction (PCR) measured in bronchoalveolar 
lavage (BAL) fluid. Diagnosis of influenza-associated aspergillosis was made by positive 
influenza PCR and a galactomannan measurement in the blood of ratio >0.5 and/or BAL of 
ratio >1.0, as described previously(22). Candida spp. were assessed by positive antigen in blood 
and Pneumocystis spp. were assessed by positive specific PCR in BAL fluid. Viral reactivation 
of cytomegalovirus (CMV) was determined by PCR in BAL fluid as described previously(23). 
Bacterial pneumonia was defined as a strong clinical suspicion of bacterial pneumonia 
and/or positive bronchial / sputum culture for Staphylococcus aureus / Streptococcus 
pneumoniae, or positive PCR for other bacterial pathogens in BAL fluid. In total, 7 patients 
with bacterial pneumonia, 6 patients with an isolated neurotrauma, and 10 healthy controls 
were included as controls. The local ethics committee of the Radboud university medical 
center approved the blood donation for the healthy volunteers (CMO 2010/10). Arterial blood 
from all patients was drawn from an arterial catheter that was already in place within 24 hours 
of ICU admission and venous blood was obtained from the healthy volunteers who provided 
written informed consent. Blood was used for assessment of circulating cytokines and ex 
vivo cytokine responses of peripheral blood mononuclear cells (PBMCs). Also, populations of 
IFN-γ-, IL-17A-, and IL-22-producing T-cells were measured by intracellular staining followed 
by flow cytometry. In addition, to further explore the effects of influenza infection on innate 
immunity, we measured ex vivo cytokine responses of PBMCs obtained from 15 healthy 
volunteers who were intranasally challenged with Fluenz, a live-attenuated influenza vaccine 
(LAIV) used as a model for an actual influenza infection in the context of an earlier study from 
our group (NCT02642237(24)). In this study, blood was sampled at baseline, 2, 14 and 29 days 
after Fluenz inoculation. Details of the Fluenz challenge study are provided elsewhere(24). 
Ex vivo PBMC stimulation
PBMCs were isolated from ethylenediaminetetraacetic acid (EDTA)-anticoagulated 
blood as described previously(25). Cells were counted using a particle counter (Beckmann 
Coulter, Woerden, The Netherlands) and cell numbers were adjusted to 5×106/mL. PBMCs 
were plated in 96-well round-bottom plates (Corning, NY, USA) at a final concentration of 
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2.5×106/mL and in a total volume of 200 μL. PBMCs were stimulated with 100 µL of culture 
medium (RPMI [Invitrogen, Carlsbad, California, USA] supplemented with 50 μg/mL 
gentamicin, 2 mM Glutamax (Gibco) and 1 mM pyruvate), Escherichia coli lipopolysaccharide 
(LPS; 10ng/mL; serotype 055:B5; Sigma-Aldrich, St. Louis, MO, USA) Pam3Cys (10 µg/
mL; EMC microcollections), heat inactivated Candida albicans (Ca; 1x106/mL; UC820), 
phytohemaglutinin (PHA; 10µg/mL SIGMA) and live Aspergillus fumigatus resting conidia 
(Asp+; 1x107/mL; V05-27). Plates were incubated at 37°C, 5% CO2 for 24 hours, 48 hours, or 
7 days. Seven-day cultures were supplemented with 10% human serum. After incubation, 
culture supernatants were collected and stored at -20°C until cytokine measurements were 
performed. PBMCs of the Fluenz-treated subjects were ex vivo stimulated with LPS (LPS; 
10ng/mL; serotype 055:B5; Sigma-Aldrich, St. Louis, MO, USA), Staphylococcus aureus (1x106/
mL, clinical isolate) and C. albicans (Ca; 1x106/mL; UC820) following the same protocols. 
Cytokine analysis
For assessment of plasma cytokine levels, EDTA-anticoagulated blood was centrifuged 
(2000g, 4˚C, 10 min) and stored at -80°C until analysis. Concentrations of cytokines in plasma 
and supernatants of PBMCs obtained from Fluenz-challenged subjects were determined 
by a simultaneous Luminex assay (R&D systems; Abingdon Science Park, UK). The lower 
detection limit was 3.2 pg/mL for all cytokines measured. Cytokines in supernatants of ex 
vivo stimulated PBMCs from the other subjects / patients were measured using ELISA (R&D 
Systems). Lower detection limits were: 78 pg/mL for IL-1β, 780 pg/mL for IL-1Ra, 78 pg/mL for 
TNF-α and 15.6 pg/mL for IL-6. 
Flow cytometry
PBMCs were isolated as described above and incubated for 4–6 hours with phorbol myristate 
acetate (PMA) (50 ng/mL) (Sigma-Aldrich, Tubingen, Germany), ionomycin (1 μg/mL) (Sigma-
Aldrich) and GolgiPlug (BD Biosciences, Breda, The Netherlands) according to the protocols 
supplied by the manufacturers. Cells were stained extracellularly using PE-Cy7–conjugated 
anti-CD4 (BD Biosciences, Franklin Lakes, New Jersey). Subsequently, cells were fixed and 
permeabilized with Cytofix/Cytoperm solution (eBioscience, Waltham, MA USA) according to 
the protocol supplied by the manufacturer. Following permeabilization, cells were stained 
intracellularly with Alexa 647–conjugated anti–IL-17A (BD Biosciences), PE-conjugated 
anti–IL-22 (R&D systems) and FITC-conjugated anti–IFNγ (eBioscience). To determine the 
populations of IL-17-, IL-22-, and IFNγ-producing T-cells measurements were performed 
on a FC500 flow cytometer (Beckman Coulter) and data were analyzed using CXP analysis 
software v2.2 (Beckman Coulter, Brea, California). 
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Statistical analysis
Because of the relatively small group sizes, normal distribution of data could not be assumed 
and data are presented as medians [IQR]. Between-group comparisons were made using 
Kruskal-Wallis tests with Dunn’s post-hoc tests. Within-group comparisons were made using 
repeated measurements ANOVA with Bonferroni post-hoc tests. Statistical analyses were 
performed using GraphPad Prism version 5.03 (GraphPad Software, San Diego, CA, USA). 
p-values <0.05 were considered statistically significant. 
RESULTS
Demographic characteristics
Demographic and clinical characteristics of the study population are listed in  Table 1. 4/7 
(58%) of influenza patients were positive for Aspergillus fumigatus, with fungal colonization 
of Candida spp. and/or co-infections with Pneumocystis spp. in two patients. Reactivation 
of CMV in BAL was observed in 2/7 (29%) of influenza patients. In patients with bacterial 
pneumonia, bacteria were isolated from bronchial / sputum cultures in 3/7 (42%) patients, 
all three caused by Staphylococcus aureus / Streptococcus pneumoniae, compared with 3/6 
(50%) of neurotrauma patients, all three caused by Staphylococcus aureus. In two of these 
neurotrauma patients, Staphylococcus aureus cultures became positive at day 5 and day 10 
and was accompanied by signs of pulmonary infection, whereas in one of these patients 
Staphylococcus aureus culture was already positive at time of admission and no signs of 
infection were evident. 
Plasma cytokine concentrations
Overall, plasma levels of most cytokines tended to be higher in ICU patients compared to 
healthy controls (Figure 1). No significant differences were observed in circulating plasma 
cytokine levels between patients with influenza and those with bacterial pneumonia or 
neurotrauma (Figure 1). 
Ex vivo cytokine production 
Except for a more pronounced TNF-α and IL-1β production in influenza patients upon 
stimulation with Candida albicans, ex vivo stimulation of PBMCs with most stimuli revealed 
no consistent differences in cytokine responses between influenza patients and the two 
groups of other ICU patients or healthy controls (Figure 2). 
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Figure 1: Plasma levels of TNF-α, IFNγ, IL-1β, IL-6, IL-17, IL-22, IL-1RA, and IL-10 measured within 24 hours 
of ICU admission in all four study groups. Data are presented as Box and Whisker plots. * indicates p<0.05 
calculated using Kruskall Wallis tests.
Figure 2: Production of TNF-α, IL-1β, IL-6 and IL-1RA in the four study groups after ex vivo stimulation of 
PBMCs with RPMI, LPS, P3C, Candida albicans (Ca) and live Aspergillus fumigatus (Asp+) and PHA. Data are 
presented as Box and Whisker plots. * indicates p<0.05 calculated using Kruskall Wallis tests. 
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In two patients with influenza-associated aspergillosis, a severe clinical hyperinflammatory 
state at ICU admission was observed. This was characterized by clinical signs of systemic 
inflammation (high fever, shivering etc.), vasodilatory shock, leukocytosis at admission and 
high levels of circulating cytokines and/or following ex vivo stimulation. In one of these two 
patients, the ex vivo immune response was examined in more detail by consecutive blood 
sampling at days 0, 1, and 7, and stimulation of PBMCs with live Aspergillus fumigatus. In 
this patient, hallmarks of an initial hyperinflammatory state were observed, characterized 
by a high production of TNF-α, IL-1β, and IL-6, whereas an immunosuppressed state was 
apparent on day 7, evidenced by completely abolished ex vivo cytokine production (Figure 3). 
Figure 3: Production of TNF-α, IL-1β and IL-6 after ex vivo stimulation with live Aspergillus fumigatus (Asp+) 
at day 0, day 1 and day 7 in one patient who developed IPA directly after influenza infection, present at ICU 
admission. 
In healthy volunteers who were intranasally challenged with the live-attenuated influenza 
vaccine Fluenz, no significant alterations in ex vivo cytokine production were observed at any 
of the time points following Fluenz inoculation compared to baseline (Figure 4). 
Expansion of cytokine-producing T-cells
Influenza patients exhibited increased percentages of circulating IL-22+ T-cells compared with 
healthy controls, while the percentages of IL-17A+ and IFNγ+ T-cells were comparable to those 
observed in healthy controls (Figure 5). 
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Figure 4: Production of TNF-α, IFNγ, IL-1β, IL-6, IL-1RA, IL-10, IL-17 and IL-22 in 15 Fluenz-inoculated healthy 
subjects upon ex vivo stimulation with LPS. Staphylococcus aureus and Candida albicans. Data are presented 
as Median and Error [IQR]. BL=baseline (Fluenz inoculation).
Figure 5: Percentage of IL-17A, IL-22, and IFNγ production within T-cells of the four study groups after staining 
and flow cytometry analysis. Data are presented as Box and Whisker plots. * indicates p<0.05 calculated using 
Kruskall Wallis tests.
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Patients with bacterial pneumonia had increased percentages of IL-22+ and IL-17A+ T-cells 
compared with healthy controls. In contrast, patients with neurotrauma did not show 
significant differences in the proportion of IL-17-, IL-22-, and IFNγ-producing T-cells compared 
with healthy volunteers.
DISCUSSION 
In the present study different cohorts of patients and volunteers were investigated to 
decipher whether patients suffering from influenza without or with secondary Aspergillus 
infection demonstrate a different immunologic phenotype that may explain the increased 
susceptibility to Aspergillus, compared to other patient groups and healthy volunteers who 
are not known for an increased susceptibility to Aspergillus. Immunoparalysis, characterized 
by an attenuated capacity of circulating immune cells to mount pro-inflammatory cytokine 
responses were not observed in patients with severe influenza and therefore cannot explain 
the increased susceptibility toward Aspergillus fumigatus observed in these patients. Our 
finding that influenza infection is not related to immunosuppression markedly differs from 
several studies that show that patients with bacterial sepsis exhibit profoundly reduced ex 
vivo cytokine responses(26-29) and most patients exhibit immunoparalysis directly following 
the initial infection. Nevertheless, not all studies confirm this(30-32), as observed with the 
variation in cytokine profiles depending on variation in age(32) or, in multiple trauma patients, 
the time between the trauma and development of sepsis(31).
In our study, no attenuated ex vivo cytokine production upon stimulation with various 
ligands was observed in influenza patients compared with healthy controls. Accordingly, 
no effects on ex vivo cytokine production after challenge with the live-attenuated influenza 
vaccine Fluenz were observed in a homogeneous group of healthy volunteers. In accordance, 
circulating cytokine responses following experimental endotoxemia were not affected 
by exposure to Fluenz(24), illustrating that Fluenz exposure does not induce systemic 
immunosuppression. Of note, all our critically ill influenza patients were treated with 
systemic steroids (2x25mg prednisolon/day), but even in this setting, no impairment in ex 
vivo cytokine production was observed. Since the other critically ill patients in the control 
cohorts did not receive systemic steroids, one may argue that an actual influenza-induced 
primed immune response may have existed in influenza patients, but that this response 
was masked by the immunosuppressive effects of steroids. Studies in influenza patients 
who did not receive steroids could elucidate whether this theory is true or not. Likewise, 
two individual influenza patients in the current study who tested positive for Aspergillus 
fumigatus showed hyperinflammation at time of hospitalization, as at early time-points they 
displayed severe clinical signs of infection and exhibited high levels of circulating cytokines 
and/or increased cytokine responses to ex vivo stimulation. This may relate to the influenza-
induced involvement of the respiratory endothelium and/or epithelia inducing an ongoing 
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stimulation of the pro-inflammatory immune response(34, 35). For this reason systemic steroids 
are part of the general treatment for severe influenza infections(36). 
Our finding that influenza-induced systemic immunoparalysis is not apparent and the 
fact that influenza-associated secondary infections are primarily located in the lungs(4, 37) may 
suggest that local pulmonary immunomodulatory effects, or e.g. mucosal damage(38) are of 
relevance. Previous studies demonstrate that influenza increases the susceptibility toward 
secondary infections by several direct, as well as indirect effects. First, influenza virus disrupts 
the respiratory epithelia, the primary barrier of the respiratory tract(21, 39, 40). Aspergillus is a 
saprophyte in the natural environment, meaning that it specializes to grow on dead organic 
matter. The influenza-induced destruction of pulmonary tissue may facilitate a niche for the 
fungus to grow(41). Second, pulmonary immunomodulatory mechanisms may play a role. For 
example, attenuated production of pulmonary pro-inflammatory cytokines was observed 
upon Streptococcus pneumoniae and Staphylococcus aureus challenges in mice infected with 
influenza(19, 20). T-cell responses may be impaired, characterized by suppressed production 
of IL-17A(42) and IL-22(42-44) and increased NK-cells derived IFNγ production, inducing thymic 
T-cell apoptosis(45). IL-17A suppression has been observed in patients with influenza-induced 
aspergillosis(46) and in influenza-infected mice(42), leading to an impaired clearance of 
Staphylococcus aureus(3). We also observed this in influenza patients in the current study, in 
which production of IL-22 by T-cells was increased compared with healthy controls, while the 
production of IL-17A and IFNγ remained low. 
The high incidence of specific secondary infections caused by Aspergillus fumigatus 
following influenza infection suggest that there might be a general immune defect in patients 
with severe influenza infection that underlies this increased susceptibility. Biological systems 
have been suggested to account for the influenza-induced defect and increased susceptibility 
toward Aspergillus fumigatus. For example, impaired NADPH-oxidase activity leading to 
defective reactive oxygen species (ROS) production(47) and LC3-associated phagocytosis, 
resulting in an insufficient capacity of macrophages to control Aspergillus growth(48, 49). 
Additional studies are needed to investigate these effector mechanisms in host defense 
against Aspergillus fumigatus.
Opportunistic fungal infections other than aspergillosis, such as those caused by 
Pneumocystis spp., are also commonly observed in influenza patients(50, 51). This was also 
observed in 1 of 7 of our influenza cohort. Furthermore, influenza infection may also result in 
the reactivation of viruses such as CMV(52), which was observed in 2 of our influenza patients. 
Remarkably, it has been demonstrated that in patients with CMV reactivation, the immune 
response to influenza is enhanced, demonstrated by increased CD8+ T-cell sensitivity and 
elevated levels of circulating IFNγ(52). 
Of note, half of the neurotrauma patients in our study showed positive cultures for 
Staphylococcus aureus. In two of these patients, cultures became positive at day 5 and day 
10 and was accompanied by clinical signs of pulmonary infection, whereas in one of the 
neurotrauma patients, Staphylococcus aureus culture was already positive at time of admission 
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and no signs of infection were evident, indicative for colonization with Staphylococcus 
aureus. This is in accordance to a recent study from our group, which demonstrates that 
sterile inflammation such as observed in multi trauma patients, is associated with profound 
immunosuppression and the development of secondary bacterial infections(53). In accordance, 
we have recently shown that viral reactivation is also evident in these trauma patients(54). 
CONCLUSIONS 
Collectively, our data indicates that influenza infection does not result in systemic suppression 
of immunity that may explain the increased susceptibility to Aspergillus fumigatus infections 
in these patients. Additional studies are imperative to elucidate the factors that underlie 
increased susceptibility to secondary Aspergillus-infection in patients suffering from severe 
influenza infections. 
Table 1. Demographic and clinical characteristics of all study groups. * indicates a positive bronchial / 
sputum culture for Staphylococcus aureus / Streptococcus pneumoniae or positive PCR for other bacterial 
pathogens in BAL fluid. 1 = one patient suffered from acute lymphatic leukemia (ALL) for which he received a 
recent autologous stem cell transplantation, one patient suffered from the auto-immune vasculitis: Morbus 
Wegener and one patient received azitromycine therapy for rheumatoid arthritis. 2 = prednisolon 2x25mg as 
standard treatment for influenza. 3 = prednisolon 1x80mg maintenance medication for systemic vasculitis of 
which he already recovered. NA=not applicable, ICU=intensive care unit, CMV=cytomegalovirus. 
Influenza 
virus
(n = 7)
Bacterial 
pneumonia 
(n = 7)
Isolated 
neurotrauma 
(n = 6)
Healthy 
controls 
(n = 10)
Total 
group  
(n = 30)
Male 3 5 4 6 18
Female 4 2 2 4 12
Age, median [IQR], (years) 52 [37-59] 69 [61-77] 56 [40-68] 28 [26-29] 44 [29-65]
Pre-existent 
immunocompromised1
3/7 (42%) 0/7 (0%) 0/6 (0%) NA 3 (15%)
Immunosuppressive medication 7/7 (100%)2 1/7 (14%)3 0/6 (0%) NA 8 (40%)
ICU length of stay [IQR], (days) 14 [9-19] 12 [7-20] 12 [3-32] NA 15 
Mortality 3/7 (42%) 2/7 (29%) 0/6 (0%) 0/10 (0%) 5 (25%) 
Bacterial pathogens* 0/7 (0%) 3/7 (42%) 3/6 (50%) NA 6 (30%) 
Staphylococcus aureus 0/7 (0%) 2/7 (29%) 3/6 (50%) NA 5 (25%)
Streptococcus pneumoniae 0/7 (0%) 1/7 (14%) 0/6 (0%) NA 1 (5%)
Fungal pathogens (BAL) 4/7 (58%) 1/7 (14%) NA NA NA
Aspergillus spp. 4/7 (58%) 0/7 (0%) NA NA NA
Candida spp. 3/7 (42%) 1/7 (14%) NA NA NA
Pneumocystis spp. 1/7 (14%) 1/7 (14%) NA NA NA
CMV reactivation (BAL) 2/7 (29%) NA NA NA NA
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Increased risk for secondary infections in 
trauma patients with viral reactivation
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Dear Editor,
Sepsis-induced immunosuppression increases patients’ vulnerability to develop secondary 
infections(1). Interestingly, immunosuppression is illustrated by viral reactivation, as in over 
40  % of sepsis patients viral PCRs become positive within 1–2  weeks following bacterial 
sepsis(2). Viral reactivation has been shown for viruses that reside latent in the host, such 
as cytomegalovirus (CMV), epstein barr virus (EBV), and herpes simplex virus (HSV), and its 
clinical relevance is illustrated by the fact that it is associated with an increased incidence of 
opportunistic infections and 90-day mortality in sepsis patients(1, 2).
Recently, we reported that an immunosuppressive phenotype is also present in 
multiple-trauma patients, illustrated by elevated IL-10 concentrations, a sustained decrease 
in HLA-DR expression, which was related to an increased incidence of bacterial infections(3). 
We now investigated if viral reactivation also occurs in patients from our previous study(3) of 
whom blood samples with a minimal follow-up of 5 days following trauma were available, 
and compared patients who displayed viral reactivation following multi-trauma to those 
who did not. Viral reactivation of HSV, CMV, and EBV was determined by PCR. For detailed 
information about the methods, see electronic supplementary material.
Baseline samples of all 31 patients included for viral PCRs were negative for EBV, CMV, 
and HSV. Twelve patients displayed viral reactivation, all of whom were positive for EBV, one 
for CMV, and two for HSV. Six out of nine patients (67 %) who displayed viral reactivation 
developed bacterial infection, whereas bacterial infection was observed in only six out of 
22 patients (27 %) who did not display viral reactivation (p=0.06). The difference in HLA-DR 
expression between emergency room admission and day 3 following trauma, a parameter 
which was previously shown to correlate with the incidence of bacterial infections(3), 
decreased in patients with viral reactivation while it increased in patients without viral 
reactivation (mean ± SEM ratios of 0.75 ± 0.12 vs. 1.20 ± 0.10, respectively, p=0.02).
We also explored plasma cytokines and found no patterns for the pro-inflammatory 
cytokines TNF-α, IL-6, and IL-8 that were related to viral reactivation. However, levels of 
the archetypical anti-inflammatory cytokine IL-10 persistent at later time points following 
trauma were higher in patients with viral reactivation compared with patients without viral 
reactivation [median (IQR) of 10.4 (2.7–18.8) vs. 4.1 (2.7–9.7) pg/mL, p=0.11 at day 5, and 
9.8 (5.6–43) vs. 3.5 (2.7–6.7) pg/mL, p=0.02 at day 7]. Furthermore, IL-10 levels at these time 
points correlated with maximum EBV viral load (Figure 1). Interestingly, this IL-10 might be 
(partly) EBD-derived, as EBV is known to produce IL-10 homologues to facilitate immune 
evasion(4). No correlations with pro-inflammatory cytokines were observed.
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Figure 1. Pearson correlations between log-transformed IL-10 plasma levels at days 5 and 7 following trauma 
and log-transformed maximum EBV viral load of the seven patients who displayed viral reactivation
The viral reactivation reported herein illustrates that trauma induces profound 
immunosuppression. In accordance with previously reported viral reactivation in sepsis 
patients(2), EBV was most prevalent, while CMV and HSV were less common, and bacterial 
infection was much more frequently encountered in patients who displayed viral reactivation. 
Furthermore, we demonstrate that decreased HLA-DR expression and plasma IL-10 levels are 
related to viral reactivation. As such, we show a robust and plausible relationship between 
an anti-inflammatory phenotype and reactivation of latent viruses that may potentially be 
causal.
In conclusion, our data further substantiate that, similar to sepsis patients, multiple-
trauma patients display profound immunosuppression, which may contribute to the 
incidence of secondary infections and increased morbidity and mortality in these patients. In 
addition, similar to its current use as a marker of immunosuppression in transplant patients(2), 
viral reactivation may represent a promising novel marker for immunosuppression in trauma 
patients. Viral PCRs becoming positive illustrate a more anti-inflammatory phenotype and 
increased risk to develop bacterial infections, thereby using patients as their own “test tubes”.
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Characterization of a model of systemic 
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continuous infusion of endotoxin
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ABSTRACT
Investigating the systemic inflammatory response in patients with critical illness such as 
sepsis, trauma and burns is complicated due to uncertainties about the onset, duration 
and severity of the insult. Therefore, in vivo models of inflammation are essential to study 
the pathophysiology and to evaluate immunomodulatory therapies. Intravenous bolus 
administration of endotoxin to healthy volunteers is a well-established model of a short-
lived systemic inflammatory response, characterized by increased plasma cytokine levels, 
flu-like symptoms and fever. In contrast, patients suffering from systemic inflammation are 
often exposed to inflammatory stimuli for an extended period of time. Therefore, continuous 
infusion of endotoxin may better reflect the kinetics of the inflammatory response encountered 
in these patients. Herein, we characterize a novel model of systemic inflammation elicited by 
a bolus infusion of 1 ng/kg, followed by a 3hr continuous infusion of 1 ng/kg/h of endotoxin 
in healthy volunteers, and compared it with models of bolus administrations of 1 and 2 ng/kg 
of endotoxin. The novel model was well-tolerated and resulted in a more pronounced 
increase in plasma cytokine levels with different kinetics and more prolonged symptoms 
and fever compared with the bolus-only models. Therefore, the continuous endotoxin 
infusion model provides novel insights into kinetics of the inflammatory response during 
continuous inflammatory stimuli and accommodates a larger time window to evaluate 
immunomodulating therapies. 
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INTRODUCTION
Systemic inflammation is a common hallmark of patients with sepsis1, trauma2, burns3, as 
well as those undergoing major surgery4. This inflammatory response follows the activation 
of specific receptors by pathogen-, or danger associated molecular patterns (PAMPs and 
DAMPs), and is characterized by the production of cytokines and chemokines. In turn, these 
cytokines and chemokines trigger complement activation and coagulation, leukocyte 
migration, and increased vascular permeability5. A dysregulated immune response can have 
detrimental effects, such as hemodynamic instability, organ dysfunction, and prolonged 
immune suppression6.
A comprehensive appreciation of the innate immune response is crucial to understand 
the pathogenesis of systemic inflammation observed in patients. However, investigating 
the innate immune response in patients is hampered by heterogeneity, uncertainties about 
the moment of onset and, in the case of sepsis, the accuracy of the diagnosis6. In order to 
overcome these impediments, models of systemic inflammation may facilitate investigations 
into the pathophysiological mechanisms and evaluate the effects of immunomodulatory 
interventions. As in vitro and animal models have obvious drawbacks concerning 
extrapolation to humans7, investigating systemic inflammation and immunomodulation is 
of great importance8. 
A controlled, transient and reproducible systemic inflammatory response in humans can 
be achieved with an intravenous (i.v.) bolus administration of endotoxin (lipopolysaccharide 
(LPS)), a compound derived from the cell membrane of Gram-negative bacteria. This 
inflammation is characterized by flu-like symptoms, fever, hemodynamic alterations and 
increased plasma levels of cytokines9. Previous studies have shown a dose-dependent effect 
of endotoxin on the magnitude of the inflammatory response, but largely unaltered kinetics 
with increasing endotoxin dosages10–12. Furthermore, repeated endotoxin administration 
studies have demonstrated the development of endotoxin tolerance, representing 
an immune suppressed state that resembles sepsis-induced immunoparalysis13. This 
experimental human endotoxemia model has been frequently used to investigate the 
pathophysiology of systemic inflammation, to assess a broad range of immunosuppressive 
and immunostimulatory drugs and non-pharmacological interventions14–17, and to evaluate 
the effects of inflammation on other biologic processes, such as iron homeostasis18 . 
Patients suffering from systemic inflammation are in most cases exposed to inflammatory 
stimuli for extended periods of time19. Therefore, a bolus administration of endotoxin likely 
poorly reflects the kinetics of the inflammatory response observed in these patients9,19, and a 
continuous infusion of endotoxin may provide a more accurate representation. Furthermore, 
as the endotoxin-induced inflammatory response is rapidly orchestrated and waned after 
bolus administration, investigational treatments are typically initiated before endotoxin 
administration. Although this approach increases the likelihood to show efficacy of the 
intervention in the experimental model, it does  not reflect the clinical situation in which 
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treatment is initiated after systemic inflammation has presented. An inflammatory model 
that develops over several hours may provide a larger time window to evaluate interventions 
once inflammation has developed. 
Taken together, the pathophysiology of systemic inflammation and immunomodulatory 
treatments are difficult to study in patients. The human endotoxemia model that is currently 
used is characterized by a rapid and short-lived systemic inflammatory response after a bolus 
administration of endotoxin. A continuous infusion of endotoxin may provide more insight 
into the  kinetics of the inflammatory response in patients with ongoing inflammation.
Herein, we characterize a novel model of systemic inflammation elicited by continuous 
endotoxin infusion (an initial endotoxin bolus of 1 ng/kg followed by 1 ng/kg/h for 3 hours). 
Additionally, we provide a context to interpret the characteristics of the continuous infusion 
model by describing  the characteristics of endotoxin models using 1 or 2 ng/kg bolus 
administrations and  responses to placebo administration. We report  the kinetics of plasma 
cytokines, hemodynamic alterations, symptoms and leukocyte changes, and  explore the 
coherence between different cytokines and their association with clinical parameters. 
METHODS
Study design
Data were obtained from the control arms of three randomized controlled studies, using 
placebo or endotoxin bolus administrations of 1 or 2ng/kg, or a bolus administration of 
1ng/kg followed by continuous infusion of endotoxin at a dose of 1ng/kg/h. Studies were 
performed after approval of the local ethics committee CMO Regio Arnhem-Nijmegen and are 
registered at ClinicalTrials.gov (NCT02642237 (December 2015); NCT02085590 (March 2014); 
NCT02612480 (November 2015), respectively). All study procedures were in accordance with 
the declaration of Helsinki, including the latest revisions.
The purpose of this report is to characterize a novel human endotoxemia model aimed 
at eliciting systemic inflammation in a more clinically relevant manner and potentially 
providing more opportunities for pharmacologic modulation. To provide an interpretational 
context, data of bolus injections of 1 and 2 ng/kg of the same endotoxin are also described. 
Because we did not include a group that received a bolus administration of 4 ng/kg (the 
same cumulative dose as used in the continuous infusion group), it needs to be stressed 
that differences between  the continuous infusion group and the bolus groups may either 
originate from a difference in infusion rate or a difference in cumulative dose. 
Study protocols
Eligible subjects were healthy, non-smoking male subjects aged 18-35 years, with a normal 
physical examination, electrocardiography, and routine laboratory values at the screening 
visit. Exclusion criteria were pre-existent disease, febrile illness in the past four weeks and 
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drug use. All subjects gave written informed consent to participate in the study. Before the 
experiment, subjects refrained from caffeine and alcohol for 24 h and from food and drinks 
for 12 h. Radial artery  cannulation (Angiocath; Becton Dickinson, USA) facilitated blood 
pressure monitoring (Edward Lifesciences, Irvine, CA, USA) and blood withdrawal. A venous 
cannula was placed in an antebrachial vene for intravenous (i.v.) hydration and endotoxin 
administration. A three-lead electrocardiogram registered heart rate. All haemodynamic 
data was recorded with an interval of 30 seconds using an in-house developed system from 
a Philips M50 monitor (Eindhoven, The Netherlands).
To prevent vasovagal responses subjects were prehydrated by infusion of 1.5L glucose 
2.5%/ NaCl 0.45% in one hour28. Purified lipopolysaccharide (LPS, US Standard Escherichia 
coli O:113 endotoxin) was obtained from the Pharmaceutical Development Section of the 
National Institutes of Health (Bethesda, MD, USA). The lyophilized powder was reconstituted 
in 5 mL NaCl 0.9% for injection and vortex mixed for 20 min. An i.v. bolus of endotoxin was 
administered at a dose of 1 ng/kg or 2 ng/kg at 0h. Continuous infusion was initiated after 
a bolus of 1 ng/kg at 0h, followed by a continuous infusion at 1 ng/kg/h for 3 h, resulting in 
a cumulative dose of 4 ng/kg shown to be safe in previous studies10–12. The placebo group 
received matched bolus volumes of vehicle (NaCl 0.9%) at 0h. Hydration was continued with 
150 ml/h for 6 h, and 75 ml/h during the rest of the experiment. Every 30 min, temperature 
was measured using a tympanic thermometer (FirstTemp Genius 2; Covidien, Dublin, Ireland) 
and flu-like symptoms (headache, nausea, shivering, muscle and back pain) were scored on 
a six-point scale (0 = no symptoms, 5 = worst ever experienced), resulting in a total symptom 
score range of 0–25.
Cytokine analysis 
Ethylenediaminetetraacetic-(EDTA) anticoagulated blood was collected at various time 
points, centrifuged (2000g, 4˚C, 10 min) and plasma was stored at -80°C until analysis. 
As plasma concentrations may differ between  assay manufacturers and batches, we re-
analyzed concentrations of TNF-α, IL-6, CXCL8, IL-10, IL-1β, MIP-1α, MIP-1β and MCP-1 in all 
samplesbatchwise in one run using a simultaneous Luminex assay (R&D systems; Abingdon 
Science Park, UK). The lower detection limits were as follows; TNFα 1,46 pg/mL, IL-1B 0,76 
pg/mL, IL-6 1,76 pg/mL, CXCL8 1,41 pg/mL, IL-10 1.22 pg/mL, IFNy 0,66 pg/mL, MIP1a 74,4 
pg/mL, MIP1B 34 pg/mL, IL-1RA 26 pg/mL and MCP-1 13,2 pg/mL. Cross-reactivity was below 
0.5% for all the cytokines, and the interassay variation was below 17%.
Leukocyte counts 
Analysis of leukocyte counts were measured using routine methods also used for patient 
samples (flow cytometric analysis on a Sysmex XE-5000). 
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Statistical analysis 
Distribution of data was tested for normality using Shapiro-Wilk test. As all data were normally 
distributed, they are presented as mean ± SEM. Total cytokine production is expressed as 
the area under the time curve (AUC) and group differences were analyzed using unpaired 
Students t-tests. Differences between groups in kinetics were analyzed using two-way analysis 
of variance (ANOVA) (group x time). Within group comparisons were made using one-way 
ANOVA followed by Bonferroni post-hoc tests. Hierarchical clustering analysis (HCA) was used 
to analyze coherence between cytokines. HCA is an unsupervised method to represent the 
relationships among variables with the length of the branch reflecting the degree of similarity. 
AUCs of cytokines from the endotoxemia groups  were log-transformed and normalized, after 
which HCA was performed using Euclidean distances and an average clustering algorithm 
(CIMminer, Genomics and Bioinformatics group, National Cancer Institute, Bethesda, MD, 
USA). This analysis identified clusters of the cytokines (AUCs) and subjects . Exploratory 
factor analysis (EFA) was performed to identify groups of cytokine responses that correlate 
to such an extent that they could be summarized into one new variable (a factor). Thereby 
EFA is an unsupervised method that identifies latent constructs (or factors) which can 
summarize data in factors that cannot be measured directly.. These factors can be used 
to assess the coherence between cytokines and to assess the relation between clusters of 
cytokines with clinical parameters. EFA was performed on log-transformed cytokine AUCs 
using Oblimin rotation, as we assume that latent constructs of cytokine data may correlate 
and not be entirely independent. The scores of the subjects on the newly derived factors, 
which summarize all the cytokine data,  were correlated with the AUC of symptoms, change 
in temperature, and change in heart rate using Pearson correlation analysis. Unless specified 
otherwise, statistical analyses were performed using Graphpad Prism version 5.0 (Graphpad 
Software, San Diego, CA, USA) and SPSS for Windows 22.0 (SPSS Inc, Chicago, IL, USA). 
P-values <0.05 were considered statistically significant. 
RESULTS
Demographic characteristics, elicitation of systemic inflammation and safety
Eligible subjects were healthy, non-smoking male subjects, aged 18-35 years. Demographic 
characteristics of the subjects are listed in Table 1. All subjects were Caucasian. There were 
no differences in baseline characteristics between the groups. All subjects received a venous 
and arterial cannula to accommodate infusion of fluids and endotoxin and frequent blood 
withdrawal and continuous blood pressure monitoring. Systemic inflammation was elicited 
by either continuous endotoxin infusion (an initial endotoxin bolus of 1 ng/kg, followed 
by 1 ng/kg/h for 3 hours) or a bolus administration of 1 or 2 ng/kg bolus administrations 
of endotoxin. The placebo group received a comparable volume of NaCl 0.9%.  No serious 
CHARACTERIZATION OF A MODEL 
OF SYSTEMIC INFLAMMATION IN HUMANS IN VIVO ELICITED BY CONTINUOUS INFUSION OF ENDOTOXIN
187
10
adverse events occurred and all subjects were well at the time of discharge, eight hours after 
initiation of endotoxin administration. 
Table 1. Demographic characteristics of subjects Data were obtained during screening visit and are 
presented as mean ±SEM. P-values were calculated using one-way ANOVAs. yrs: years, cm: centimeter, kg: 
kilogram, BMI: body mass index, m: meter
Placebo
n=15
bolus
 1 ng/kg
n = 10
bolus
2 ng/kg
n = 15
bolus 1ng/kg+ 
continuous 3ng/kg
n = 10
p-value
Age [yrs] 21.5 ± 0.5 21.1 ± 0.9 21.7 ± 0.7 23.6 ± 1.6 0.30
Height [cm] 181 ± 2 185 ± 2 185 ± 2 182 ± 2 0.40
Weight [kg] 77 ± 3 78 ± 3 78 ± 3 77 ± 4 0.98
BMI [kg/m²] 23.4 ± 0.9 22.8 ± 0.7 23.0 ± 0.8 23.2 ± 0.7 0.96
Plasma cytokines and chemokines
To determine serial plasma levels of cytokines Tumor Necrosis Factor (TNF)-α, interleukin (IL)-1β, 
IL-6 and IL-10 (Figure 1) and chemokines (C-X-C-motif) ligand (CXCL)8 (also known as IL-8), 
Monocyte Chemoattractant Protein (MCP)-1, Macrophage Inflammatory Protein (MIP)-1α 
and MIP-1β, blood was frequently sampled throughout the experiment. All plasma cytokine 
concentrations were below detection limits in all subjects prior to endotoxin administration 
and significantly increased afterwards (Figure 2). In the placebo group, no increases in any of 
the cytokines and chemokines were observed.
Kinetics of plasma cytokines and chemokines
In the continuous infusion group, the kinetics of all cytokines and chemokines were markedly 
different compared with bolus administration of 2 ng/kg (Figure 1 and 2). Of note, in the 
continuous infusion group plasma levels of TNF-α and MIP-1α already decreased before 
endotoxin infusion was stopped. The differences between 1 and 2 ng/kg bolus administration 
groups were less pronounced, and only reached statistical significance for TNF-α, IL-1β, IL-10 
and MIP-1α. 
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Figure 1. Kinetics and total production of cytokines. In the left panels, plasma concentrations of Tumor 
Necrosis Factor (TNF)-α, Interleukin(IL)-1β, IL-6 and IL-10 over time are depicted. The arrow represents the 
time of bolus endotoxin administration, the grey bar represents the period of endotoxin infusion in the 
continuous endotoxin group. Data are expressed as mean ± SEM pg/mL. Differences between groups were 
evaluated using 2-way ANOVAs (of time x group), and interaction term p-values are displayed. In the right panels, 
dot plots of the area under the time-concentration curve (AUC) with mean ± SEM are shown. Differences between 
groups were evaluated using Students t-tests. * p<0.05, ** p<0.01, * p<0.0001, # p=0.05-0.10. 
Total cytokine and chemokines production
The total cytokine response, expressed as the area under the time-concentration curve 
(AUC), was higher for IL-1β, IL-6, IL-10, MCP-1 and MIP-1α in the continuous infusion group 
compared with the 2 ng/kg bolus group, but similar for TNF-α and CXCL8. There was a trend 
toward higher total production of MIP-1β in the continuous infusion group. Except for higher 
production of IL-10 in the 2 ng/kg bolus administration group, there were no differences in 
total cytokine production between the 1 and 2 ng/kg bolus groups. 
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Figure 2. Kinetics and total production of chemokines. In the left panels, plasma concentration of CXC 
motif ligand (CXCL) 8, Monocyte Chemoattractant Protein (MCP) and Macrophage Inflammatory Protein (MIP)-
1α and 1β over time are depicted. The arrow represents the time of bolus endotoxin administration, the grey 
bar represents the period of endotoxin infusion in the continuous endotoxin group. Data are expressed as 
mean ± SEM pg/mL. Differences between groups were evaluated using 2-way ANOVAs (of time x group), and 
interaction term p-values are displayed. In the right panels, dot plots of the area under the time-concentration 
curve (AUC) with mean ± SEM are shown. Differences between groups were evaluated using with Students 
t-tests. * p<0.05, ** p<0.01, * p<0.0001. 
Clinical parameters
Endotoxin-induced flu-like  symptoms (headache, nausea, shivering, muscle and back 
pain)  reported by the subjects were scored every 30 minutes at 0-5 points. These 
symptoms remained at baseline in placebo-treated subjects, whereas the onset of flu-
like symptoms was observed one hour after initiating endotoxin administration (Figure 3). 
Continuous endotoxin infusion resulted in prolonged, but equally severe, flu-like symptoms 
in comparison to 2 ng/kg bolus administration. Small differences in the kinetics of the 
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symptom scores were identified between the 1 and 2 ng/kg bolus administration groups. 
However, the total burden of symptoms, represented by the area under the time-symptom 
curve, was identical in these groups. The rise in temperature was markedly more pronounced 
in the continuous administration group compared with the 2 ng/kg bolus group, whereas 
there were no differences in the temperature response between the 1 and 2 ng/kg bolus 
administration groups (Figure 3). Although an endotoxin-dose-dependent increase in heart 
rate was observed, mean arterial pressure decreased to a similar extent in all subjects, also 
in those who received placebo (Figure 3). 
Figure 3. Kinetics and area under the curve of clinical parameters. In the left panel, change over time of 
symptoms (arbitrary units), temperature (ᵒC), heart rate (beats per minute (bpm)), and mean arterial pressure 
(MAP) (mmHg) over time are depicted. The arrow represents the time of bolus endotoxin administration, the 
grey bar represents the period of endotoxin infusion in the continuous endotoxin group. Data are expressed as 
mean ±SEM. Differences between groups were evaluated using 2-way ANOVAs (of time x group), and interaction 
term p-values are displayed. In the right panel, dot plots of the area under the time-concentration curve (AUC) 
with mean ± SEM are shown. The AUC of temperature, heart rate and MAP was corrected for baseline. Differences 
between groups were evaluated using with Students t-tests. * p<0.05, ** p<0.01, * p<0.0001. 
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Hematological parameters
Endotoxemia resulted in neutrophilia, and a mono- and lymphocytopenia, with the nadir 
at two and four hours, respectively (Figure 4). These hematologic changes were more 
pronounced in the continuous infusion group compared with bolus administration of 2 ng/
kg endotoxin. Neutrophilia was similar after a endotoxin bolus of 1 and 2 ng/kg, while the 
kinetics of circulating monocyte and lymphocyte numbers differed slightly, yet significantly.
Figure 4. Time course of leukocytes. Bars represent mean ± SEM of circulating numbers of neutrophils, 
monocytes and lymphocytes. Differences between groups were evaluated using 2-way ANOVAs (time x 
group), and interaction term p-values are displayed. 
Hierarchical clustering and exploratory factor analysis
To identify relationships and similarities between cytokines and subjects, we performed 
hierarchical clustering analysis on cytokine responses and subjects. This analysis revealed a 
separate cluster for the anti-inflammatory cytokine IL-10, while three clusters were identified 
consisting of CXCL8, TNF-α and MCP-1, MIP-1α and MIP-1β, and IL-6 and IL-1β (Figure 5). 
Subjects clustered into three distinct groups; those who received continuous infusion (middle 
rows), those with low cytokine responses (upper rows) after bolus administration, and those 
with high cytokine responses (lower rows) after bolus administration. To explore to what 
extent cytokines responses are related, we performed exploratory factor analyses. This is 
an unsupervised method that can identify latent constructs (factors) in a multi-dimensional 
data set. The loading of a variable on a factor represents the relative weight of the variable in 
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the factor. Exploratory factor analyses revealed similar grouping of cytokines (Table 2); with 
high loadings of CXCL8 and TNF-α in factor 1, a high loading of IL-10 in factor 2, a high negative 
loading of IL-1β and IL-6 in factor 3, and high loadings of MIP-1α and MIP-1β in factor 4. 
These factors explain 92% of the variance in the dataset. Factor 3, which has high negative 
loadings of IL-1β and IL-6, correlated with symptoms and change in temperature (Figure 6). 
As such, high values of  IL-1β and IL-6 are associated with higher symptom severity and a 
larger increase in temperature. Change in heart rate correlated with factor 2, which has a high 
loading of IL-10. 
Table 2. Exploratory factor analysis pattern matrix. Pattern matrix after oblimin rotation with Kaiser 
Normalisation as obtained from EFA on log-transformed normalized area’s under time-concentration curves 
of cytokines after endotoxin administration. Only loadings >0.1 are displayed. 
Factor 1 Factor 2 Factor 3 Factor 4
% of variance explained 64.5% 10.9% 9.2% 7.5%
CXCL8 0.999
TNF-α 0.805 0.189
 MCP-1 0.472 0.213 -0.255 0.256
IL-10 1.010
IL-1β -1.008
IL-6 0.243 0.262 -0.688
MIP-1β 0.989
MIP-1β 0.302 0.730
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Figure 5. Hierarchical clustering of cytokines and chemokines and subjects. Each subjects occupies 
a row and each cytokine or chemokines occupies a column. The color code shows the normalized, log-
transformed plasma concentration below (blue) or above (red) the mean, or at the median (black). The 
vertical axis on the left shows the color code of each subject classified as 1 ng/kg (light grey), 2 ng/kg (dark 
grey) or continuous infusion (black). 
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Figure 6. Correlations of factors with clinical parameters. Correlations between individual score on Factor 3 
and the area under the curve (AUC), Factor 3 and symptoms (Panel A) and the baseline-corrected AUC of 
temperature (Panel B) and Factor 2 and the baseline-corrected AUC of heart rate (Panel C). R and p-values 
were calculated using Pearson correlations. 
 
DISCUSSION
Herein, we characterize a novel human in vivo model of systemic inflammation elicited by 
continuous endotoxin infusion. Furthermore, we provide a framework for interpretation 
of this model by also describing two models of systemic inflammation elicited by bolus 
administration of endotoxin. This novel model of continuous infusion resulted in a higher 
production of IL-6, IL-10, MCP-1 and MIP-1α, and different kinetics of all cytokines as well 
as circulating leukocyte numbers. Furthermore, it resulted in a more pronounced rise in 
temperature and heart rate, and prolonged duration of flu-like symptoms. As such, this 
novel model induces a more pronounced and sustained systemic inflammatory response. 
There were no relevant differences in cytokine responses, clinical parameters, and leukocyte 
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kinetics between bolus administrations of 1 or 2 ng/kg endotoxin. In addition, unsupervised 
clustering and exploratory factor analysis revealed identical clusters of cytokines, some of 
which are clearly associated with clinical symptoms and fever. 
We are the first to describe a model of continuous infusion of endotoxin at a relatively high 
dose of 1 ng/kg/h. Low dose endotoxin infusion of another E coli  derived batch (G2 B274, 
0.075 ng/kg/h) has been described previously20. At this lower dose, endotoxin infusion 
increased body temperature with 0.5 ᵒC, and cytokine levels peaked to 5-10 and 20-70 pg/
mL for TNF-α and IL-6, respectively20. These changes are far more discrete compared with the 
higher dose continuous infusion model reported here, in which body temperature rises with 
2.5 ᵒC and peak levels of TNFα and IL-6 are 340 pg/ml and 1000 pg/mL respectively. As such, 
low dose infusion mimics low-grade inflammation, as observed in chronic illnesses such 
as metabolic syndrome, atherosclerosis and type 2 diabetes20, whereas high dose infusion 
results in more profound systemic inflammation as observed in patients with sepsis. The 
cumulative dose of 4 ng/kg of endotoxin has been administered safely as a bolus in previous 
studies10–12. Therefore, no safety issues were expected, and indeed no serious adverse events 
occurred.   
Previous studies have evaluated the dose-effects of different batches of endotoxin, in 
bolus administrations ranging from 0.5 ng/kg to 4 ng/kg10–12. These studies have shown that 
the extent of inflammation elicited by endotoxin administration is dose-dependent, but the 
difference between successive dosages may be too small to be significant. Similarly, we did 
not observe a  clear dose-dependent effect concerning the 1 and 2 ng/kg endotoxin bolus 
administrations, although this was not the primary goal of this study. For most cytokines, the 
total response in the continuous model was higher compared to the 2 ng/kg bolus model. 
Although our study design does not allow to differentiate whether this is due to dose or 
infusion mode, these data indicate a more profound systemic inflammatory response using 
the continuous infusion protocol. However, in this context it is noteworthy that the total 
production of TNF-α and CXCL8 remained similar to that observed after bolus administration 
of 2 ng/kg endotoxin. TNF-α is known as the primary mediator in the inflammatory response 
and CXCL8 attracts and activates leukocytes to the site of infection21. Speculatively, both 
TNF-α and CXCL8 are under the control of a negative feedback mechanism that prevents 
unrestrained triggering of the inflammatory cascade, thereby prohibiting an uncontrolled pro-
inflammatory response. This theory is supported by the observation that in the continuous 
endotoxin infusion group, plasma levels of TNF-α are already declining while endotoxin 
infusion continues. This phenomenon is also observed in patients with sepsis, in whom 
plasma levels of TNF-α decline rapidly and therefore do not represent disease severity22. In 
contrast to the restrained production of TNF-α and CXCL8, we observed a fourfold increase in 
IL-10 and IL-6 during continuous endotoxin infusion in comparison to bolus administration. 
IL-10 is the archetypal anti-inflammatory cytokine which inhibits the production of TNF-α 
and IL-1β. IL-6 exerts both pro- and anti-inflammatory effects, as it not only activates B- and 
T-lymphocytes and triggers the acute phase response and the coagulation cascade, but also 
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can inhibit production of TNF-α21. Therefore, the distinct surge in IL-10 and IL-6 levels may be 
part of the negative feedback mechanism that controls TNF-α and CXCL8. Understanding the 
orchestration of the pro- and anti-inflammatory balance is of great interest, as a shift toward 
anti-inflammation is observed in patients with ongoing systemic inflammation23. This shift 
is presumed to prevent collateral damage of the pro-inflammatory response, but can also 
result in loss of immunocompetence and subsequently increase susceptibility to secondary 
infections. In sepsis patients, this phenomenon is termed sepsis-induced immunoparalysis24, 
although it is also observed in patients following trauma25 and cardiac resuscitation26 within 
hours after the insult. Therefore, the disproportionate production of anti-inflammatory 
cytokines during continuous infusion may mirror inflammation-induced immunoparalysis 
observed in patients. 
Two independent, unsupervised clustering methods yielded similar groups of cytokines. 
Although these analyses uncover the relationships between cytokines, they do not provide 
a theoretical framework to explain these relationships and need to be interpreted with 
caution. Nevertheless, some notable relationships are observed. First, the primordial anti-
inflammatory cytokine IL-10 has its own cluster, which explains 10% of the variance of the 
data Second, the aforementioned pro-inflammatory cytokine TNF-α and the chemokine 
CXCL8 are closely linked. The third group consists of IL-1β and IL-6, which are both potent 
pyrogens. The last group consists of MIP-1α and MIP-1β, both chemokines produced by 
macrophages, which attract and activate granulocytes and stimulate the production of other 
cytokines. Perhaps not surprisingly, component 3, with pyrogens IL-6 and IL-1β correlates 
significantly with the development of fever and symptoms. A direct correlation between the 
level of cytokines and clinical outcomes was previously unidentified10. It appears plausible 
that, using exploratory factor analysis, we have increased the power to identify meaningful 
correlations by quantifying the response of each individual on factors, which are groups of 
cytokines that act alike, instead of the cytokines by themselves. 
Endotoxemia models have limitations. First, endotoxemia is an experimental model 
of inflammation, which only embodies certain aspects of the pathophysiology of sepsis, 
trauma, burns, and major surgery. However, as these conditions are heterogeneous by 
themselves, their pathogenesis is difficult to study in patients. Therefore, endotoxemia 
models should be envisioned as a complementary method to study the pathophysiology of 
systemic inflammation, in addition to in vitro, ex vivo and animal studies, and clinical studies 
in patients. Second, we did not identify relevant changes in mean arterial blood pressure in 
comparison to the placebo group. This is in contrast to the findings of a previous study in 
which a bolus administration of 4 ng/kg EC-5 endotoxin resulted in a profound hyperdynamic 
state with depressed left ventricular ejection fraction and reduced myocardial contractility27. 
Perhaps a bolus administration of 4 ng/kg, instead of a gradual infusion is required to produce 
such effects. The herein described models should therefore be used with apprehension to 
study hemodynamic changes in patients with systemic inflammation, and other models of 
sepsis may be more suitable for this purpose. We have not included a group in which a bolus 
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injection of 4 ng/kg was administered to identify if differences between bolus and continuous 
infusion are the resultant of differences in dose or infusion rate. This limits the interpretation 
as to what extent the differences between the models are caused by dose or infusion mode. 
The human model of systemic inflammation evoked by continuous infusion of endotoxin as 
described in the present study provides several new research opportunities. In bolus models, 
the inflammatory response comes and goes rapidly, limiting the possibility to demonstrate 
an effect of an intervention initiated following endotoxin administration. With continuous 
infusion, inflammation develops more gradually and is sustained for several hours, which 
extends the time window to demonstrate an effect of a therapeutic intervention, probably to 
a time point after initiation of endotoxin infusion. This is highly relevant, as in most patients 
with systemic inflammation, such as those suffering from sepsis, trauma or burns, there will 
be no opportunity for treatment before the inflammatory insult. Being able to demonstrate 
efficacy of an intervention administrated during inflammation would improve the clinical 
applicability. In addition, although still relatively short-lived, continuous endotoxin infusion 
may better represents the physiologic response of sustained immune triggering as observed 
in patients, including the emerging negative feedback mechanisms and development of 
endotoxin tolerance.
 In conclusion, continuous infusion of endotoxin elicits a safe, reproducible, controlled, 
systemic inflammatory response in humans in vivo, which lasts for several hours. This 
model provides new options to study the innate immune response during continuous 
exposure to inflammatory stimuli. Furthermore,  it offers a larger time window to evaluate 
immunomodulatory interventions following the onset of inflammation. 
CHAPTER 10
198
REFERENCES
1. Hotchkiss, R. S. & Karl, I. E. The pathophysiology and treatment of sepsis. N. Engl. J. Med. 348, 
138–150 (2003).
2. Lord, J. M. et al. The systemic immune response to trauma: An overview of pathophysiology and 
treatment. Lancet 384, 1455–1465 (2014).
3. Finnerty, C. C. et al. Cytokine Expression Profile Over Time in Severely Burned Pediatric Patients. 
Shock 26, 13–19 (2006).
4. Watt, D. G., Horgan, P. G. & McMillan, D. C. Routine clinical markers of the magnitude of the systemic 
inflammatory response after elective operation: A systematic review. Surg. (United States) 157, 
362–380 (2015).
5. Patel, P. N., Shah, R. Y., Ferguson, J. F. & Reilly, M. P. Human Experimental Endotoxemia in Modeling 
the Pathophysiology, Genomics, and Therapeutics of Innate Immunity in Complex Cardiometabolic 
Diseases. Arterioscler. Thromb. Vasc. Biol. 525–535 (2014). doi:10.1161/ATVBAHA.114.304455
6. Cohen, J. et al. Sepsis: a roadmap for future research. Lancet Infect. Dis. 15, 581–614 (2015).
7. Seok, J. et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. 
Proc. Natl. Acad. Sci. U. S. A. 110, 3507–12 (2013).
8. Andreasen, A. S. et al. Human endotoxemia as a model of systemic inflammation. Curr. Med. Chem. 
15, 1697–705 (2008).
9. Bahador, M. & Cross, A. S. From therapy to experimental model: a hundred years of endotoxin 
administration to human subjects. J. Endotoxin Res. 13, 251–79 (2007).
10. Suffredini,  a F., Hochstein, H. D. & McMahon, F. G. Dose-related inflammatory effects of intravenous 
endotoxin in humans: evaluation of a new clinical lot of Escherichia coli O:113 endotoxin. J. Infect. 
Dis. 179, 1278–1282 (1999).
11. Kuhns, D. B., Alvord, W. G. & Gallin, J. I. Increased circulating cytokines, cytokine antagonists, and 
e-selectin after intravenous administration of endotoxin in humans. J. Infect. Dis. 171, 145–152 
(1995).
12. Elin, R. J. et al. Properties of reference escherichia coli endotoxin and its phthalylated derivative in 
humans. J. Infect. Dis. 144, 329–336 (1981).
13. Draisma, A., Pickkers, P., Bouw, M. P. W. J. M. & van der Hoeven, J. G. Development of endotoxin 
tolerance in humans in vivo. Crit. Care Med. 37, 1261–1267 (2009).
14. Ramakers, B. P. et al. Dipyridamole augments the antiinflammatory response during human 
endotoxemia. Crit. Care 15, R289 (2011).
15. van der Poll, T., Coyle, S. M., Barbosa, K., Braxton, C. C. & Lowry, S. F. Epinephrine inhibits tumor 
necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. 
J. Clin. Invest. 97, 713–9 (1996).
16. van Eijk, L. T. et al. Effect of the anti-hepcidin Spiegelmer® lexaptepid on inflammation-induced 
decrease in serum iron in humans. Blood 124, 2643–2646 (2014).
17. Leentjens, J. et al. Reversal of immunoparalysis in humans in vivo: a double-blind, placebo-
controlled, randomized pilot study. Am. J. Respir. Crit. Care Med. 186, 838–45 (2012).
CHARACTERIZATION OF A MODEL 
OF SYSTEMIC INFLAMMATION IN HUMANS IN VIVO ELICITED BY CONTINUOUS INFUSION OF ENDOTOXIN
199
10
18. van Eijk, L. T. et al. The effect of iron loading and iron chelation on the innate immune response 
and subclinical organ injury during human endotoxemia: A randomized trial. Haematologica 99, 
579–587 (2014).
19. Parker, S. & Watkins, P. Experimental models of gram-negative sepsis. Br. J. Surg. 88, 22–30 (2001).
20. Taudorf, S., Krabbe, K. S., Berg, R. M. G., Pedersen, B. K. & Møller, K. Human models of low-grade 
inflammation: bolus versus continuous infusion of endotoxin. Clin. Vaccine Immunol. 14, 250–5 
(2007).
21. Blackwell, T. S. & Christman, J. W. Sepsis and cytokines: current status. Br. J. Anaesth. 77, 110–117 
(1996).
22. Gomez, H. G. et al. Immunological Characterization of Compensatory Anti-Inflammatory Response 
Syndrome in Patients With Severe Sepsis: A Longitudinal Study. Crit. Care Med. 42, 771–780 (2014).
23. Leentjens, J., Kox, M., van der Hoeven, J. G., Netea, M. G. & Pickkers, P. Immunotherapy for the 
adjunctive treatment of sepsis: from immunosuppression to immunostimulation. Time for a 
paradigm change? Am. J. Respir. Crit. Care Med. 187, 1287–93 (2013).
24. Hotchkiss, R. S., Monneret, G. & Payen, D. Immunosuppression in sepsis: A novel understanding of 
the disorder and a new therapeutic approach. Lancet Infect. Dis. 13, 260–268 (2013).
25. Timmermans, K. et al. Plasma levels of danger-associated molecular patterns are associated with 
immune suppression in trauma patients. Intensive Care Med. 42, 1–11 (2016).
26. Timmermans, K. et al. The Involvement of Danger-Associated Molecular Patterns in the 
Development of Immunoparalysis in Cardiac Arrest Patients. Crit. Care Med. 43, 2332–2338 (2015).

Amelia Draper, Rebecca M Koch, Jos W van der Meer, Matthew A J Apps, Peter 
Pickkers, Masud Husain, Marieke E van der Schaaf
Neuropsychopharmacology 2018;5: 1107-1118
Chapter 11
Effort but not reward sensitivity is altered 
by acute sickness induced by experimental 
endotoxemia in humans
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ABSTRACT
Sickness behavior in humans is characterized by low mood and fatigue, which have been 
suggested to reflect changes in motivation involving reorganization of priorities. However, 
it is unclear which specific processes underlying motivation are altered. We tested whether 
bacterial endotoxin Escherichia coli lipopolysaccharide (LPS) affected two dissociable 
constructs of motivational behavior, ie, effort and reward sensitivity. After familiarization with 
5 effort levels, participants made a series of accept/reject decisions on whether the stake 
offered (1, 4, 8, 12, or 15 apples) was ‘worth the effort’ (10%, 27.5%, 45%, 62.5%, and 80% 
of maximal voluntary contraction in a hand-held dynamometer). Effort and reward levels 
were parametrically modulated to dissociate their influence on choice. Overall, 29 healthy 
young males were administered LPS (2 ng/kg; n=14) or placebo (0.9% saline; n=15). The 
effort-stake task, and self-reported depression and fatigue were assessed prior to LPS/
placebo injection, 2 and 5 hours post-injection. Cytokines and sickness symptoms were 
assessed hourly till 8 hours after LPS injection. LPS transiently increased interleukin (IL)-6 
and tumor necrosis factor (TNF)-α, sickness symptoms, body temperature and self-reported 
fatigue, and depression post-injection relative to baseline and placebo. These changes 
were accompanied by LPS-induced decreases in acceptance rates of high-effort options, 
without significantly affecting reward sensitivity 2 hours post-injection, which were partially 
recovered 5 hours post-injection. We suggest that LPS-induced changes in motivation may 
be due to alterations to mesolimbic dopamine. Our behavioral paradigm could be used 
to further investigate effects of inflammation on motivational behavior in psychiatric and 
chronic illnesses.
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INTRODUCTION
Motivational symptoms such as apathy and fatigue are common in patients with psychiatric 
disorders including depression, schizophrenia, and bipolar disorder(1). A growing field of 
research suggests that inflammation may contribute to these motivational symptoms(2-4). 
This is supported by observations of elevated levels of pro-inflammatory cytokines 
interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in people who suffer from chronic 
major depression(5-7) and observations of neuroinflammation in patients with bipolar 
disorder(8-10) and schizophrenia(4, 11).
Systemic inflammation in humans typically induces a cluster of non-specific symptoms 
(ie, sickness behavior) including fatigue, depression, and apathy(12). Studies of sickness 
behavior in animals suggest that these behavioral changes might be mediated by cytokine 
effects on the central nervous system(13-15). Following pathogen exposure, pro-inflammatory 
cytokines are released by activated immune cells to orchestrate the physiological 
immunologic response(16). These pro-inflammatory cytokines also have a critical role in the 
regulation of immune influences on brain function(17) and have shown to affect dopamine 
function in mesolimbic brain regions(18, 19). Dopamine has repeatedly been associated 
with both reward and effort-based decision making, but it remains to be determined how 
inflammation affects effort and reward influences on behavior.
Several human studies have investigated reward learning and mesolimbic functioning 
after treatment with the inflammatory cytokine interferon alpha (IFN-α) or acute inflammation 
challenges. These studies demonstrated altered reward learning(20) and reductions in reward-
related ventral striatal activity, that was associated with inflammation-induced increases in 
depression, fatigue, and anhedonia(19, 21, 22).
By contrast, research with animals suggest that inflammation affects effort expenditure, 
rather than reward processing(23-26). In a two-choice (high-effort/high-reward vs. low-effort/
low-reward) paradigm(27), administration of IL-1β shifted rodent’s choice toward the low-
effort/low-reward option. Importantly, reward sensitivity remained intact as high-reward 
preferences were unaffected(25). Another study demonstrated that inflammation reduced 
the overall effort investment (ie, number of responses), whereas the better high-effort/high-
reward option was still favored(28). A version of this latter paradigm was recently assessed 
in humans where participants chose between high-effort/high-reward and low-effort/low-
reward options. Reward magnitude and probability was modulated(29). Although participants 
selected the high-effort/high-reward options at the same rate during inflammation compared 
to placebo, they selected a greater proportion of the high-effort options when the probability 
to win the reward was high. Thus, participants still performed the high-effort options during 
inflammation to gain a higher reward, suggesting that they are still reward sensitive.
Paradigms used to date have been limited in the dissociation of reward and effort 
influences as they typically compare high-reward/high-effort options with low-reward/
low-effort options. Accordingly, in the current investigation, we aimed to test whether 
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systemic inflammation differentially affects reward or effort processing in healthy human 
volunteers using a recently developed effort-stake choice paradigm(30, 31). In this paradigm, we 
parametrically modulate effort and reward choices by providing options with combinations 
of different levels of reward and effort, allowing us to dissociate effort and reward influences 
on choice.
Our second aim was to explore the relationship between changes in motivational 
behavior and changes in fatigue and depression or pro-inflammatory cytokine response. 
Informed by current literature highlighting the role of IL-1β, IL-6, and TNF-α in various chronic 
conditions that express motivational symptoms, including in major depressive disorder(2, 5, 7, 32), 
rheumatoid arthritis(33); and cancer-related fatigue(33-37), as well as the effects of acute 
administration of IL-6 and IL-1β on animal behavior(25, 26, 28, 38), we focused our investigation on 
these three pro-inflammatory cytokines.
MATERIALS AND METHODS
General Session Procedure
This study was part of a larger clinical trial at the department of intensive care medicine 
of the Radboudumc in Nijmegen in the Netherlands investigating the effects of human 
endotoxemia followed by the administration of a live-attenuated influenza vaccine ‘Fluenz’ 
on the immune response (ClinicalTrials.gov: NCT02642237). The human endotoxemia 
sessions took place 1 week before the administration of Fluenz and were therefore not 
confounded by this second part of the clinical trial. Participants received either Escherichia 
coli-derived lipopolysaccharide (LPS) at a dose of 2 ng/kg or saline (0.9% NaCl) intravenously. 
They were randomly assigned to the LPS or placebo condition on the morning of testing by 
an unaffiliated research nurse and deblinding of conditions took place after all data had been 
collected. To control for individual differences in baseline performance, behavioral testing 
took place at three time points: session 1: 45 minutes before injection; session 2: 2 hours post-
injection and; session 3: 5 hours post-injection. ‘Timing was based on previous experiences 
from our group showing that sickness symptoms are limited 2 hours after LPS administration, 
whereas cytokine levels are still high(39, 40). All study procedures were in accordance with the 
declaration of Helsinki, including the latest revisions and approved by the local medical 
ethics committee (CMO: 2015/2058).
Participants
Thirty healthy, non-smoking Caucasian males aged 18–35 years old (median age 21; IQR: 
20–23) without any medical/psychiatric history or current use of (prescription) drugs were 
recruited by the Radboud University Medical Centre Intensive Care Research Unit (see Table 1; 
Supplementary Materials for inclusion and exclusion criteria). All subjects were bachelor 
or master students from the local universities. To reduce potential variation related to 
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gender or hormonal fluctuations in female menstrual cycle(41-44), only male subjects were 
used. Participants were asked to refrain from food (12 hours) as well as caffeine and alcohol 
(24 hours) before the LPS/placebo challenge. One volunteer was excluded due to vomiting 
that interfered with task performance during session 2 (LPS group: n=14, placebo group: n=15). 
Table 1: Characteristics of Participants
  LPS group (n=14) Placebo group (n=15)
  Median IQR Median IQR p-value 
(between groups t-test)
Age (years) 21 20–23 22 19–23 0.90
Height (cm) 180 178–188 186 178–189 0.16
Weight (kg) 75 70–84 79 71–87 0.65
BMI (kg/m)2 23 20–26 23 22–25 0.93
Force-Level Familiarization
After estimation of maximum voluntary contraction (MVC) (see Supplementary Materials 
for details on apparatus and MVC estimation), the five effort levels were set as 10%, 27.5%, 
45%, 62.5%, and 80% of each individual’s MVC, and represented as sections on the trunk of 
an apple tree (Figure 1b). Beginning at effort level 1, participants practiced squeezing to the 
required force and holding their grip at that force for 2 seconds (Figure 1c). The trunk of the 
tree filled up with red as the dynamometer was squeezed, and turned yellow as soon as the 
required force was reached. Each effort level was performed twice sequentially from level 1 
to level 5 using the dominant hand. Force-level familiarizations were repeated at the start of 
each session to remind participants of the effort required for each level.
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Figure 1. (a) Example of the feedback participants saw during calibration phase. (b) Representation of how 
effort and stake levels were presented to participants. Effort level was indicated by where the yellow line 
appeared on the tree’s trunk, starting at the bottom for effort level 1 and moving up to effort level 5 at the 
top. In the example pictured effort is set at level 3 corresponding to 45% MVC. Stake level is indicated by the 
number of apples on the tree, which ranged from 2 to 16 apples. In the example pictured stake is set at stake 
level 3 corresponding to 8 apples. (c) All the stages of the task that were repeated during each session. In 
force-level familiarization stage, participants had to reach each effort level twice, starting at effort level one 
(pictured) and moving up to effort level 5. They then completed the NASA task-load index questionnaire. 
During the decision phase, each of the 25 conditions were presented four times each in a pseudo-random 
order. Participants just had to select YES or NO to each offer. For the execution phase, 26 trials from the 
decision phase were randomly selected for the participant to perform. If an offer they had accepted (YES) was 
selected, they saw the command ‘start squeezing!’ and were able to attempt to reach the force level required 
to win the apples. If an offer they had rejected (NO) was selected the message ‘offer rejected’ appeared on the 
screen and they waited for the next trial to begin.
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Experimental Task
Participants were presented with a series of offers, in the form of the apple trees, and they 
had to select YES or NO, by lightly squeezing the right or left dynamometer, depending on 
if they evaluated the stake offered to be ‘worth the effort’. Twenty-five possible offers (all 
combinations of the 5 effort levels and 5 stake levels (1, 4, 8, 12, or 15 apples)) were each 
sampled four times in a pseudo-random order, totaling 100 trials in each session (Figure 1).
To make each judgment behaviorally relevant, participants were told that 26 decisions 
would be randomly selected for them to perform immediately following the decision phase. 
These 26 trials were then presented during an execution phase. If the offer was accepted, 
participants had 5 seconds to reach the required effort level and hold it for 2 seconds. If 
they were successful, they received feedback stating how many apples they had won. If the 
offer was rejected, the tree appeared on screen with the message ‘offer rejected’, meaning 
they were not able to attempt to win the apples offered (Figure 1c). Participants were told 
at the start of the day they would be rewarded based on the number of apples (worth 3 
cents each) they gathered during this execution phase. Ten trials were practiced before 
session 1 to familiarize them with the stake/effort relationships. To control for changes in 
perceived task demand, participants performed a NASA task-load index questionnaire(45) 
after each familiarization session. Participants rated temporal, physical, and mental demand; 
frustration, effort required and their performance for each effort level.
Measurement of Sickness Behavior and Mood
Physical sickness symptoms were measured before LPS administration (T=0) and at 
30-minutes intervals until 8 hours after LPS administration (17 measurements). Participants 
were asked to rate from 0 (absent) to 5 (very severe) the severity of six common symptoms: 
nausea, headache, muscle aches, back pain, shivers, and vomiting. Self-reported mood 
was assessed using the depression and fatigue subscales of the profile of moods state 
questionnaire (POMS (46)) at the start of each session (see Supplementary Materials for 
details on the subscale items).
Measurement of Cytokines in Plasma
EDTA-anticoagulated blood was collected at: 1, 1.5, 2, 3, 4, 6, and 8 hours after LPS 
administration, centrifuged (2000 g, 4 °C, 10 minutes), and stored at −80 °C until analysis. 
Plasma concentrations of cytokines of interest (TNF-α and IL-6) were measured using a 
simultaneous (entered together in one batch) Luminex assay (R&D systems; Abingdon Science 
Park, UK, Human high sensitivity cytokine kit, catalog numbers LHSCM000, LHSCM210, 
LHSCM206, www.rndsystems.com). Statistical analyses to calculate plasma concentrations 
were performed using Graphpad Prism version 5.0 (Graphpad Software, San Diego, CA, USA). 
Lower detection limits in plasma and intra-assay coefficients of variation (C.V.) were; 0.22 pg/
mL (C.V. 1.54%) for TNF-α and <0.86 pg/mL (C.V. 0.92%) for IL-6. We initially also aimed at 
assessing IL1-RA and IL1-β because of the suggested association between IL1 and fatigue(33). 
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Unfortunately, luminex assays of IL1-RA failed and measures were considered unreliable as 
concentrations of IL1-RA exceeded the upper detection limit (>15 296 pg/mL, C.V.=0.046%). 
IL-1β was excluded from analyses because plasma concentrations did not exceed lower 
detection limits at 2 hours post-injection (0.79 pg/mL, C.V.=0.30%).
Statistical analysis
Behavioral Task
The percentage of accepted offers for each of the 25 conditions (5 effort and 5 stake levels) was 
the key variable for each participant. We first tested whether LPS induced a change in choice 
behavior between session 1 and session 2. Acceptance rates were entered into a 5 (effort 
level) × 5 (stake level) × 2 (time) × 2 (groups) AVOVA. On the basis of our hypothesis, we were 
specifically interested in whether LPS affected effort and/or stake sensitivity. Accordingly, our 
tests of interests were the effort × time × stake × group interaction and, if significant, the effort 
× time × group and stake × time × group interactions. If LPS induced a significant change in 
choice behavior, we subsequently ran an ANOVA comparing session 1 and session 3 to test 
whether the LPS-induced changes in choice behavior recovered to baseline.
These analyses were repeated with generalized estimating equation (GEE) using a binary 
logistic model and exchangeable working correlation structure, which is better suited for 
binomially distributed categorical outcomes. Effort level, stake level, and trial (1–100) were 
mean centered and entered as continuous variables, session and group (LPS/placebo) were 
entered as factors, and the model contained all main effects and interactions.
Subjective Measures, Cytokines, and Physiology
A total score for sickness symptoms was calculated for each subject at each time point. 
Febrile response and sickness symptoms were entered into a repeated-measures ANOVA with 
the factors time (17 levels) and group. Plasma concentrations of cytokines (TNF-α and IL-6) 
were entered into a repeated-measures ANOVA with the factors time (8 levels) and group.
Total scores for depression and fatigue were calculated as mean score on the POMS 
subscales for each session. A repeated-measures ANOVA with the factors time (3 levels) and 
group was performed for fatigue and depression scores separately. Similar to our behavioral 
analysis, we first assessed LPS-induced changes between session 1 and 2. If significant, we 
assessed whether changes recovered to baseline by comparing session 1 and 3. Post-hoc 
Bonferroni-corrected independent t-tests were calculated, where appropriate.
Relationship Between Effort/Stake Sensitivity and Mood and Cytokines
To assess whether LPS-induced changes in behavior were associated with changes in mood 
and/or cytokines, we first calculated the individual levels of effort and reward sensitivity 
via a binomial logistic regression in Matlab with effort and stake level as predictors and 
the decisions (yes/no) as dependent variable for each subject. The β’s were standardized 
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by dividing by the standard error to minimize the impact of inflated β’s (Apps et al, 2015) 
(Supplementary Table S2). Change (session 2−session 1) in the standardized β’s were used 
to assess relationships with LPS-induced changes in mood and/or cytokines. Two stepwise 
multiple regressions were used with change in effort sensitivity and change in stake sensitivity 
as dependent variable. Change in depression, change in fatigue, peak concentration of IL-6, 
and peak concentration of TNF-α were entered as predictor variables in both regressions. All 
regressions were computed using only data from the LPS group. Statistical threshold for all 
stepwise multiple regression analyses were Bonferroni-corrected for multiple comparisons.
Control Analyses
To assess whether LPS effects were explained by alterations in perceived physical demand, 
we assessed LPS effects on total scores of the NASA task-load index questionnaire (sum of 
each section) using a repeated-measures ANOVA with the factors effort, time, and group. We 
additionally assessed LPS effects on the NASA task-load index subscales ‘physical demand’ 
(How physically demanding was the task?) and ‘effort’ (how hard did you have to work to 
accomplish the task?) using repeated-measures ANOVA with the factors effort, time and 
group, and on the sickness symptom ‘muscle aches’ using repeated-measures ANOVA with 
the factors time and group. When no groups’ differences were found, we tested whether LPS 
effects on behavior remained significant when the NASA subscales or the sickness symptom 
‘muscle aches’ were added as covariate into the ANOVA on acceptance rates.
Finally, we assessed the relationship between standardized β’s from the binomial logistic 
regression and other variables that may confound the behavioral results (ie, total sickness 
symptoms, muscle aches, febrile response, NASA physical demand, and NASA effort) within 
the LPS group using Pearson’s correlation analysis. Total sickness symptoms and febrile 
response could not be added as covariate in the ANOVA because they were significantly 
affected by LPS (see ‘Results’) and therefore violate the assumption of homogeneity of 
regression slopes(47).
RESULTS
Behavioral Task
Results are presented in Figure 2 and Supplementary Tables S1 and S2. As shown previously 
in healthy people(30, 31), there were significant main effects of effort and stake on acceptance 
rates, demonstrating that both groups were sensitive to the effort and stake manipulations 
(acceptance rates increase with higher stake and lower effort levels) (stake: F(4,108)=131.2, 
p<0.001, effort: F(4,108)=117.2, p<0.001).
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Figure 2 (a) The mean percentage of accepted offers during the decision phase for each of the 25 conditions 
(5 effort × 5 stake). Left column is results from the LPS group, right column is results from the placebo group. 
Top row is results from session 1, middle row from session 2, and bottom row is from session 3. (b) The mean 
percentage of accepted offers during session 2 collapsed across each effort (left) and stake (right) level. Error 
bars represent the standard error of the mean. *p<0.05 in a Student’s t-test.
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LPS effects on stake differed significantly from LPS effects on effort (stake × effort × time × 
group: (F(16,432)=1.81, p=0.028), with significant group effects on effort-related acceptance rates 
(effort × time × group: F(4,108)=3.2, p=0.016), but not stake-related acceptance rates (stake × 
time × group: F(4,108)=0.4, p>0.7). Breakdown of the interaction by group revealed that effort-
related acceptance rates were reduced in the LPS group (stake × effort × time: F(16,208)=3.12, 
p<0.001; effort × time: F(4,56)=4.93, p=0.002; stake × time: F(4,56)=1.77, p=0.15), but not in the 
placebo group (stake × effort × time: F(16,208)=1.17, p=0.29; effort × time: F(4,56)=1.13, p=0.34; 
stake × time: F(4,56)=2.28, p=0.11). Further breakdown of the effort × time × group interaction by 
session revealed that there was no between group difference at session 1 on any of the effort 
levels (all p>0.05), and that the LPS group accepted less offers than the placebo group for the 
highest effort level during session 2 (80%: T(27)=−2.695, p=0.012; 62.5%: T(27)=−1.843, p=0.076). 
This between group difference on effort was not present during session 3, compatible with 
partial recovery (effort × stake × time × group: F(16,432)=1.295, p=0.196; effort × time × group 
(F(4,108)=0.366, p=0.833; stake × time × group (F(4,108)=0.999, p=0.411).
These findings were confirmed with GEE (stake × effort × time × group: β=−0.026, SD=0.13, 
p=0.043; effort × time × group: β=−0.85, SD=0.22, p<0.001; stake × time × group: β=0.36, 
SD=0.19, p=0.062). Breakdown of the interaction by group revealed that effort but not stake-
related acceptance rates were reduced in the LPS group (stake × effort × time: β=0.24, SD=0.11, 
p=0.021; effort × time: β=0.75, SD=0.20, p<0.001; stake × time: β=−0.12, SD=0.13, p=0.35), 
whereas the trend observed for the stake × time × group interaction was driven by a trend 
in the placebo group (stake × effort × time: β=−0.02, SD=0.08, p=0.81; effort × time: β=−0.14, 
SD=0.10, p=0.17; stake × time: β=0.27, SD=0.14, p=0.053). Further breakdown of the effort × 
time × group interaction by session revealed that there was a between group difference at 
session 2 (stake × effort × group: β=−0.31, SD=0.13, p<0.016; effort × group: β=1.03, SD=0.25, 
p<0.001; stake × group: β=−0.46, SD=0.24, p=0.053) but not at session 1 (stake × effort × group: 
β=−0.066, SD=0.23, p=0.42) or session 3 (stake × effort × group: β=−0.184, SD=0.12, p=0.14) 
(Supplementary Tables S3 and S4).
Total rewards obtained in the execution phase ranged between €2.67–€6.42 for session 1, 
€1.25–€6.39 for session 2, and €1.41–€6.39 for session 3 and did not differ between groups 
(all p>0.05) (Supplementary Table S2). All subjects were able to successfully perform all effort 
levels twice before each session, indicating that LPS did not affect the ability to perform high-
effort trials.
Subjective Measures, Cytokines, and Physiology
LPS, but not placebo, induced an increase in sickness symptoms (group × time: F(1,26)=18.9, 
p<0.001), which peaked at 1.5 hours post-injection. Importantly, sickness symptoms were 
significantly higher in the LPS group relative to the placebo group at session 2, whereas no 
group differences were observed at session 1 prior to injection, nor at session 3 at 5 hours 
post-injection (session 1 T(27)=1.37, p>0.1; session 2: T(27)=2.15, p<0.05; session 3: T(27)=0.30, 
p>0.7, Figure 3a; Supplementary Table S5).
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Figure 3. (a) Time course of mean total sickness symptoms scores. (b) Time course of febrile response. (c) 
Time course of mean plasma cytokine level for IL-6. (d) Time course of mean plasma cytokine level for TNF-α. 
Error bars represent the standard error of the mean.
LPS resulted in a 1±0.6 °C (mean±SD) increase in temperature (F(16,432)=13.4, p<0.001) and 
marked increases in all cytokines of interest at session 2 (IL-6: F(7,189)=32.48, p<0.001; TNF-α: 
F(7,189)=88.83, p<0.001) (Figure 3b–d). Temperature and cytokines reduced back to baseline by 
8 h from injection. The placebo group showed no change in any of the cytokines throughout 
the whole recorded period.
LPS affected self-reported depression and fatigue levels (depression time × group: 
F(1,27)=10.997, p=0.003; fatigue time × group: F(1,27)=23.6, p<0.001). Specifically, the LPS group 
reported feeling significantly more depressed and fatigued than the placebo group during 
session 2 (depression: T(27)=3.609, p<0.001; fatigue: T(27)=4.806, p<0.001), but not session 1 
(depression: T(27)=1.517, p=0.141; fatigue: T(27)=0.915, p=0.368). The time × group interaction 
effect was no longer significant for fatigue or depression when looking at session 3 vs. session 1 
(depression: T(27)=1.579, p=0.220; fatigue: T(27)=2.477, p=0.127). However, direct comparisons 
revealed that the LPS group remained significantly more depressed than the placebo group 
during session 3, but only marginally more fatigued (depression: T(27)=2.221, p=0.035; fatigue: 
T(27)=1.942, p=0.063) suggesting only partial recovery for fatigue (Figure 4a).
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Figure 4. (a) Mean profile of mood state (POMS) score for the fatigue (left) and depression (right) subscales for 
each session. (b) Total NASA task-load index score for each effort level for session 1 (left) and session 2 (right). 
Error bars represent standard error of the mean. *p<0.05 in a Student’s t-test.
Relationship Between Effort/Stake Sensitivity and Mood and Cytokines
No relationship between changes in motivational behavior and mood or cytokines were 
observed: POMS scores for depression and fatigue, IL-6 or TNF-α did not remain in the 
stepwise multiple regression analyses as significant predictors for LPS-induced change in 
effort or stake sensitivity (all p>0.1, Supplementary Table S6).
Control Analyses
The LPS group did not differ from the placebo group on the total NASA score or any of the NASA 
subscales (no significant interaction effects, minimum p>0.05, Figure 4b; Supplementary 
Table S5) indicating that LPS did not affect perceived (physical) demand of the requested 
effort levels. LPS effects on muscle aches did not differ between the groups (F(1,27)=1.11, p=0.30). 
         Adding the factor ‘physical demand’ as covariates to the main analyses did not affect our 
main result (F(16,400)=1.802, p=0.029), and no relationships were observed between ‘physical 
demand’ and effort sensitivity (r(14)=0.34, p=0.02). However, adding the subscale ‘effort’ as 
covariate to the main analyses resulted in a trend for the effort × stake × time interaction 
(F(16,400)=1.65, p=0.054). Change in NASA effort was also marginally correlated with change in 
effort sensitivity (r=0.369, p=0.053) (Supplementary Table S6).
Adding muscle aches a covariate in the analysis of decisions did not affect our main 
result (F(16,400)=1.70, p=0.044, Supplementary Table S1). No relationships between LPS effects 
on behavior and muscle aches, total sickness symptoms, and febrile response were observed 
(all p>0.05, Supplementary Table S6).
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DISCUSSION
In this study, we used a relatively new paradigm that parametrically modulates offers with 
respect to stake and the effort required to obtain that reward(30, 31). We demonstrate that 
experimentally induced endotoxemia using LPS in humans reduces otherwise healthy 
participant’s willingness to accept high-effort options, without significantly altering reward 
sensitivity.
It has been suggested that sickness behavior is an adaptive motivational state that 
involves reprioritization of the costs and benefits of expending effort, rather than simply being 
general physical weakness(12). Our results support this claim: LPS reduced acceptance rates of 
high-effort options, whereas the ability to perform the task was not changed. All participants 
were able to successfully perform the effort levels during a familiarization phase prior to their 
decisions and participants reported no differences in perceived demand to perform the task 
as indexed by the NASA task-load index. This suggests that the changes we observed are due 
to altered motivation, rather than a change in physical strength or ability.
Changes in motivation are common across a broad range of psychiatric and medical 
conditions(48-51). There is increasing evidence that inflammation may have an important role 
in development of amotivated states(3, 19, 52-57). Here, we found that LPS increased cytokines 
and concomitantly altered motivational behavior and mood supporting the concept that 
inflammation could have a role in development of symptoms such as depression and 
fatigue(2, 21, 32, 58, 59).
However, we could not demonstrate direct relationships between LPS-induced behavioral 
changes and cytokine concentrations or mood. This could be due to our small sample size, 
lacking the power to detect such associations. In addition, the immune manipulation we 
used (LPS) induced robust increases with little variation in multiple cytokines that strongly 
interact with one another, making it difficult to disentangle which cytokine is responsible 
for the observed change in behavior. Future studies that induce more variation, eg, by using 
different dosages or selectively stimulate or inhibit cytokines could provide more insight on 
the role of specific cytokines on change in behavior. Although many studies have suggested 
relationships between motivational behavior and mood, actual reports of these relationships 
have been limited(29, 60). One reason for this could be that the POMS was not sensitive enough 
to detect subtle alterations in depressive mood and fatigue. Alternatively, because our task 
dissociated between the sub-constructs of motivation (effort and reward)(61), it may have 
captured behavior that is not necessarily reflected by the subjective reports of fatigue and 
depression(58).
To the best of our knowledge, there has only been one previous human study that 
investigated effort and reward processing during inflammation(29). That pioneering 
investigation used two-option choices (high-reward/high-effort vs. low-reward/low-effort) 
and showed that after LPS the high-effort option was still favored, more so when the 
probability of gaining the reward was also high. There was no difference between LPS and 
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placebo conditions in the number of high-effort choices. Although our results may at first 
appear to contradict these findings, both studies demonstrated that reward sensitivity was 
not affected by LPS. In addition, the two studies differed in important ways.
First, in Lasselin et al’s forced-choice design, participants had to perform an action on 
each trial (meaning they updated their experience of the effort options), and they chose to 
perform the high-effort actions to gain a higher reward at the same rate as after placebo. In 
our design, participants only had the option to perform actions they considered ‘worth the 
effort’ for the reward offered, ie, they could choose to do nothing, which led to a reduction in 
choice of high-effort options during inflammation. Furthermore, our paradigm parametrically 
modulated effort and reward, rather than offering two-option choices. In this way, our task 
allowed participants to gain the high rewards at a lower effort level, meaning gaining the 
largest reward was not contingent on putting in the highest effort. Second, the previous 
human study(29) had a probability dimension, the likelihood of gaining the reward on high-
effort trial was variable, an aspect which we did not test. Our task was simpler: reward 
was always given if the participant reached the effort level required. Finally, the previous 
investigation tested their participants 4 hours post-LPS, while we tested participants 2 hours 
post-LPS, which might be why our subjects were more effort sensitive. Indeed, the alterations 
in effort sensitivity were partly recovered 5 hours after LPS.
One potential mechanisms through which cytokines can affect motivational behavior 
is through interference with brain dopamine function(2). Indeed, effort- and reward-related 
components of motivated behavior have consistently been linked to dopamine signaling(62-64). 
For example, using a variation of the task reported here, Chong et al 2015 observed that 
patients with Parkinson’s disease, who often experience motivational symptoms, were willing 
to put in more effort to gain rewards when they were ON dopaminergic drugs compared to 
when they were OFF them. Animal work has also shown that dopamine depletion in the 
nucleus accumbens causes similar changes in effort-based choice behavior as observed 
here(65). However, previous neuroimaging work has mainly focused on LPS effects on reward-
related processes, showing reduced reward-related signals in the ventral striatum(19, 20, 22). 
Given the partial dissociable brain networks of effort and reward processing(66, 67), the neural 
alterations related to LPS effects on effort-based choice remained to be determined. We 
unfortunately do not have brain imaging data to compare to previous work(19, 20, 22). Future 
studies are needed to better dissociate the neural mechanisms of inflammation effects on 
effort- and reward-related processes.
Insights into immune-to-brain pathways gained from acute immune manipulation 
studies are important for better mechanistic understanding of motivational deficits in 
psychiatric conditions, and could lead to new pharmaceutical targets. Indeed, dopamine 
enhancing drugs like methylphenidate or levodopa can reverse inflammation effects(26, 38, 68) 
and has some effects on reducing fatigue in humans(69-72). It remains to be investigated 
whether other dopamine manipulations would also reverse inflammation effects on 
motivational symptoms. Here we show that our task is sensitive to immune manipulation 
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on dissociable sub-constructs of motivational behavior (reward and effort) in humans. This 
paradigm is therefore promising for further human research on immune-mediated changes 
in motivational behavior, and for testing of pharmacological targets to treat motivational 
symptoms. These could include targets at the immunological level by inhibiting pro-
inflammatory cytokines; a method that has reduced fatigue symptoms in some medical 
conditions(73, 74), but also targets at the central level, affecting dopamine function, for patients 
groups in which immune-alterations are less prominent(33).
This study has several limitations. First, the sample size was small, lacking power to 
detect relevant associations between individual immune responses, motivated behavior, 
and mood. Second, we used a relatively high dose of LPS (2 ng/kg). This inherently also 
induce sickness symptoms that could affect the blindness of the conditions and potentially 
confound task performance. Although we show that our effects are specific to effort and not 
reward-based decisions, and that sickness symptoms were not directly correlated with effort-
based choice within the LPS group, it is unfortunately statistically impossible to dissociate 
sickness symptoms from behavioral alterations, as these factors are not independent(47). 
Simply lowing the dose might not help as this inherently also reduces the behavioral effects, 
while still inducing significant increases in sickness symptoms(75). Instead, future studies might 
potentially be able to dissociate these factors, eg, by assessing effects of co-administration 
with centrally acting drugs that do not affect sickness symptoms. Finally, we tested only men, 
whereas clinical work indicates that motivational symptoms such as depression are more 
prone in woman(76). In addition, several studies highlight the importance of sex differences 
in immune–brain interactions that likely mediate the LPS effects on mood and behavior(42-44). 
This, therefore, limits generalizability of our results.
In summary, experimental endotoxemia reduced, otherwise, healthy participant’s 
willingness to engage in high-effort options, while reward sensitivity was not significantly 
altered. This change in motivation was not due to the task being perceived as more effortful. 
Endotoxemia concomitantly induced an increase in subjective reports of depression 
and fatigue. The behavioral paradigm used in this study provides a human model to 
further investigate brain mechanisms underlying inflammation effects on motivational 
behavior. A better understanding of these mechanisms in humans will be important for 
further development and testing of pharmaceutical targets to treat motivational deficits in 
psychiatric disorders.
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SUPPLEMENTARY MATERIAL
Apparatus
Stimulus was programmed using the Psychtoolbox (http://psychtoolbox.org) in MATLAB 
(the Math Works Inc., USA) and presented on a laptop computer, while participants sat up 
straight in their hospital bed. Participants responded by squeezing one of two TSD121B-MRI 
hand dynamometers (BIOPAC Systems Inc., USA), which have a sample rate of 500 Hz. The 
force signal from the hand dynamometers was digitized and fed into the stimulus laptop in 
real time, and recorded in MATLAB. The experimental task used in this study was a modified 
version of the apple gathering task described previously (Bonnelle et al, 2015, 2016). 
Estimation of maximum voluntary contraction
At the beginning of Session 1, participants were asked to squeeze the dynamometer as 
strongly as they could using their dominant hand. Visual feedback was provided of a black 
bar filling up with red from the bottom, the level of which corresponded to the amount of 
force being applied to the dynamometer (Figure 1A). The procedure was repeated three 
times, with a yellow line, positioned on the bar at the level of maximum force recorded thus 
far, serving as a target to exceed. Maximum voluntary contraction (MVC) was estimated as 
the maximum force recorded from all three attempts. It was kept constant throughout all 
sessions for each individual.
Profile of Moods 
The subscales depression (8 items) and fatigue (6 items) were presented as visual analogue 
scales with opposing moods at each extreme, presented on a tablet computer using 
qualtrics online survey software (https://www.qualtrics.com). The items were comparable to 
the 4-item scales used in other LPS studies (e.g. Eisenberger et al., 2010). 
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Complete exclusion criteria:
• Female sex
• Pre-existent lung disease, including asthma
• A history of allergic rhinitis 
• Use of any medication
• Current smoker or more than 5 pack-year history
• Use of recreational drugs within 21 days prior to start of the study
• Use of caffeine or alcohol within 1 day prior to start of the study
• Surgery or trauma with significant blood loss or blood donation within 3 months prior 
to start of the study
• Participation in another clinical trial within 3 months prior to start of the study
• Frequent nosebleeds 
• Recent nasal or otologic surgery
• (suspected) influenza infection during the last year
• Clinically significant acute (febrile) illness or a common cold within four weeks prior 
to start of the study
• History of frequent vaso-vagal collapse or of orthostatic hypotension 
• History, signs or symptoms of cardiovascular disease. 
• History of allergic reaction to Fluenz™, eggs / gelatin / gentamicin
• History of Guillain-Barré Syndrome
• Cardiac conduction abnormalities on the ECG consisting of a 2nd degree atrioventricular 
block or a complex bundle branch block.
• Hypertension (defined as RR systolic > 160 mmHg or RR diastolic > 90 mmHg).
• Hypotension (defined as RR systolic < 100 mmHg or RR diastolic < 50 mmHg).
• Renal impairment (defined as plasma creatinin >120 μmol/l).
• Liver function abnormality: alkaline phosphatase>230 U/L and/or ALT>90 U/L
• CRP > 20 mg/L, WBC > 12x109/L
Table S1: ANOVA and ANCOVA results on behavioral choice data without and with potential confounding 
factors included as covariate. * p<0.05, ^p<0.1 
x stake*time*group effort*time*group effort*stake*time*group
covariate F p F p F p
No covariate 0.476 0.753 3.184 0.016* 1.81 0.028*
Muscle aches 0.439 0.741 2.671 0.036* 1.697 0.044*
NASA physical demand 0.446 0.775 2.289 0.065^ 1.802 0.029*
NASA effort 0.492 0.741 2.284 0.065^ 1.65 0.054^
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Table S2: mean (SE) of % accepted offers for each effort and reward level per group and session, mean 
T-values (SE) of effort and reward sensitivity calculated from the binomial logistic regressions per group and 
session and the total number of apples worth 3 cents each (SE) obtained in the execution phase. 
LPS Placebo
Session 1 2 3 1 2 3
% yes Effort
10% of MVC 82.5(4.6) 81.1(3.2) 79.3(4.1) 82.3(4.4) 78(5.8) 79.3(6.7)
27,5 % of MVC 80.4(3.4) 71.1(4.5) 70.4(5.9) 74(4) 71.3(7.5) 72.3(9.3)
45% of MVC 64.3(5.2) 52.1(3.9) 48.6(5.7) 62.3(5.8) 58.7(8.6) 53(7.7)
62,5% of MVC 38.2(7.8) 12.5(1.6) 21.1(3.8) 39.7(7.4) 30.3(7.1) 27.3(7)
80% of MVC 26.8(7.9) 2.9(5) 6.8(4.1) 26(7.1) 23(7.3) 18(6.6)
% yes reward
1 apples 20.4(6.5) 13.6(4) 12.9(5) 19.3(5.9) 21.7(7.3) 22.3(7)
4 appels 42.5(7.5) 26.4(2.5) 26.1(4.4) 37.7(6.8) 31(8) 33.7(7.7)
8 apples 63.9(5.2) 48.6(2.6) 51.1(4.5) 63(5.5) 61.3(6.2) 58(7)
12 apples 81.1(4.5) 64.6(3.5) 66.1(4.6) 81.3(4.5) 70(5.1) 66.3(6.9)
15 apples 84.3(4.9) 66.4(1.6) 70(3.8) 83(4.6) 77.3(7.1) 69.7(7)
T-value of binomal logistic regression
Effort -2.9(0.5) -3.9(0.3) -3.9(0.2) -2.6(0.5) -2.6(0.5) -2.7(0.5)
Stake 3.4(0.4) 3.3(0.3) 3.5(0.3) 3.4(0.4) 3(0.4) 2.3(0.5)
Reward obtained in execution phase
Total number of apples 150(11) 115(4) 124(9) 147(10) 134(15) 133(15)
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Table S3. Results from generalized estimating Equation (GEE) analysis using a binary logistic model with 
choice (yes/no) as dependent variable and effort (5 levels), stake (5 levels), session (2 levels), trial (100 trials) 
as predictor variables, comparing the LPS and Placebo groups (upper part) and per group separately (lower 
parts). Effects of interest and relevant post-hoc tests are presented in bold.
    Session2 vs Session1   Session3 vs Session1
    beta SD p   beta SD p
LPS vs PLACEBO
Repeated 
variables
Session 0.141 0.5781 0.002 1.031 0.3899 0.008
Trial 1.029 0.3326 <.001 -0.008 0.0035 0.019
Effort -1.924 0.182 <.001 -0.476 0.1903 <.001
Stake 1.362 0.1857 <.001 1.243 0.2042 <.001
Effects of 
interest
 
Stake*effort*time*group -0.263 0.1297 0.043 -0.194 0.1532 0.205
Effort*time*group -0.851 0.2213 <.001 -0.394 0.2963 0.184
Stake*time*group 0.357 0.191 0.062 0.422 0.2722 0.121
LPS group
Repeated 
variables
Session .1.042 0.3218 0.001 1.04 0.3758 0.006
Trial -0.016 0.0033 <.001 -0.008 0.0034 0.016
Effort -1.948 0.1822 <.001 -0.130 0.1856 <.001
Stake 1.378 0.1907 <.001 1.26 0.1937 <.001
Effects of 
interest
 
Stake*effort*time 0.248 0.1072 0.021 0.055 0.1363 0.687
Effort*time 0.752 0.2033 <.001 0.269 0.2667 0.268
Stake*time -0.123 0.1321 0.353 0.001 0.1896 0.997
PLACEBO group
Repeated 
variables
Session 0.437 0.2756 0.113 0.713 0.3868 0.065
Trial 0.001 0.0015 0.887 -0.001 0.0019 0.509
Effort -0.948 0.1658 <.001 -0.962 0.1684 <.001
Stake 0.948 0.1282 <.001 0.769 0.1531 <.001
Effects of 
interest
 
Stake*effort*time -0.018 0.0755 0.813 -0.143 0.0755 0.057
Effort*time -0.141 0.1029 0.17 -0.154 0.1769 0.383
Stake*time 0.268 0.1388 0.053 0.473 0.2114 0.025
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Table S4. Results from generalized estimating Equation (GEE) analysis per session separately using a binary 
logistic model with choice (yes/no) as dependent variable and effort (5 levels), stake (5 levels), trial (100 trials) 
and group (LPS/placebo) as predictor variables. Effects of interest and relevant post-hoc tests are presented 
in bold. 
    Session1
    beta SD p
LPS vs PLACEBO
Repeated variables group -0.553 0.6522 0.397
Trial -0.013 0.0055 0.016
Effort -1.222 0.1509 <.001
Stake 1.281 0.173 <.001
Effects of interest
 
Stake*effort*group 0.066 0.0828 0.427
Effort*group 0.136 0.2248 0.544
Stake*group -0.069 0.2317 0.766
  Session2   Session3
  beta SD p   beta SD p
0.244 0.4818 0.612 0.379 0.5653 0.502
-0.016 0.0034 <0.001 -0.008 0.0034 0.016
-1.966 0.1827 <0.001 -1.509 0.1861 <.001
1.39 0.1979 <0.001 1.27 0.1894 <.001
0.305 0.1268 0.016 0.184 0.1243 0.139
1.031 0.252 <0.001 0.546 0.2547 0.032
-0.456 0.2361 0.053   -0.5 0.2444 0.041
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Table S5. Mean (SE) of subjective reports on mood, NASA task load index and sickness symptoms, F-values 
represent group*time interactions, POMS = Profile of Moods *=p<0.05, ns = not significant. 
Condition LPS Placebo F-value 
Session 1 2 3 1 2 3 T2vsT1 T3vsT1
POMS
Depression 28.4(3) 37.5(3.4) 32.8(3.1) 22(3) 19.7(3.5) 22(3.7) 10.997* 1.597 ns
Fatigue 33.5(3.9) 58.5(4.4) 48.7(5.4) 28.9(3.1) 28.7(4.3) 33.6(5.5) 23.6* 2.48 ns
NASA task load index
Mental 4.1(0.6) 5.2(1) 5.2(0.9) 5.7(0.8) 4.5(0.8) 4.5(0.8) 3.385 ns
Physical 6.5(0.6) 7.3(0.6) 7.4(0.5) 7.9(0.7) 7.6(0.7) 8(0.8) 1.584 ns
Temporal 4.9(0.6) 5.9(0.7) 6(0.8) 5.4(0.8) 5.1(0.9) 5.1(0.8) 0.966 ns
Performance 4.3(0.5) 5.7(0.8) 5.9(0.8) 5.3(0.6) 5(0.8) 5.5(0.9) 1.121 ns
Effort 6.4(0.7) 7.4(0.8) 7.6(0.7) 8.4(0.9) 7.1(0.8) 7.9(0.8) 3.181 ns
Frustration 8(1.1) 6(0.9) 5.1(0.8) 8.6(1.2) 4.9(0.7) 5.3(0.8) 1.056 ns
Total 30.6(3.1) 37.5(4.1) 37.2(4.1) 37.3(3.6) 34.1(3.9) 36.3(4.1) 3.238 ns  
Sickness 1.654
Total 0.3(0.2) 2.4(0.5) 0.3(0.2) 0.7(0.2) 0.9(0.6) 0.4(0.2) 6.408*  ns
Table S6. Standardized beta’s or Pearson’s correlations between LPS induced changes on effort/stake 
sensitivity and cytokines, mood, sickness symptoms and perceived task demand (NASA) within the LPS group. 
effort stake
  r/beta p r/beta p
IL-6 0.34 0.236 -0.337 0.238
TNF-α 0.307 0.286 -0.356 0.221
POMS depression -0.11 0.708 0.256 0.419
POMS Fatigue -0.306 0.288 0.235 0.419
Muscle aches 0.351 0.219 -0.256 0.376
Sickness Total -0.042 0.886 0.332 0.246
Febrile response 0.367 0.196 -0.092 0.754
NASA physical demand 0.278 0.153 -0.124 0.53
NASA effort 0.369 0.053 -0.253 0.195
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Effects of serostatus and gender on the 
HRV-16-induced local immune response
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HIGHLIGHTS
• HRV-seropositivity results in a diminished immune response upon HRV infection.
• Gender does not influence the HRV-induced immune response.
• Only seronegative subjects should be included in future HRV studies.
• Both sexes can be included without stratification in future HRV studies.
ABSTRACT
 
Background: The “experimental cold model” is widely used to investigate effects of HRV 
infection. However, effects of serostatus and gender on the HRV-induced immune response 
have not been clarified.
Methods: 40 healthy seropositive and seronegative (1:1) male and female (1:1) subjects were 
inoculated with HRV-16.
Results: HRV infection increased viral load in nasal wash, which tended to be more 
pronounced in seronegative subjects. Furthermore, HRV infection increased levels of IP-10, 
IL-6, and IL-10 and leukocyte numbers in nasal wash of seronegative, but not of seropositive 
subjects. No differences in any of the parameters were found between both sexes.
Conclusion: The HRV-induced local immune response is diminished in seropositive subjects 
compared with seronegative subjects, while gender does not influence this response. These 
results have important implications for the design of future experimental cold studies: 
seronegative subjects, from both sexes can be included.
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INTRODUCTION
Human rhinoviruses (HRVs) are the most frequent cause of the common cold(1) and 
the “experimental cold model” is widely used to investigate the pathogenesis of HRV 
infection, including the effects on pulmonary function(2), allergies(3), COPD(4), and asthma 
exacerbations(2). In most experimental cold studies, only seronegative subjects have been 
included, as it is assumed that serostatus may influence the HRV-induced immune response. 
However, hitherto only the effects of serostatus on clinical parameters such as secretion 
production, nasal mucociliary clearance, and symptoms have been evaluated(5, 6). These 
were found to be less pronounced in seropositive subjects(5, 6), but immunologic effects are 
unknown.
Furthermore, it also remains to be determined whether gender influences the HRV-
induced immune response. Next to pathophysiological implications, clarification of these 
issues is important with regard to the design of future (intervention) studies that utilize the 
experimental cold model. For instance, it will reveal whether solely seronegative subjects 
can be included when evaluating immunologic endpoints and whether both sexes can be 
included without stratification.
MATERIAL AND METHODS
Study design
This study was part of a larger trial that also aimed to investigate systemic effects of HRV 
infections and effects of two subsequent HRV challenges. This study is registered at 
ClinicalTrials.gov (NCT01823640) and was approved by the local medical ethics committee 
CMO Arnhem-Nijmegen (NL42503.091.12; CMO 2012/476). 40 healthy male and female 
subjects (ratio 1:1), aged 18–35  years of which 22 were seronegative for HRV-16 (virus 
neutralization titer [VNT]  <  1:4 in all subjects), and 18 seropositive for HRV-16 (VNT ⩾  1:4; 
median [IQR] 1:8 [8–24]) were inoculated intranasally with 102 TCID50 units of HRV-16. After 
excluding subjects that had a positive viral load at baseline, 33 subjects remained, of which 
27 (82% infection rate) showed positive infection (positive viral load and/or seroconversion 
[defined as ⩾fourfold increase in antibody titer at day 28 post-inoculation compared with 
baseline(2), and were thus eligible for immunological analyses (Figure 1). Nasal washings for 
viral load, leukocyte, and chemokine/cytokine quantification were collected daily, from the 
day of inoculation (day 0) until day 14. Symptom scores were obtained twice daily throughout 
the study period using an online symptoms diary (LimeSurvey Project Hamburg, Germany), 
using the Wisconsin Upper Respiratory Symptom Survey (WURSS-24)(7). Serum antibody 
titers were determined at baseline and at day 28.
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Figure 1. Flowchart of the study based on infection rate.
HRV-16 virus and inoculation procedure
Safety-tested Good Manufacturing Practice (GMP+) grade inoculum pools of HRV-16 were 
supplied by Respivert Ltd. (MM#400472 Lot#R2011038, London, UK). Each cryovial contained 
0.2 mL of HRV-16 at a dose of 2 * 10
2 TCID50 units/mL and was diluted in Hartmann’s solution 
to a concentration of 102 TCID50 units/mL and stored at −80 °C. Per infection day, one aliquot 
of HRV-16 was cultured in fourfold on a MRC-5 cell monolayer in 10-fold dilutions of samples, 
positive and negative controls in order to assess infectivity. Cell plates were placed at 33 °C 
with 5% CO2 for seven days and observed for the development of cytopathic effects (CPE). 
The Reed-Muench formula was used to calculate the viral titer(8). Viral titers were all in the 
expected infectivity range (101–102 TCID50 units/mL) and positive and negative control wells 
positive and negative for CPE, respectively.
Subjects were inoculated with HRV-16 by instillation of 102 TCID50 (Tissue Culture 
Infectious Dose in 50% of subjects, based on previous studies(9)) units of HRV-16, diluted in 
0.5 mL 0.9% saline into each nostril. Subjects remained in the recumbent position for two 
minutes after instillation and refrained from touching their nose for 30 minutes.
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Antibody titer analysis
A standard end-point neutralization assay for HRV-16 was used to quantify the levels of HRV-
neutralizing antibodies in the serum of every subject at baseline to determine seronegative 
subjects, and to study the VNT increase 28  days after HRV inoculation. The assay was 
performed on MRC-5 cells at 37 °C and 5% CO2. Two-step serum dilutions starting at 1:4 were 
incubated with 102 TCID50 HRV-16 for 1 hour at 37 °C before inoculation on MRC-5 cells. Serum 
controls were included on each plate to test for toxicity, and a positive control of anti-HRV-16 
was added to each test plate. The formation of CPE was examined daily and after 7 days, the 
cultures were scored for CPE. The Reed-Muench formula was used to calculate the antibody 
titer(8). HRV-infection was defined as positive viral load and/or seroconversion.
Nasal wash
Nasal wash for viral load, leukocyte, and cytokine quantification were collected daily from 
subjects according to the method described by Naclerio(10). Nasal wash from two nostrils was 
pooled, centrifuged (6000 rpm, 4 °C, 20 minutes), and stored at −80 °C until analysis.
Viral load
Viral load was determined from nasal wash as described previously(11). Briefly, nucleic 
acids were extracted from each sample using the MagNA Pure LC (with Total Nucleic Acid 
Isolation Kit) and PCRs were performed on the LightCycler 480 with Probes Master Mix (Roche 
Diagnostics, Almere, The Netherlands) using commercial validated primer and probe-mixes 
(Diagenode, Liège, Belgium). Cycling conditions were 95 °C for five minutes, followed by 40 
cycles of 95 °C (15 seconds), 55 °C (15 seconds) and 72 °C (20 seconds). Virus amount was 
recorded semi-quantitatively based on the cycle threshold value (Ct value). All samples in 
which virus was detected (Ct < 40) were considered as having a positive viral load. For samples 
in which no virus was detected, the Ct value was set as 40 to allow fold change calculations. 
Fold change from baseline (Ct = 40) was calculated using the formula 2ΔCt.
Cytokine analysis
Nasal wash samples were collected at various time points, centrifuged (6000  rpm, 4  °C, 
20 minutes) and stored at -80 °C until analysis. Concentrations of IFN-γ, TNF-α, IL-1β, IL-6, IL-8, 
IL-10 were measured using a simultaneous Luminex assay (Milliplex; Millipore, Billerica, MA, 
USA). IP-10 was measured using ELISA (R&D Systems, Minneapolis, MN, USA). Lower detection 
limits were 3.2 pg/mL for IFN-γ, TNF-α, IL-1β, IL-6, IL-8, IL-10, and 156 pg/mL for IP-10.
Leukocyte numbers
Analysis of leukocyte numbers and differentiation from nasal wash was measured using 
routine analysis methods also used for patient samples (flow cytometric analysis on a 
Sysmex XE-5000).
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Statistical analysis
According to the Kolmogov-Smirnov test, all data were non-normally distributed. Therefore, 
demographic data are presented as medians [interquartile range] and between-group 
comparisons were made using Mann-Whitney U and Kruskall-Wallis tests. Categorical data 
were analyzed using Fisher exact tests. All other data are presented as geometric mean and 
95% CI. For these data, within-group differences over time were analyzed on log-transformed 
data using repeated measures one-way ANOVA followed by Dunnett’s post hoc test and 
between-group differences were analyzed on log-transformed peak levels in the first four 
days post-inoculation using unpaired Student’s t-tests. Correlations were analyzed using the 
method described by Bland and Altman(12). For reasons of clarity, only upper or lower bounds 
of the 95% CI are shown in the figures. Statistical analyses were performed using Graphpad 
Prism version 5.0 (Graphpad Software, San Diego, CA, USA) and SPSS statistics version 20 
(IBM Corporation, Armonk, NY, USA). p-values <0.05 were considered statistically significant.
RESULTS
There were no significant differences in baseline characteristics between the groups (Table S1). 
Infection rate was 18/20 (90%) for seronegative subjects and 9/13 (69%) for seropositive 
subjects (p=0.18, see Figure 1). Following HRV inoculation, viral load in nasal wash increased 
in both seronegative and seropositive subjects (Figure 2), but the increase in viral load tended 
to be less pronounced in seropositive subjects. HRV infection resulted in increased levels of 
IP-10, IL-6, and IL-10 in nasal wash of seronegative subjects, but, despite relatively marginal 
differences in viral load between both serostatus groups, this increase was absent or less 
pronounced in seropositive subjects (Figure 2). IFN-γ, IL-1β, and TNF-α levels were below 
the detection limit in virtually all subjects, and no clear profiles were observed following 
HRV infection. IL-8 showed only subtle increases following HRV infection. Of note, IL-6 levels 
increased in 15 out of 18 seronegative subjects, compared with concentrations found before 
inoculation, but in only one out of nine seropositive subjects. Likewise, IL-10 levels increased 
in 16 out of 18 seronegative subjects, but in none of the seropositive subjects. In line with 
the chemokine/cytokine data, numbers of leukocytes and neutrophils in nasal wash were 
significantly higher in seronegative subjects compared with seropositive subjects following 
HRV infection (Table S2). In seronegative subjects, there was a positive correlation between 
viral load and IP-10 levels (Figure S1). Although modestly, viral load was also positively 
correlated with IL-6 and IL-10 levels in these subjects (Figure S1). Symptom scores showed no 
significant increases after HRV infection (data not shown). For all parameters, no differences 
were found between male and female subjects (Table 1).
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Figure 2. Left panel: Viral load and cytokine levels in nasal wash in seronegative (S−, n=18) and seropositive 
(S+, n=9) subjects who displayed positive infection. Right panels: Peak viral load and cytokine/chemokine 
levels during the first four days post-inoculation. Data are represented as geometric mean and 95% CI. * 
indicates p < 0.05 compared with baseline (day 0, before HRV inoculation).
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Table 1. Differences in various parameters between seronegative (S−) and seropositive (S+) males (M) and 
females (F) who displayed positive infection. Data are represented as proportions or geometric mean [95% 
CI] of peak levels during the first four days post-infection. NW: nasal wash.
S− 
F (n = 9)
S− 
M (n = 9)
p-value
Positive infection (%) 9/10 (90%) 9/10 (90%) 1.00
Viral load (fold increase) 4856 [857–27,515] 9069 [1638–50,211] 0.56
IP-10 NW (pg/mL) 5461 [2382–12,520] 7073 [3245–15,417] 0.61
IL-6 NW (pg/mL) 27 [9–82] 37 [13–109] 0.66
IL-8 NW (pg/mL) 7825 [7823–7827] 7828 [7823–7833] 0.25
IL-10 NW (pg/mL) 21 [8–59] 44 [15–130] 0.28
Leukocytes NW (106/L) 0.05 [0.02–0.15] 0.09 [0.03–0.3] 0.42
S+ 
F (n = 4)
S+ 
M (n = 5)
p-value
Positive infection (%) 5/10 (50%) 4/10 (40%) 1.00
Viral load (fold increase) 1058 [371–1948] 493 [370–57,791] 0.89
IP-10 NW (pg/mL) 1211 [720–1421] 1979 [996–4388] 0.29
IL-6 NW (pg/mL) 3.2 [3.2–3.2] 3.2 [3.2–9.4] 0.45
IL-8 NW (pg/mL) 145 [98–258] 214 [109–446] 0.34
IL-10 NW (pg/mL) 3.2 [3.2–3.2] 3.2 [3.2–3.2] 1.00
Leukocytes NW (106/L) 0.01 [0.01–0.04] 0.03 [0.01–0.04] 0.45
DISCUSSION
Herein, we show that, despite a substantial infection rate following HRV challenge in 
seropositive subjects, their local immune response was diminished compared with 
seronegative subjects. Furthermore, there was a distinct trend toward reduced viral load in 
seropositive subjects, suggesting accelerated elimination of the virus. These effects are likely 
due to the presence of specific neutralizing antibodies, which have been shown to induce 
rapid clearance of respiratory viruses and attenuation of the immune response. For instance, 
the RSV-specific neutralizing antibody palivizumab, attenuates both viral load and cytokine 
production in mice infected with RSV(13). However, cellular immunity might also play a role in 
the observed effects of serostatus(1).
Although infection rate was high, infection did not result in a significant increase in 
clinical symptoms. Related to this, no differences between seronegative and seropositive 
subjects were observed. This indicates that HRV infections can often be asymptomatic, which 
is also supported by the fact that seven asymptomatic subjects were excluded for a positive 
viral load at baseline. Alternatively, it may also indicate that the HRV used was relatively 
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avirulent, in which case conclusions about cytokine responses should be interpreted 
cautiously. Nevertheless, we did measure robust increases in levels of several cytokines and 
the differences in cytokine responses between seronegative and seropositive subjects were 
pronounced. The percentage of subjects that displayed a positive viral load at baseline was 
relatively high in this study, possibly related to the season in which the study was carried out 
(January–April).
Previous experimental cold studies included both sexes without stratification(2, 14). In vitro, 
no differences between males and females in IP-10 expression upon stimulation of peripheral 
blood mononuclear cells with HRV-16 were found(15). In line with this, we found no evidence 
of gender differences in the response to HRV infection in vivo.
In conclusion, we report that even in the subjects that fulfill the criteria of HRV infection, 
seropositive subjects demonstrate a diminished local immune response, while gender 
does not influence this response. These results have important implications for the design 
of future (intervention) experimental cold studies. First, because of the profound effects of 
serostatus on the local immune response, only seronegative subjects should be included, 
and second, both sexes can be included and there appears no need to stratify the results 
based on gender.
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SUPPLEMENTARY MATERIAL
Supplementary tables
Table S1. Demographic characteristics of the 27 subjects who displayed positive infection. Parameters were 
assessed during the screening visit. M:male, F:female, BMI: body mass index, S-: seronegative for HRV-16, S+: 
seropositive for HRV-16. Data are presented as medians [interquartile range].
      S-
F (n = 9)
      S-
 M (n = 9)
      S+
F (n = 4)
     S+
M (n = 5)
Total group 
(n = 27) 
p-value 
between 
groups
Age 
(years) 
22 [21-25] 22 [22-26] 24 [22-25] 25 [22-28] 23 [22-25] 0.67
Height 
(cm) 
 168 [166-174]  182 [176-187]  173 [164-179]  185 [179-188]  175 [168-186] 0.48 M 
0.50 F
Weight 
(kg) 
66 [56-71] 74 [72-84] 60 [59-77] 75 [73-93] 72 [64-78] 0.70 M 
0.84 F
BMI  
(kg/m2) 
23 [20-24] 24 [23-25] 22 [20-25] 23 [21-26] 24 [23-24] 0.49 M 
1.00 F
Table S2. Leukocytes in nasal wash. Baseline and peak leukocyte numbers in nasal wash during the first four 
days post-inoculation in seronegative (S-) and seropositive (S+) subjects who displayed positive infection. 
*indicates p<0.05 (HRV S- vs. HRV S+). Data are represented as geometric mean 95% CI.
baseline 
S- (n = 18)
baseline
S+ (n = 9)
HRV
S- (n = 18)
HRV
S+ (n = 9)
p-value 
Leukocytes 
(106/L)
0.03 [0.00-0.18] 0.02 [0.00-0.4] 0.07 [0.03-0.14]* 0.02 [0.01-0.03] 0.04 
Neutrophils 
(106/L)
0.02 [0.00-0.15]  0.01 [0.00-0.11] 0.06 [0.03-0.13]* 0.01 [0.01-0.02] 0.01 
Mononuclear 
cells (106/L)
0.01 [0.00-0.03] 0.00 [0.00-0.5] 0.02 [0.01-0.04] 0.00 [0.00-0.01] 0.11 
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SUPPLEMENTARY FIGURES   
Figure S1. Correlations between viral load and IP-10, IL-6, and IL-10 in nasal wash during the first four days 
post-inoculation in seronegative (S-) subjects who displayed positive infection.
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Chapter 13
Monitoring the dynamics of bacterial 
communities in the upper respiratory tract 
by a Gram-specific PCR method
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ABSTRACT
Currently, microbiota are analysed by 16s ribosomal RNA gene amplicon or shotgun 
metagenomic sequencing, requiring high quality samples, resulting in complex data sets, 
detailed to the species level. From a clinical perspective, this high resolution is not always 
required, and compositional changes in Gram-positive and Gram-negative bacteria might 
be more informative. In this study we have applied a Gram-specific PCR method to monitor 
bacterial dynamics of the upper respiratory tract during experimental human pneumococcal 
colonization and a human Rhinovirus challenge infection. A significant shift (p=0.01) in Gram-
ratio after pneumococcal exposure and a return to baseline after 14 days was observed in 
the pneumococcal colonization model. In the human Rhinovirus infection study, a 5.9-fold 
increase (p=0.04) in variance was observed after infection as compared to placebo treated 
subjects. This Gram-specific PCR method is an easy and attractive tool to assess the dynamics 
of bacterial communities allowing a straightforward analysis.
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INTRODUCTION
In the field of infectious diseases, microbiome analyses have become pivotal in our 
understanding of how infections are acquired and how pathogens colonize, persist and 
spread. This is especially important in the upper respiratory tract, where colonization 
often precedes invasive disease. The microbiome is associated with disease(1-4), where 
interactions between bacteria and viruses can substantially impact the immunological 
responses and clinical outcome(5-8). A well- known example is co-infection of Influenza virus 
and Streptococcus pneumoniae, which leads to a more severe course of disease(9, 10). Viral 
infections can also be significantly influenced by the presence of bacteria or their ligands(11, 12). 
In vitro pre-exposure to Gram-positive Streptococcus pneumoniae was found to enhance 
viral replication of human metapneumovirus11 and in the presence of lipopolysaccharides, 
a Gram-negative cell wall component, infection with respiratory syncytial virus or influenza 
virus was reduced by 80%(11).
The molecular techniques most commonly used for microbiome analysis are 16s 
rRNA gene amplicon or shotgun metagenomic sequencing to study the composition of the 
bacterial communities in depth, to species level. However, these methods are costly, time-
consuming and require a lot of expertise for data analysis and interpretation. Despite the 
existence of these methods, they have not been applied for diagnostic purposes, which is 
likely due to the high level of complexity.
In the present study, we have applied a robust and sensitive real-time PCR-based method 
to distinguish Gram-positive from Gram-negative bacteria in the upper respiratory tract, 
which could potentially be used as a diagnostic or research tool to monitor the dynamics of 
the bacterial composition in a simplified manner. 
To assess the value of this PCR-based method, nasal wash samples collected in a human 
Streptococcus pneumoniae carriage model and an experimental human Rhinovirus (HRV-16) 
infection model were used.
We show that this method allows for monitoring changes in Gram-negative and Gram-
positive ratios of bacterial communities in the upper respiratory tract. Therefore, this method 
can potentially contribute to the understanding of the involvement of immunological 
mechanisms activated by ligands derived from the different groups of bacteria in the context 
of more severe mucosal infections.
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MATERIALS AND METHODS
Real-time Polymerase Chain Reaction
The primers (Forward: 5’-CAA CGC GAA GAA CCT TAC C-3’ and Reverse: 5’-ACG TCA TCC CCA 
CCT TCC-3’) and probe sequences were designed to distinguish Gram-positive and Gram-
negative bacteria (13). We have improved the method by using different labels and quenchers 
for both Gram- positive (5’-TEX-ACG ACA ACC ATG CAC CAC CTG-BHQ2-3’) and Gram-negative 
(5’-Cy5-ACG ACA GCC ATG CAG CAC CT-BHQ2-3’) probes. The PCR was performed using 
SsoAdvancedTM Universal Probe Supermix (Bio-Rad, USA) with 300nM of each primer and 
200nM of each probe on a CFX-96 q PCR (Bio-Rad, USA). The PCR program had an initial 
denaturation step of 120 seconds at 95oC, followed by 40 cycles of 5 seconds at 92oC and 15 
seconds at 62oC. The data was processed in CFX-manager 3.1 (Bio-Rad, USA) and Cq-values 
were obtained by using the regression as Cq determination mode. Duplicates were averaged 
and excluded if the standard error of the mean exceeded 0.5.
To assess the specificity, purified DNA from a relevant Gram-positive (Streptococcus 
pneumoniae) and Gram-negative bacterium (Haemophilus influenzae) was tested separately 
or in combination. Subsequently, a 10-fold dilution series of 4 dilutions of genomic DNA 
(0.15ng, 0.015ng, 0.0015ng and 0.00015ng per strain) was made and measured to determine 
the PCR efficiency. From this dose-response-curve, the y intercept and slope were determined 
to establish the Gram-ratio formula (equation 1), where A represents the Gram-positive and 
B the Gram-negative (Figure 1C and D).
Equation 1: Gram-ratio = 10^((Cq A - y intercept A)/(Slope A)) / 10^((Cq B - y intercept B)/(Slope B))
Equation 2: Gram-ratio = 10^((Cq − 11.87)/(−3.476)) / 10^((Cq − 12.18)/(−3.543))
Analysis of nasal wash samples from human experimental infection models 
The Gram-specific PCR was tested on nasal wash samples taken from experimentally infected 
individuals in a Rhinovirus infection study and nasal wash samples from a pneumococcal 
challenge model. Both studies were approved by the medical ethical committees, carried out 
in accordance with the approved protocols and after written consent was obtained from all 
subjects before being enrolled. For the human pneumococcal carriage study, all participants 
were non-smoking adults aged 18-60 years. For the human Rhinovirus infection study, all 
participants were healthy non-smoking adults aged 18-35 years. A detailed description of the 
pneumococcal carriage and Rhinovirus infection study is provided elsewhere(14-16).
To determine the quality and reproducibility of our method we firstly assessed the Gram-
ratio baseline by comparing the subjects in each study before challenge.
For both studies, the Gram-ratio was measured at different time points. Only subjects for 
which samples at all time points were available were included in this study. The results were 
analysed with respect to shifts in the Gram-ratio, represented by significant differences in the 
mean of a population against the baseline. In addition, the difference in Gram-ratio between 
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two time points (variance) was analysed between pre- and post-challenge in comparison 
with the unchallenged group.
Figure 1. RT-qPCR specificity for the negative probe, n=2 (Mean+SD); A: Streptococcus pneumoniae; B: 
Haemophilus influenzae (A). RT- qPCR specificity for the positive probe, n=2 (Mean+SD); A: Streptococcus 
pneumoniae; B: Haemophilus influenzae (B). RT-qPCR dose- response-curve for the Gram-negative probe, 
n=8 (Mean+SD) (C). RT-qPCR dose-response-curve for the Gram-positive probe, n=8 (Mean+SD) (D).
RESULTS
Specificity and efficiency of the Gram-specific PCR
In this real-time PCR a 16s gene primer set in combination with two probes were used to 
measure either the Gram-positive or Gram-negative bacteria in the microbiome of the 
upper respiratory tract. No background signals were detected, as evidenced by the fact 
that Cq-values were only measured in the presence of template DNA (Figure 1), confirming 
the specificity of the probes. To study the efficiency, a dose-response-curve was plotted for 
both the Gram-positive as well as the Gram-negative probe (Figure 1C and D), displaying low 
standard deviations for the 8 replicates. Efficiency was determined at 95.6% for the Gram-
positive and 93.8% for the Gram-negative probe. Subsequently, the y intercepts and slopes 
were added to the Gram-ratio formula (equation 2).
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Analysis of nasal wash samples from human experimental infection models
The Gram-ratios measured in the nasal samples taken before challenge from the subjects 
participating in the Streptococcus pneumoniae and Rhinovirus studies were normally 
distributed and the differences were not statistically significant (Figure 2).
Figure 2. The Gram-ratio determined in nasal washes prior to challenge collected in the Streptococcus 
pneumoniae colonization study, n=12, (A) and the human Rhinovirus infection study, n=15 (B). The data 
shown represent individual ratios and the means with the standard deviations.
In the human pneumococcal carriage study, the Gram-ratios for all challenged subjects were 
plotted as a function of time to compare those that acquired carriage (Figure 3A) to those that 
did not (non-carriers) (Figure 3B). 
Subjects that did not develop pneumococcal carriage displayed a consistent Gram-
ratio throughout time, with no significant shifts. In contrast, a significant shift in Gram-ratio 
was observed in subjects that acquired pneumococci between 7 days pre-challenge in 
comparison with both 2 (p=0.01) and 7 (p=0.04) days post-challenge. When comparing the 
ΔGram-ratio of the subjects with or without carriage no significant difference in variance was 
found (Figure 4A). 
No significant shifts were observed in the Gram-ratios of subjects successfully infected 
by Rhinovirus (Figure 3C) or treated with a placebo (Figure 3D). Interestingly however, in 
infected subjects, the variance (difference in Gram-ratio between two timepoints) in Gram-
ratio increased a 5.9-fold in comparison to the placebo (PBS buffer) treated subjects (p=0.04) 
(Figure 4B).
MONITORING THE DYNAMICS 
OF BACTERIAL COMMUNITIES IN THE UPPER RESPIRATORY TRACT BY A GRAM-SPECIFIC PCR METHOD
249
13
Figure 3. Nasopharyngeal Gram-ratios in subjects colonized with Streptococcus pneumoniae, n=7 
(A). Nasopharyngeal Gram-ratios in subjects without colonization Streptococcus pneumoniae, n=5 (B). 
Nasopharyngeal Gram-ratios in subjects infected by human Rhinovirus, n=15 (C). Nasopharyngeal Gram-
ratios in subjects placebo treated in human Rhinovirus study, n=7 (D). The data represents individual ratios 
and the mean with the standard deviation, * = P ≤ 0.05.
Figure 4. Variance in Gram-ratio, comparing the ΔGram-ratios at days -7 and 2 days after challenge between 
subjects with (n=7) or without (n=5) carriage of Streptococcus pneumoniae (A). Variance in Gram-ratio, 
comparing the ΔGram-ratios between 0 and 2 days post-infection (n=15) compared to the placebo (n=7) 
treated subjects (B). The variance is shown as individual ΔGram-ratio (dot) with the mean (column) and 
standard deviation (whisker), * = P ≤ 0.05.
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DISCUSSION
In this study a simple method was developed to monitor the dynamics of bacterial 
communities in the upper respiratory tract (URT). This method was applied to determine 
the influence of pathogen exposure on the ratios of Gram-positive and Gram-negative 
bacteria. For this purpose, two human URT infection models were used: the pneumococcal 
colonization and the Rhinovirus infection model.
In the Streptococcus pneumoniae challenge model, healthy adults were intranasally 
inoculated with Streptococcus pneumoniae serotype 6B, after which colonization was 
monitored by measuring colony forming units (CFU) in nasal wash samples taken at different 
time points(14). It was concluded that this model is a true representation of natural carriage and 
that colonization is a dynamic event. In a follow-up study, the nasopharyngeal microbiome 
of experimentally challenged volunteers was analysed by 16s rRNA gene amplicon 
sequencing(17). This study revealed an association of pre-challenge microbiome diversity with 
induced carriage of Streptococcus pneumoniae and observes shifts in the microbiome profile 
after pneumococcal exposure, indicating that subjects who acquired carriage often diverted 
from their original profile.
Allen et al. previously demonstrated that human Rhinovirus exposure influences the 
relative abundance of the dominant phyla(18). In addition, Haemophilus, Neisseria and 
Propionibacterium species differed significantly in abundance between the infected and non-
infected individuals. Although in our study no significant shift in Gram-ratio was observed, 
the bacterial microbiome of each subject differed throughout the viral challenge, where the 
variability measured within subjects was lower than the between-subject variability.
Interestingly, by measuring the Gram-ratios before infection in the two independently 
performed studies at different locations (i.e. pneumococcal colonization study in Liverpool, 
UK and the Rhinovirus infection study in Nijmegen, the Netherlands) a baseline value of 
the Gram-ratio for healthy non-smoking adults could be established despite differences in 
geography and inclusion criteria.
The Gram-ratios were analysed at different time points. In the human pneumococcal 
carriage study, the subjects that did not acquire carriage showed a consistent Gram-ratio 
over time. However, those who became carriers displayed a significant shift in the mean ratio 
after the pneumococcal challenge. This agrees with the microbiome analysis performed 
by Cremers et al., using 16s rRNA gene amplicon sequencing. They also concluded that 
microbiome profiles of subjects who acquired pneumococci often diverted from their original 
profile(17). In addition, we show that the dynamics of the microbiome can be monitored over 
time, and that the Gram-ratio returned to the pre-challenge level at day 14 post-challenge.
In the human Rhinovirus infection study, no significant shifts in Gram-ratios were 
observed, but variance increased significantly following infection. The standard deviation 
of the population was higher than the mean of the ΔGram-ratios, thus implying that the 
variance between subjects in the population is greater than within subjects over time, which 
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is in agreement with the observations of Allen et al.(18, 19). Due to the low nucleic acid content 
of the nasal wash samples of the experimental human Rhinovirus (HRV-16) infection model, 
16s rRNA gene amplicon sequencing could not be performed. Therefore, we were unable 
to make a direct comparison between 16s rRNA gene amplicon sequencing and the Gram-
specific PCR. This underscores the great advantage of this real-time PCR-based method, it is 
a sensitive method and can be used when DNA content is too low for 16s rRNA gene amplicon 
sequencing.
Although the re/solution of the Gram-specific PCR is significantly lower when compared 
to 16s rRNA gene amplicon sequencing, we believe it to be of great value for a quick and simple 
determination of the dynamics of bacterial communities in time. Furthermore, it can be used 
when yields of purified DNA are too low to perform 16s rRNA gene amplicon sequencing. This 
method would allow to measure the effects of interventions such as vaccination or nutrition 
on shifts in the composition of bacterial communities.
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In this thesis, immunological pathogen-host interactions are investigated in experimental 
bacterial and viral human and murine challenge models. In addition, several immunological 
pathogen-host interactions are assessed in patients, and human challenge models are 
methodologically assessed and utilized for broader purposes, such as the investigation of 
sickness behavior and nasopharyngeal microbiota dynamics.
Part I Immunological pathogen-host interactions
Chapter 2 provides an overview of the current knowledge on bacteria and virus-induced 
immunosuppression and the accompanying susceptibility toward various secondary 
infections. It has become evident that not only bacterial sepsis and virulent viruses such 
as influenza induce immunosuppression, but also mild respiratory virus infections caused 
by the human rhinovirus (HRV) and respiratory syncytial virus (RSV) can do so as well, often 
through similar immunosuppressive mechanisms. Immunosuppression is associated with 
the development of secondary bacterial and fungal infections, and with viral reactivation. 
Also, mixed viral infections and persistence of influenza, RSV, and HRV viral loads are the 
result of immunosuppression, prolonging the respiratory infection. Specific localizations 
and combinations of pathogens may be due to a common localization or to a common 
immunological signaling cascade. As secondary infections are associated with attributable 
morbidity and mortality, further elucidation of general and pathogen-specific mechanisms 
that are responsible for immunosuppression and the search for markers that identify an 
overactive or suppressed immune response are highly warranted, as this will facilitate the 
development and implementation of more personalized therapeutic interventions to tailor 
the immune response. Gene-expression profiling represents an example of such an approach 
which is currently under development. 
In chapter 3, the repeated experimental human endotoxemia model was used to mimic 
sepsis-induced immunoparalysis. As expected, a second lipopolysaccharide (LPS) 
administration one week after the first, resulted in a profoundly suppressed systemic 
innate immune response. We investigated whether the immunostimulatory therapies 
interferon gamma (IFN-γ) and Granulocyte-macrophage colony-stimulating factor (GM-CSF) 
administered in-between the LPS challenges reversed this endotoxin tolerant phenotype. 
Compared with placebo-treated subjects, IFN-γ partially restored the production of the 
pro-inflammatory cytokine TNF-α, while further attenuating the production of the anti-
inflammatory cytokine IL-10 upon the second LPS administration. Furthermore, IFN-γ 
prevented the reduction in flu-like symptoms in response to the second LPS administration, 
and increased the expression of the well-known immunoparalysis marker HLA-DR, signifying 
improved monocyte function. Effects of GM-CSF were similar, but less pronounced. These 
results indicate that IFN-γ partially restores endotoxin tolerance in vivo in humans and could 
represent a viable therapeutic target to reverse sepsis-induced immunoparalysis. 
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In chapter 4, we investigated whether the development of endotoxin tolerance as described 
in chapter 3, influences the response toward a viral infection, induced by the mucosal live-
attenuated influenza vaccine (LAIV) Fluenz. We used this approach as a model system to 
investigate the effects of immunoparalysis induced by a systemic bacterial infection on the 
response to a subsequent infection with influenza administered in another body compartment: 
the respiratory mucosa. We found that an endotoxin-tolerant state does not influence the 
response toward a subsequent viral challenge with Fluenz, shown by similar viral loads and 
IgG titers for the different Fluenz A/B strains and similar leukocyte responses in nasal wash 
between the LPS–Fluenz and placebo–Fluenz groups. Also, the Fluenz-induced increase in 
temperature, peak expiratory flow (PEF) and IL-6, G-CSF and IP-10 concentrations in nasal 
wash were similar between both groups. These data suggests that immunosuppression after 
a bacterial infection does not alter the response to a subsequent viral infection. This could 
explain why secondary infections with opportunistic bacteria or fungi and viral reactivation 
are frequently observed in patients suffering from a primary bacterial sepsis, but de novo 
viral infections are relatively uncommon. The absence of an attenuated immune response 
upon a viral challenge observed in our study could be due to compartment-specific effects. 
It is plausible that the mucosal compartment in which Fluenz is administered and the initial 
antiviral immune response mounted, is not tolerized by a preceding LPS administration. 
Furthermore, the human endotoxemia model and the resulting immunosuppressive effects 
could be too mild to affect antiviral immunity. Finally, the pathophysiology induced by the 
use of the LAIV Fluenz may not be comparable with the actual pathogenic influenza virus, 
because it is an attenuated virus which may not show same infectivity, tissue tropism and 
virus dissemination as actual influenza. 
In chapter 5, we investigated whether the mild and locally administered human rhinovirus 
(HRV) also induces hallmarks of immunosuppression. To this end, we set up the HRV challenge 
model in our department, and investigated local and systemic immune response parameters 
upon repeated HRV administration (two challenges separated by one week time). Our data 
show that the primary HRV infection induced a marked increase in viral load and levels of 
IP-10 (a pro-inflammatory cytokine that is typically increased in respiratory virus infections) 
in nasal wash, while a similar trend was observed for IL-6 and IL-10. Apart from an increase 
in IP-10 plasma levels, HRV infection neither induced systemic effects, nor lower respiratory 
tract effects, measured by PEF. Although the second HRV challenge resulted in a similar 
viral load, IP-10 and IL-6 in nasal wash did not increase, which is in sharp contrast to the 
response upon the first HRV challenge. Also, in subjects who were challenged with HRV twice, 
a significant decrease in IP-10 plasma levels was observed upon the second HRV challenge, 
compared with the first. This indicates that a second HRV challenge one week after the first 
results in a less pronounced response of several innate immune parameters, implying that 
relatively mild viruses can also induce immunosuppression. This could have consequences 
for vulnerable patient groups such as the elderly, and might influence vaccination strategies. 
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In chapter 6, we investigated viral-bacterial interplay by administering LPS to influenza-
infected mice to evaluate whether influenza induces immunological priming or tolerance 
toward a secondary LPS challenge. LPS challenges were performed in either the acute (day 4) 
or the recovery phase (day 10) of influenza infection to assess the kinetics of the influenza-
induced effects. Our data reveal that an LPS challenge in the acute phase of influenza 
infection results in an enhanced pulmonary pro-inflammatory innate immune response, 
shown by a synergistic increased production of all pro-inflammatory cytokines in the lungs, 
but not in plasma. This synergism indicates that influenza infection actually modulates the 
immune response to a subsequent challenge with LPS. This was accompanied by a tendency 
toward increased pulmonary MPO content, reflecting neutrophil influx, but only in the acute 
phase of infection. No signs of influenza-induced immunological tolerance were observed 
up till 10 days post-infection. When combining these data with previous findings in which 
this influenza-induced priming is associated with necrotic pneumonia and acute respiratory 
distress syndrome (ARDS), it appears that this enhanced immune response is not beneficial 
in terms of protection against secondary infections, but rather damaging by increasing 
immunopathology.
Part II  Clinical implications of pathogen-host interactions
In chapter 7, we investigated a cohort of influenza patients to identify influenza-associated 
risk factors for ICU admission and ICU mortality. We identified Obstructive and Central 
Sleep Apnea Syndrome (OSAS;CSAS) as new independent factors related to ICU admission 
in patients with influenza infection. Other factors that were identified include a history of 
myocardial infarction and BMI>30. ICU patients developed renal failure, bacterial and fungal 
secondary infections more frequently compared with patients who were not admitted to 
the ICU. The proportion of secondary infections of all origins in ICU-admitted patients was 
higher compared with patients who remained at the normal ward. As expected, the most 
common bacterial pathogens were Staphylococcus aureus and Streptococcus pneumoniae, 
reflecting a transition from normal colonization of the upper respiratory tract to infectious 
disease. Furthermore, Aspergillus fumigatus was observed in 18% of the influenza patients, 
which is in line with high the incidence described in literature. Secondary infections were 
associated with ICU admission, but not with ICU mortality, which is contrast with earlier 
studies. Factors related to ICU mortality included diabetes mellitus and renal failure, whereas 
a trend was observed for the systemic use of immunosuppressive drugs. Factors associated 
with a complicated disease course, ICU admission and mortality could be related to an 
immunocompromised state, either caused by comorbidities, immunomodulatory therapies 
or directly resulting from influenza infection. These factors ease the early identification of 
influenza patients at risk for a complicated disease course. Furthermore, early treatment of 
influenza-induced superinfections may prevent ICU admission and improve outcome. 
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The high incidence of Aspergillus fumigatus infections in influenza patients was further 
investigated in chapter 8. We assessed whether influenza induces a specific immune defect 
by determining various immunological parameters in ICU patients with severe influenza 
infections, bacterial pneumonia, and isolated neurotrauma, as well as in healthy controls. 
Plasma cytokines and the cytokine production by peripheral blood mononuclear cells 
(PBMCs) upon ex vivo stimulation with various ligands was determined, as well as the ex vivo 
capacity to expand IL-17-, IL-22-, and IFN-γ-producing T-cell populations. Our data indicate 
that no clear alterations in the above-mentioned parameters were observed in influenza 
patients compared with all control groups, indicating that influenza does not induce systemic 
immunoparalysis and no specific systemic immune defect could be identified that could 
explain the increased susceptibility toward Aspergillus fumigatus. Furthermore, we found 
that both hyperinflammation and immunosuppression co-existed in one patient, making it 
challenging to design tailor-made therapies.
In chapter 9, we investigated whether similar to sepsis, trauma also results in viral reactivation. 
Our study in multi trauma patients demonstrates that this is indeed the case, with reactivation 
of epstein barr virus (EBV) being most prevalent, while cytomegalosvirus (CMV) and herpes 
simplex virus (HSV) were less common. Furthermore, the incidence of bacterial infections 
was higher in patients who displayed viral reactivation compared with those who did not. 
Also, decreased HLA-DR expression and plasma IL-10 levels were shown to be related to viral 
reactivation, suggesting a causal relationship between an immunosuppressive phenotype 
and reactivation of latent viruses. So, similar to sepsis patients, multiple-trauma patients 
display profound immunosuppression, which may contribute to the incidence of secondary 
infections and increased morbidity and mortality in these patients. In addition, similar to its 
current use as a marker for immunosuppression in transplant patients, viral reactivation may 
represent a promising novel marker for immunosuppression in trauma patients. 
Part III Methodological considerations and broad applicability of human in vivo 
challenge models 
Patients suffering from systemic inflammation are in most cases exposed to inflammatory stimuli 
for extended periods of time. Therefore, in chapter 10, a model of continuous LPS infusion, 
which may be more relevant to the clinical situation, was characterized and compared to models 
using various bolus administrations of various dosages of LPS. Continuous LPS infusion was well-
tolerated and resulted in a more pronounced and protracted increase in plasma cytokine levels. 
Furthermore, the continuous LPS model resulted in more prolonged clinical symptoms and fever 
compared with the bolus models. We conclude that the continuous LPS infusion model provides 
novel insights into the kinetics of the inflammatory response to continuous inflammatory stimuli 
as observed in infections, (auto)immune diseases and for example, multi-trauma injuries. In 
addition, it accommodates a larger time window to evaluate immunomodulatory therapies.
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In chapter 11, we used the experimental human endotoxemia model to assess whether 
LPS influences two dissociable constructs of motivational behavior, i.e. effort and reward 
sensitivity. As expected, LPS led to increased levels of circulating cytokines, sickness symptoms, 
and increased body temperature. Also, relative to baseline and placebo group, signs of self-
reported fatigue and depression were observed post LPS-administration. These changes 
were accompanied by LPS-induced decreases in acceptance rates of high-effort options 
without significantly affecting reward sensitivity two hours post-injection, which partially 
recovered five hours post-injection. These LPS-induced changes in motivation may be due 
to alterations to mesolimbic dopamine, as previous neuroimaging work has showed that 
LPS administration reduces reward-related signals in the ventral striatum. Also, dopamine-
enhancing drugs like methylphenidate or levodopa were shown to reverse inflammation effects 
and reduce fatigue in humans. Our behavioral paradigm could be used to further investigate 
effects of inflammation on motivational behavior in psychiatric and chronic illnesses. 
In chapter 12, we investigated the effects of serostatus and gender on the HRV-
induced immune response in the newly set up HRV challenge model described in 
chapter 5, in order to improve the methodology of future studies using this model. 
HRV infection resulted in an increased viral load in nasal wash, which tended to be 
more pronounced in seronegative subjects. Strikingly, HRV infection increased levels 
of IP-10, IL-6, and IL-10 and leukocyte numbers in nasal wash of seronegative, but not 
of seropositive subjects. No differences in any of the studied parameters were found 
between both sexes. These results have important implications for the design of future 
intervention studies. First, because of the profound effects of serostatus on the local 
immune response, only seronegative subjects should be included, and second, both 
sexes can be included and there appears no need to stratify subjects based on gender. 
In chapter 13, the HRV challenge model was used to investigate a novel real-time PCR-
based method for bacterial microbiota analysis. This easy to use and affordable method 
can distinguish Gram- positive from Gram-negative bacteria. Our technical validation 
experiments showed this method to be robust, specific, and sensitive. Furthermore, it was 
used to determine the composition of the nasopharyngeal microbiota before and after 
HRV infection and pneumococcal challenge. A significant increase in microbiota variance 
was observed in subjects after HRV infection compared with placebo-inoculated subjects. 
In the pneumococcal challenge model, a significant shift in Gram-ratio 2 and 7 days after 
pneumococcal exposure was observed, which normalized after 14 days. These results are 
in line with previous microbiome studies using much more costly and complex analysis 
methods. We therefore conclude that this novel method represents an attractive tool to 
assess the bacterial microbiome, because of its sensitivity, ease of use and straightforward 
analysis, and that it allows for determination of the effects of interventions such as 
vaccination or nutrition on shifts in the bacterial community composition.
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In this final chapter, results described in this thesis are discussed in light of recent studies in 
the field. In addition, future perspectives and general conclusions are presented. 
Differential pathogen-host interactions
Severe respiratory bacterial and viral infections remain one of the major causes of morbidity 
and mortality worldwide(1). Mortality resulting from the primary infection can be caused by 
hyperinflammation, leading to ‘collateral’ injury(2, 3) of which the consequences include organ 
damage and ultimately, death(4, 5). Based on these events, therapeutic interventions in the 
past were almost exclusively aimed at inhibiting this hyperinflammatory response. However, 
without exception, these trials have failed to show any benefit in terms of outcome, and over the 
years, focus has therefore shifted away from hyperinflammation toward immunosuppression 
as a detrimental mechanism in infectious diseases. Observational studies have demonstrated 
that a significant proportion of patients succumb at later stages of infection, often from 
secondary pulmonary bacterial or fungal infections(6-10). These opportunistic infections are 
in a large part the result of immunosuppressive mechanisms induced by the host’s reaction 
toward the primary pathogen, thereby facilitating outgrowth of otherwise often harmless 
pathogens. Immunosuppressive mechanisms induced by bacterial sepsis, influenza virus as 
well as RSV and HRV, and the secondary pulmonary bacterial and fungal infections that are 
often associated with these primary infections are extensively described in chapter 2. This 
chapter details the considerable overlap between immunosuppressive mechanisms induced 
by different causative pathogens, resulting in functional defects in leukocytes, decreased 
antigen-presenting ability and decreased production of pro-inflammatory cytokines, in turn 
resulting in a more anti-inflammatory profile. However, there are also important differences 
between the different pathogens, which became apparent in the various studies described in 
this thesis, as elaborated on below.
In the first part of this thesis, immunological pathogen-host interactions were investigated in 
various experimental murine and human models. In chapters 3 and 4, the primary challenge 
agent used was bacterial endotoxin (LPS). In chapter 3, subjects were intravenously 
challenged with LPS twice, separated by one week, and it was demonstrated that a LPS 
challenge results in profoundly suppressed pro-inflammatory cytokine responses upon 
the second LPS challenge. These data indicate that a bacterial challenge renders the host 
immunotolerant toward a subsequent bacterial challenge. In chapter 4, an equally potent 
immune response toward the live-attenuated influenza vaccine (Fluenz) was observed in 
subjects that were challenged with either LPS or placebo one week before. From this study, 
it can be concluded that bacterial challenge-induced immunotolerance does not influence 
the immune response toward a secondary viral challenge. In chapters 5 and 6, the primary 
challenge agents used were viruses. In chapter 5, intranasal inoculation with the human 
rhinovirus (HRV) resulted in a blunted response upon a second HRV challenge one week later. 
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In contrast, a hyperinflammatory immune state was observed when LPS was administered to 
mice that were primarily infected with influenza in chapter 6. 
Based on these studies, it is tempting to speculate that a secondary challenge with 
the same pathogen results in a suppressed response, which is not observed when two 
different pathogens are administered consecutively (no effect on the immune response 
as observed in the LPS-Fluenz study and hyperinflammation as observed in the influenza-
LPS study). However, the observation in the LPS-Fluenz study is not in accordance with 
the clinical situation observed in bacterial sepsis, where patients often display profound 
immunosuppression and develop secondary infections with a wide variety of different 
pathogens(11-15). Although secondary viral infections are not common, reactivation of latent 
virus infections occur frequently(15). Possibly, the experimental human endotoxemia model 
is too mild to induce immunological tolerance to all secondary inflammatory challenge 
agents. Furthermore, healthy subjects were used, which naturally differ considerably from 
severely ill sepsis patients. Other factors may also play a role in this apparent discrepancy, 
including the fact that Fluenz is a live-attenuated virus instead of a pathogenic wild type 
virus.
The hyperinflammatory state observed when LPS was administered to influenza-infected 
mice in chapter 6 appears not to be in line with observations in influenza patients, in which 
immunosuppression and the occurrence of secondary infections with various pathogens are 
frequently observed(10, 16-19). Naturally, murine data cannot easily be extrapolated to human 
influenza patients because of host-specific differences, but different murine studies have shown 
contrasting results as well. Some studies describe influenza-induced immunosuppression(20, 21), 
while many others report a primed response upon a secondary (pulmonary) bacterial 
challenge(22-24). These equivocal results make it difficult to assess whether influenza induces 
immunological priming or tolerance. In addition, these discrepancies may be due to 
differences in the secondary challenge, i.e. live bacteria or a purified bacterial component 
such as LPS, which impedes clear delineation of intrinsic immunomodulatory effects. Timing 
might be an important factor as well, as different time frames between the first and second 
challenges have been used. In chapter 6, a hyperinflammatory state was observed when 
LPS was administered at day 4 of influenza infection, and this effect was still apparent at day 
10 of influenza infection, albeit to a lesser extent. In this context, bacterial pathogens appear 
to exert more consistent immunosuppressive effects than respiratory viral pathogens, as 
immunosuppressive mechanisms often appear shortly after the primary hit with live bacteria 
or a bacterial compound. This is for instance reflected by a profound tolerant state of circulating 
immune cells within hours after the LPS challenge, as demonstrated in chapters 3 and 4, 
whereas this is not consistently the case for respiratory virus infections(22, 23, 25). 
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The observed hyperinflammation in influenza infection might also be due to additional 
viral-specific effects that are not directly related to modulation of the immune response. 
For instance, respiratory viruses may induce more direct effects that can contribute to 
tissue damage, the most important of which is damage to the respiratory epithelium. 
Haemagglutinin, a glycoprotein found on the surface of the influenza virus molecule, 
mediates virus attachment by binding to sialic acids on epithelial cell surface proteins, 
initiating endocytosis. Subsequently, the sialidase activity of the neuraminidase enzyme 
cleaves sialic acids from the surface of epithelial cells and from mucins that aim to bind 
and eliminate virions, thereby disrupting the epithelial-endothelial barrier of the pulmonary 
alveolus(26). This damaging process results in perpetuation of inflammation(27, 28). In addition, 
epithelial damage increases the chance of invasion through increased expression of bacterial 
adherence factors, representing a non-immunological mechanism which plays a role in the 
increased susceptibility for secondary pulmonary infections observed in patients suffering 
from viral infections(26). 
In contrast to bacterial sepsis and endotoxin tolerance, in which immunosuppression 
involves both local as systemic immunity(6, 29, 30), the suppression of innate immune 
responses by HRV appears to be limited to the local environment, as described in chapter 5. 
Of note, the reduced plasma levels of IP-10 (CXCL-10) observed after the second HRV challenge 
in our study may suggest that HRV infection induces systemic immunosuppression as well. 
However, the HRV-induced increase of plasma cytokines was limited to IP-10; circulating 
levels of other cytokines remained unaltered. As IP-10 was by far the most profoundly 
induced cytokine in nasal wash, IP-10 levels in plasma might result from spillover from 
the nasal mucosa into the circulation instead of actual systemic production, and that the 
reduced concentration in plasma is due to local (nasal) immunosuppression. It is unknown 
why the HRV-induced innate immunosuppression appears to manifest mainly locally, but 
a likely explanation is that respiratory viruses predominantly target respiratory epithelial 
cells in which they replicate, and do not or only accidently cause viremia. In accordance, 
viruses that specifically infect tissues other than those of the respiratory tract do cause 
immunosuppression in these specific compartments. An example of this is the human 
papillomavirus (HPV) that induces local immunosuppression in the cervical microenvironment 
through enhancing the production of IL-10 by keratinocytes, macrophages and Langerhans 
cells(31). Viruses with a broader tissue tropism causing infections at different sites throughout 
the body are more likely to induce systemic immunosuppression, which has indeed been 
demonstrated for measles virus causing generalized (systemic) rash and subsequently 
systemic immunosuppression(32, 33). 
An important difference between the effects of bacterial and respiratory viral pathogens that 
deserves attention concerns the occurrence of viral reactivation and newly acquired or “de 
novo” viral infections. Previous work describes that bacterial-induced immunosuppression 
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is associated with the reactivation of multiple viruses(15, 16), a phenomenon which is further 
detailed later on in this chapter. However, based on chapter 4, it apparently does not 
predispose to de novo viral infections. In accordance, to the best of our knowledge, secondary 
de novo viral infections following bacterial-induced immunosuppression such as in sepsis are 
not described in literature. In contrast, de novo viral infections are reported following primary 
respiratory virus infections, as described in chapters 2 and 7. It is largely unknown what 
causes these pathogen-specific differences regarding the susceptibility toward de novo viral 
infections. Possibly, viruses that are already (latently) present in the host reactivate when 
immunity is compromised, especially in case of systemic immunosuppression which is often 
observed following bacterial infections. 
The first part of this thesis clearly indicates that LPS, a bacterial component, induces 
immunosuppression, while a primary infection with viral pathogens induces both 
hyperinflammatory and immunosuppressive responses. Whether the immune response 
is more skewed toward hyperinflammation or immunosuppression is determined by a 
combination of factors such as the nature of the causative pathogen, induction of direct 
tissue-damaging effects, but also timing of the secondary challenge / infection, and level 
of primary infection are likely playing a role. The immune status is often simplified as being 
either “hyperinflammatory” or “immunosuppressive”, but ours and other data indicate 
that these states actually show great overlap and can both be involved in the increased 
susceptibility toward secondary infections. In addition, both immune states can co-exist at 
the same time in the same patient, as observed in sepsis(6, 34) and influenza infection(25, 35-37). 
This makes it challenging to apply immunomodulatory therapies in sepsis, but also in severe 
viral infections. Still, the response is often more skewed toward a particular phenotype, 
urging the need for stratification of patients which may benefit from a certain type of 
immunomodulatory therapy, which is further discussed below. In conclusion, it is more 
appropriate to use the term “dysregulated immune response”, reflecting an impaired ability 
to adequately fight pathogens without causing excessive collateral damage. This terminology 
is also used in the new definition of sepsis, defining it as “a life-threatening organ dysfunction 
caused by a dysregulated host response to infection”(38). 
As outlined above, it is vital to be able to accurately gauge the immune status of patients 
for application of targeted immunomodulatory therapy, an approach known as “precision 
medicine”. This is the prime focus for the infectious diseases research field in the near future 
and future prospects on this topic are discussed in detail later on in this chapter. Development 
of viable therapies that can modulate the immune system in these selected patients is of 
equal importance. In chapter 3, we demonstrated that the immunostimulatory compound 
IFN-γ was most effective in reversing sepsis-induced immunoparalysis in an experimental 
setting. IFN-γ has also shown promise as a therapy to reverse immunosuppression in 
patients, although the currently available evidence is limited to case series(39-41). Other 
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immunostimulatory therapies are currently under investigation as well, including GM-
CSF(42), anti-PD(L)-1 and IL-7(16). Anti-PD(L)-1 has previously been shown to activate anti-
tumor immune responses in patients with previously incurable metastatic disease(43, 44), 
and has shown favorable effects in murine models of sepsis-induced immunoparalysis(45, 46). 
Unfortunately, a clinical trial with anti-PD-1 in sepsis patients was recently discontinued 
by the sponsor due to other priorities. IL-7 is another promising compound which was very 
recently shown to increase T-cell proliferation and activation and reverse the marked loss of 
CD4+ and CD8+ cells in a small study in patients with septic shock and severe lymphopenia(47). 
The study was not powered to detect any effects on clinically relevant endpoints, therefore, 
results of future larger trials with this compound are eagerly awaited.
In this thesis, we mainly focused on the innate immune response. However, in both 
pulmonary (localized) as well as systemic viral and bacterial infections, T-cell responses 
are impaired, which for instance has been demonstrated in patients with influenza(48) and 
bacterial sepsis(49). In our viral challenge models, we only performed serology as a measure 
of adaptive immunity, which was unaffected as well. Of note, LPS administration does not 
result in a measurable antibody response, so serology was not performed in the endotoxemia 
studies described in this thesis. Regarding B-, and T-cells, we have learned from chapter 10 
and previous work that these cell numbers show a pronounced decline shortly after LPS 
challenge and return to normal values within 24 hours(50). Remarkably, CD8+ T-cell numbers 
are increased at 2 days post-endotoxin administration, an effect which persists up to 20 days 
after administration(51). This is suggestive of homeostatic proliferation in replenishment of 
this cell subtype to the circulation, a phenomenon that is also observed in patients with 
septic shock. We did not perform assays to investigate T-cell immunity in any of our studies, 
which is the main determinant of viral adaptive immunity and a main component of adaptive 
immune defense in bacterial infections. For instance, the HRV-induced (innate) tolerance 
effect is hypothesized to be caused by a type I interferon-induced CD8+ T-cell-mediated 
anti-viral state precluding viral replication(52). As such, measuring T-cell responses could have 
provided valuable information concerning the pathogen-host interactions described in this 
thesis, and should be a focus of future work. In addition, other human challenge models such 
as the Staphylococcus aureus(53) or Streptococcus pneumoniae(54) colonization models, provide 
promising opportunities to further deepen the knowledge on pathogen-host interactions. 
Clinical implications of pathogen-host interactions
As described in the previous section, influenza infection is associated with high morbidity and 
mortality. Almost 10% of patients with influenza infections require ICU admission(55). It would 
be of great value to be able to identify patients at risk for a severe disease course at an early 
stage to allow for early and accurate therapeutic management. In chapter 7, we reviewed a 
database of two academic hospitals in the Netherlands to identify influenza-specific factors 
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associated with ICU admission and mortality. We observed that next to respiratory failure as 
main determinant for ICU admission, a history of obstructive sleep apnea syndrome (OSAS) 
/ central sleep apnea syndrome (CSAS), myocardial infarction and BMI>30 kg/m2 were 
more frequently observed in ICU patients with influenza compared with influenza patients 
at the normal ward. Also, non-survivors were more likely to suffer from (pre-existent) renal 
failure and diabetes mellitus. Although the impact of these results may be limited due to 
the observational and retrospective character of the study as well as relatively small group 
sizes, these identified characteristics could aid the health care provider to identify influenza 
patients at risk for a complicated disease course. In addition, we investigated the incidence 
of influenza-associated pulmonary co-infections in the same database. In accordance with 
previous work, Staphylococcus aureus, Streptococcus pneumoniae and Aspergillus fumigatus 
were the predominant causative pathogens of influenza-induced pulmonary co-infections. 
Also, viral co-infections, such as RSV, HRV, human metapneumovirus and coronavirus were 
observed relatively frequently. The incidence of these infections was higher in ICU patients 
compared with patients at the ward, indicating that a more severe disease course is a key 
factor in the susceptibility toward co-infections. Co-infection with Aspergillus fumigatus 
was observed in 20-25% of influenza patients at the ICU, and was associated with increased 
mortality(10, 56). This high incidence of influenza-associated aspergillosis may suggest that 
a severe influenza infection causes a specific immune defect that may account for the 
increased susceptibility toward this particular fungal infection. We investigated various 
immunological parameters in patients with severe influenza infections who were admitted 
to the ICU in chapter 8 to elucidate whether or not influenza induces specific immune 
defects which could explain the increased susceptibility to Aspergillus fumigatus, but 
were not able to identify such defects. An alternative explanation for the high vulnerability 
toward Aspergillus fumigatus could involve the aforementioned influenza-induced direct 
damage to the respiratory epithelium, resulting in perpetuation of inflammation and 
increased adherence of Aspergillus fumigatus. This is supported by the hyperinflammatory 
phenotype that was observed in several influenza patients described in chapter 8, and 
also by the primed immune response upon a secondary challenge with LPS in influenza-
infected mice in chapter 6. Alternatively, discrepancies could be due to differences in 
timing of the secondary infection relative to the initial influenza infection as discussed 
before. This is supported by data of several influenza patients in chapter 8, in which a 
severely immunosuppressed state was observed following the initial hyperinflammatory 
state. In addition, it is likely that genetic predisposition could be of influence in the 
increased susceptibility toward Aspergillus fumigatus as well. Indeed, previous murine 
studies identified defects in the complement system linked to the susceptibility for invasive 
aspergillosis(57) and in patients, single-nucleotide polymorphisms (SNPs) in the genes 
TLR1, CLEC7A (dectin-1), PLAT, VEGFA, and DENND1B were found to be associated with 
aspergillosis, and may therefore represent candidate genes for increased susceptibility(58). 
Also, genetic defects in patients with chronic granulomatous disease (CGD)(59) that are 
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linked to their increased susceptibility toward Aspergillus fumigatus, such as impaired 
NADPH-oxidase activity, could be involved in influenza patients as well. However, none of 
these studies have investigated the role of influenza virus in this increased susceptibility 
toward Aspergillus fumigatus, which thus remains an important topic for future studies.
Similar to pathogen-induced immunosuppression, the rapid manifestation of an 
immunosuppressed state is also observed following trauma. A recent study from our 
group revealed that multi-trauma patients displayed a dominant immunosuppressive 
phenotype already at the trauma scene, and that release of so-called Danger-Associated 
Molecular Patterns (DAMPs) play an important role in this phenomenon(60). Next to the 
immunosuppressive state, reactivation of latent viruses was also observed in these 
multi-trauma patients. We elaborated on these findings in chapter 9, by showing that 
this phenomenon is associated with an increased risk for secondary bacterial infections 
in these patients, illustrating a clinically relevant consequence of trauma-induced 
immunoparalysis. Whether viral reactivation itself results in a more severe disease 
course or represents an epiphenomenon is unknown. Several studies have reported an 
association between viral reactivation following severe bacterial infections and increased 
mortality(15, 16), and following influenza or RSV infections(19, 61-63). It remains to be determined 
whether viral reactivation intrinsically contributes to mortality, or merely reflects a severe 
immunosuppressive state of the host, a condition which is known to be associated with 
increased mortality.
Although notoriously difficult, determining the immune status of a patient is vital for 
immunomodulatory precision medicine to succeed, and progress is being made in this field. 
For instance, it was recently shown that severe initial hyperinflammation and clinical signs 
of organ dysfunction are associated with more severe secondary infections and worsened 
clinical outcomes in sepsis patients(64). Therefore, one could anticipate on the disease course 
and apply certain therapies, such as early administration of systemic steroids, or later 
intervention with immunostimulatory agents. Also, surgical removal of inflamed tissue could 
reduce ongoing hyperinflammation, a strategy which is applied in necrotizing pancreatitis(65) 
and necrotizing pneumonia(66). Necrosis is a form of cell injury caused by external factors 
such as infection, toxins or trauma, leading to dysregulated clearance of cell components, 
resulting in premature cell death in living tissue by autolysis(67). Nevertheless, it is clear that 
accurate biomarkers that identify an overactive or suppressed immune response are still 
highly warranted to increase the efficacy of immunomodulatory therapies. Such markers 
will enable the development and implementation of more personalized therapeutic 
interventions to control the immune response, and can also be used to monitor efficacy 
of immunomodulatory treatments. This could provide more targeted and thereby safer 
and cost-effective therapies. Currently, HLA-DR expression(68) and lymphopenia (arguably 
reflecting lymphocyte apoptosis)(47) are the only parameters used to gauge the immune 
CHAPTER 15
272
state in sepsis patients. An interesting marker that reflects immunosuppression is the 
aforementioned viral reactivation, which has previously also been demonstrated in patients 
with sepsis(6, 15), influenza(61), RSV(69), and HRV(70) infections. Viral reactivation could present a 
promising new biomarker for immunosuppression caused by infections, trauma or otherwise 
immunosuppression-inducing states. Using this approach, patients can function as their own 
“test tubes”, as viral PCRs that become positive illustrate a more anti-inflammatory phenotype 
and increased risk to develop bacterial or fungal infections on which therapies could be 
adjusted. Gene-expression profiling is another attractive strategy that is currently under 
development. Using this approach, the expression of thousands of genes is used to assess 
the condition of cells, having an unbiased and global picture of cellular activity. These profiles 
can be used to predict the course of disease, which may facilitate personalized therapies in 
the near future(71, 72). It may be argued that the measurement of viral reactivation and specific 
gene transcription profiles would be of added value to the currently used biomarkers (HLA-DR 
expression and lymphopenia), to further refine the identification of a patient’s immune 
status. In addition, general patient characteristics such as age should also be included in the 
algorithm supporting the medical decision including the selection of treatment(73). Figure 1 
depicts a conceptual algorithm for the triage of patients presenting in an inflamed state. 
Methodological considerations and broad applicability of human in vivo challenge 
models 
As observed in this thesis, human bacterial and viral challenge models can be used to 
investigate a wide range of immunological pathogen-host interactions. Moreover, these 
models also have broader applicability. In chapter 10-13, methodological considerations 
of these models and studies employing these models for non-immunological objectives are 
described.
Various endotoxin dosing strategies were investigated in humans in vivo in chapter 10. 
Compared with the well-established bolus administration model, the novel model employing 
continuous endotoxin infusion may be representative of the clinical situation in infected 
patients, who are exposed to inflammatory stimuli for protracted periods. This continuous 
model may also prove to be valuable model aspects of other conditions that involve ongoing 
(sterile) inflammation, such as major trauma, burns, chronic pain(74), type 2 diabetes, auto-
immune diseases, and atherosclerosis(75). Furthermore, the continuous model extends the 
time window to apply therapeutic interventions after initiation of endotoxin infusion, such as 
various vasopressors(76) or immunomodulatory therapies (chapter 3) that have already been 
investigated in the endotoxin bolus administration model.
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Figure 1. Conceptual algorithm for triage of a patients’ immune state. A dysregulated immune system can 
be skewed toward hyperinflammation or immunosuppression, based on the currently used markers HLA-DR 
expression and lymphopenia, supplemented with viral reactivation and genetic profiling. Immunomodulatory 
therapies are independent of the cause of the dysregulated immune state, as mechanisms show large 
overlap for sterile and infectious (bacterial as well as viral) inflammation. Patients’ age is an independent 
factor influencing the immune response and should be taken into account in the decision which therapies 
are applied.
In chapter 11, the experimental human endotoxemia model was used to investigate sickness 
behavior. We observed that endotoxemia changed the motivation to perform tasks and 
increased the subjective experience of depression and fatigue. Previous research indicates 
that a patients’ mental state is a strong determining factor in sickness behavior and health 
outcomes. For example, strong personality and high intelligence positively influences health 
outcomes(77). However, it is difficult to objectify this association. The human endotoxemia 
model may be used to objectively investigate the effect of psychological factors on the 
immune response. For example to relate mental state and different coping strategies to the 
immunological response during human endotoxemia. Also, this model could be used to test 
the effects of pharmaceutical targets with compounds such as NMDAR antagonists(78) that are 
used to treat motivational deficits in psychiatric disorders.
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For the applicability of the developed HRV challenge model, we investigated the effects 
of gender and serostatus on the HRV-induced immune response in chapter 12. We 
demonstrate that the HRV-induced local immune response is attenuated in seropositive 
subjects compared with seronegative subjects, while gender does not influence this 
response. In addition, because it is important to know whether a crossover design could 
be applied in future studies using the HRV model, we evaluated whether a crossover design 
for both short intervals (innate immune response; chapter 5) and long intervals (adaptive 
immune response; chapter 12) would be feasible. Our data unequivocally show that neither 
a crossover design using a short interval, nor a design using longer time intervals is feasible. 
The former is due to a strongly suppressed innate immune response and the latter due to 
antibody formation that starts approximately one week after HRV infection and severely 
impacts the immune response. Consequently, large groups of subjects will be needed for 
intervention studies using this model. Another reason for the need of a significant number of 
subjects is because of the large variation in the data, in particular for symptom scores. This is 
probably because this respiratory viral model is too mild to induce large effects. 
In chapter 13, the influence of HRV infection on the composition of the nasal microbiota 
was assessed. To measure this, a Gram-specific PCR method was used and turned out to be 
an easy, quick and thereby attractive tool to assess the dynamics of bacterial communities 
allowing a straightforward analysis. This study shows that, in addition to the investigation 
of pathogen-host interactions, human challenge models provide a suitable platform to 
investigate and validate new analysis methods. 
CONCLUSIONS
This thesis exemplifies that both respiratory viral as well as bacterial pathogens can cause 
a dysregulated immune response, defined as an impaired state of the host to combat 
infections without causing excessive collateral damage. There are many similarities, but also 
differences between the underlying mechanisms involved. Similarities include a skewed 
immune response toward a more anti-inflammatory profile and increased vulnerability 
toward secondary infections. A hyperinflammatory component appears to be more evident 
in respiratory virus infections, possibly because virulent viruses induce direct epithelial 
damage and thereby cause ongoing hyperinflammation, but also facilitating adherence 
of pathogens. A dysregulated immune response is also observed in sterile inflammation 
such as in trauma, where it involves largely similar mechanisms as observed in infections. 
Furthermore, viral reactivation occurs in a considerable proportion of trauma patients and is 
associated with increased vulnerability toward infections. The high mortality associated with 
many secondary pulmonary infections indicates the need for effective immunomodulatory 
therapies, of which IFN-γ represents a promising example. Nevertheless, there is a strong 
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unmet need for accurate identification of a patient’s immune status. The algorithm provided 
in Figure 1 provides a conceptual framework which could be used as an initial guide for 
patient triage. Finally, next to exploring immunological pathogen-host interactions, human 
challenge models are excellently suited to investigate non-immunological parameters and 
analysis techniques.
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NEDERLANDSE SAMENVATTING
In dit proefschrift staan de immunologische (dat wil zeggen: betrekking hebbende op het 
immuunsysteem) interacties tussen ziekteverwekkers en de gastheer centraal. Met behulp 
van experimentele virale en bacteriële modellen bij zowel gezonde vrijwilligers als muizen, 
hebben we specifieke interacties tussen de ziekteverwekkers en het immuunsysteem 
onderzocht, zoals beschreven in deel 1. In deel 2 hebben we deze interacties bestudeerd 
in patiënten, waarbij we ons gericht hebben op het influenzavirus. Ook hebben we gekeken 
of virussen die latent aanwezig zijn weer actief gaan vermenigvuldigen (‘virale reactivatie’) 
na steriele ontsteking, geïnduceerd door een ernstig trauma. In het laatste deel hebben we 
de in dit proefschrift gebruikte experimentele virale en bacteriële modellen methodologisch 
beoordeeld en ingezet voor bredere doeleinden, zoals voor onderzoek naar ziektegedrag en 
het bestuderen van de bacteriesamenstelling in de neus. 
Deel I Immunologische interacties tussen ziekteverwekkers en gastheer
In hoofdstuk 2 worden de huidige inzichten over de onderdrukking van het aangeboren 
immuunsysteem, veroorzaakt door verschillende bacteriën en virussen, weergegeven in 
een overzichtsartikel. Dit fenomeen werd aanvankelijk alleen gezien bij bacteriële sepsis 
(een zeer ernstige infectie, die ook wel bekend staat als bloedvergiftiging) en ernstige 
virusinfecties. Er is echter gebleken dat immuunsuppressie, ook wel ‘immuunparalyse’ 
genoemd, ook optreedt bij mildere virusinfecties in de luchtwegen, veroorzaakt door 
bijvoorbeeld het verkoudheidsvirus (humane rhinovirus; HRV) en het respiratoir syncytieel 
virus (RSV). Dit verloopt bovendien volgens vergelijkbare mechanismen als bij ernstige 
infecties. Immuunsuppressie kan leiden tot secundaire bacteriële en schimmelinfecties, en 
tot de reactivatie van virussen. Bovendien hebben we gevonden dat virussen langer in de 
gastheer aanwezig blijven en blijkt ook dat er co-infecties met verschillende virussen kunnen 
optreden. Secundaire infecties die ontstaan door immuunsuppressie gaan gepaard met een 
hoge mortaliteit. Daarom is het essentieel om de algemene en specifieke mechanismen van 
immuunsuppressie veroorzaakt door verschillende ziekteverwekkers te ontrafelen, teneinde 
deze patiënten beter te kunnen behandelen. De behoefte aan indicatoren voor zowel 
immuunsuppressie als voor een overactieve immuunrespons neemt sterk toe, omdat dit de 
ontwikkeling en implementatie van patiëntspecifieke therapieën mogelijk kan maken. 
In hoofdstuk 3 wordt gebruik gemaakt van het experimentele endotoxinemiemodel 
bij gezonde vrijwilligers om sepsis-geïnduceerde immuunparalyse na te bootsen. In dit 
model wordt lipopolysaccharide (LPS), een opgezuiverd bestanddeel van de bacteriële 
celwand, tweemaal toegediend. Bij de tweede LPS toediening, een week na de eerste 
toediening, vonden we een sterk onderdrukte systemische immuunrespons, ook wel 
‘endotoxinetolerantie’ genoemd. In dit onderzoek hebben we vervolgens onderzocht of 
CHAPTER 16
286
de toediening van immuunsysteem-stimulerende medicijnen, namelijk interferon gamma 
(IFN-γ) en granulocyt macrofaag kolonie stimulerende factor (GM-CSF), tussen de twee LPS 
toedieningen in kan voorkómen dat er endotoxinetolerantie optreedt. IFN-γ bleek inderdaad 
in staat om de productie van het ontstekingsbevorderende eiwit TNF-α gedeeltelijk te 
herstellen, in combinatie met een afgenomen productie van het ontstekingsremmende eiwit 
IL-10. De expressie van HLA-DR, een bekende indicator voor immuunparalyse, was duidelijk 
verhoogd bij de met IFN-γ behandelde proefpersonen, indicatief voor een verbeterde functie 
van monocyten, een specifiek type witte bloedcellen. Deze resultaten wijzen erop dat IFN-γ 
in staat is om endotoxinetolerantie gedeeltelijk te voorkomen. GM-CSF gaf vergelijkbare 
resultaten, maar in minder sterke mate. 
In hoofdstuk 4 hebben we onderzocht of de in hoofdstuk 3 beschreven endotoxinetolerantie 
de immuunrespons op een secundaire virale infectie beïnvloedt bij gezonde vrijwilligers. 
Om een virale infectie na te bootsen maakten we gebruik van het vaccin Fluenz, bestaande 
uit een verzwakt influenzavirus, dat werd toegediend via de neus. Proefpersonen kregen 
eerst LPS of placebo toegediend, een week later gevolgd door Fluenz. We ontdekten dat 
endotoxinetolerantie de immuunreactie op de toediening van het virus niet beïnvloedt. 
Dit concludeerden we op basis van de hoeveelheid virus en witte bloedcelen in de neus 
en de concentraties immunoglobulines (IgG) in het bloed, deze waren namelijk niet 
significant verschillend tussen de verschillende groepen (LPS-Fluenz en placebo-Fluenz). 
Bovendien waren de door het virus veroorzaakte verhoging in temperatuur en piekwaarde 
in snelheid van uitademing (PEF) vergelijkbaar in beide groepen, evenals de concentraties 
van de ontstekingsbevorderende eiwitten IL-6, G-CSF en IP-10 in de neus. Deze uitkomsten 
suggereren dat de immuunsuppressie die ontstaat na een bacteriële infectie geen invloed 
heeft op de immuunrespons veroorzaakt door een secundaire virale infectie. Dit kan 
verklaren waarom secundaire infecties veroorzaakt door opportunistische bacteriën of 
schimmels alsmede virale reactivaties wél voorkomen bij patiënten met een primaire 
bacteriële sepsis, maar dat de novo virusinfecties nauwelijks worden waargenomen in deze 
patiëntengroep. Onze bevindingen kunnen meerdere oorzaken hebben. Ten eerste kan het 
zijn dat het neusslijmvliescompartiment waarin het influenzavirus wordt toegediend en 
waar een antivirale immuunrespons in gang wordt gezet, daadwerkelijk niet tolerant wordt 
na toediening van LPS. Ten tweede is het mogelijk dat endotoxinemie en de bijbehorende 
immuunsuppressie te mild zijn om effect te hebben op de antivirale immuniteit. Tot slot 
is het vermeldenswaardig dat de effecten van het verzwakte virus mogelijk niet geheel 
vergelijkbaar zijn met die van het echte virulente influenzavirus. 
In hoofdstuk 5 hebben we onderzocht of mildere virussen ook immuunsuppressie 
kunnen veroorzaken. We hebben hiervoor gebruik gemaakt van de toediening van het 
verkoudheidsvirus HRV aan gezonde vrijwilligers. HRV werd tweemaal toegediend met 
een week ertussenin en we maten verschillende parameters die de lokale en systemische 
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immuunrespons weergeven. We zagen dat de eerste toediening van HRV leidde tot een 
toename in de hoeveelheid virus en IP-10 in de neus. IP-10 is een ontstekingsbevorderend 
eiwit waarvan bekend is dat het aangemaakt wordt tijdens virusinfecties in de luchtwegen. 
Eenzelfde patroon werd gezien voor het ontstekingsbevorderende eiwit IL-6. HRV leidde echter 
niet tot systemische immunologische effecten of veranderingen in de lagere luchtwegen. Na 
de tweede HRV toediening werd er een vergelijkbare hoeveelheid virus gedetecteerd, echter 
de concentraties IP-10 en IL-6 in de neus namen niet toe, in tegenstelling tot de effecten 
waargenomen na de eerste HRV toediening. Het was zelfs zo dat de hoeveelheid IP-10 in 
het bloed significant daalde na de tweede HRV toediening ten opzichte van de eerste HRV 
toediening. Dit suggereert dat toediening van HRV resulteert in de onderdrukking van een 
specifiek deel van het aangeboren immuunsysteem. 
In hoofdstuk 6 beschrijven we de resultaten van onderzoek naar de effecten van een 
influenza-infectie op de LPS-geïnduceerde immuunrespons in muizen. LPS werd 4 
of 10 dagen na infectie met influenza via de luchtwegen toegediend. Hierbij is dag 4 
representatief voor de acute fase van influenza-infectie en dag 10 voor de herstelfase. 
Dit met als doel om meer inzicht te krijgen in de kinetiek van influenza-geïnduceerde 
effecten op de immuunrespons. De resultaten lieten zien dat de door LPS veroorzaakte 
immuunrespons niet onderdrukt, maar juist meer uitgesproken is tijdens de acute fase 
van de influenza-infectie. Dit bleek uit een synergistisch verhoogde productie van alle 
ontstekingsbevorderende eiwitten in de longen van de muis. Een en ander ging tevens 
gepaard met een trend in toename van het myeloperoxidase (MPO) in de longen, wat 
duidt op verhoogde aantallen ontstekingscellen. Deze synergie impliceert dat influenza 
de immuunrespons veroorzaakt door LPS kan beïnvloeden. Deze effecten werden 
overigens alleen waargenomen tijdens de acute fase van de influenza-infectie, niet tijdens 
de herstelfase. Het beeld van een overactieve immuunrespons waargenomen in ons 
onderzoek wordt in de literatuur geassocieerd met zeer ernstige longontstekingen en de 
ontwikkeling van het zogenaamde Acute Respiratoire Distress Syndroom (ARDS). Het is dus 
goed mogelijk dat de zeer uitgesproken immuunrespons op een bacteriële infectie tijdens 
een influenza-infectie eerder schadelijk dan bevorderlijk is voor de gastheer. 
Deel II Klinische implicaties van interacties tussen ziekteverwekkers en gastheer 
In hoofdstuk 7 hebben we in twee academische ziekenhuizen in Nederland een cohort van 
influenzapatiënten bestudeerd om meer inzicht te krijgen in de risicofactoren die leiden 
tot opname op de Intensive Care (IC) en die geassocieerd zijn met een verhoogde sterfte in 
deze patiëntengroep. De resultaten lieten zien dat Obstructief-, en Centraal Slaap Apneu 
Syndroom (OSAS; CSAS), het doorgemaakt hebben van een hartinfarct en een BMI>30 kg/
m2 vaker gezien worden bij patiënten met influenza-infecties die op de IC belanden in 
vergelijking met patiënten die op een gewone ziekenhuisafdeling blijven liggen. Patiënten 
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met influenza-infecties op de IC blijken tevens vaker nierfalen en secundaire infecties te 
ontwikkelen. Met betrekking tot secundaire bacteriële infecties werden de ziekteverwekkers 
Staphylococcus aureus en Streptococcus pneumoniae het vaakst waargenomen; wat betreft 
de secundaire schimmelinfecties werd voornamelijk Aspergillus fumigatus gevonden. Deze 
laatste infectie was aantoonbaar bij 18% van de patiënten met influenza-infecties in het IC 
cohort. Deze bevindingen zijn overeenkomstig met eerdere onderzoeken uitgevoerd door 
anderen. Echter, alhoewel de bovengenoemde ziekteverwekkers vaker werden gevonden bij 
IC patiënten dan bij patiënten op de gewone ziekenhuisafdeling, waren infecties met deze 
verwekkers niet geassocieerd met een verhoogde mortaliteit in vergelijking met patiënten 
zonder deze secundaire infecties, terwijl dit eerder wel zo is beschreven. Diabetes mellitus en 
nierfalen waren in ons cohort wel geassocieerd met een verhoogde mortaliteit op de IC, en 
corticosteroïden leken hier ook aan bij te dragen. De factoren die geassocieerd zijn met een 
gecompliceerd ziektebeloop, IC opname en IC mortaliteit houden mogelijk verband met een 
verzwakt immuunsysteem, wellicht veroorzaakt door andere onderliggende aandoeningen, 
gebruik van ontstekingsremmende medicijnen of door de influenza-infectie zelf. Wanneer 
we deze factoren in een vroeg stadium kunnen identificeren bij patiënten, dan zouden 
bepaalde preventieve of therapeutische maatregelen ingezet kunnen worden. Verder zou 
het vroegtijdig behandelen van secundaire infecties de prognose kunnen verbeteren bij 
bepaalde patiëntgroepen en misschien wel opname op de IC kunnen voorkomen. 
In hoofdstuk 8 zijn we dieper ingegaan op het vele voorkomen van infecties veroorzaakt door 
de schimmel Aspergillus fumigatus bij patiënten met influenza-infecties. Onze hypothese was 
dat het influenzavirus specifieke delen van het immuunsysteem kan uitschakelen, waardoor 
deze schimmel gemakkelijker kan uitgroeien en zo ziekte kan veroorzaken. Om deze hypothese 
te testen hebben we verschillende immunologische parameters van patiënten met influenza-
infecties op de IC vergeleken met die van patiënten met een bacteriële longontsteking of 
een geïsoleerd neurotrauma en met gezonde vrijwilligers. Hiervoor hebben we de volgende 
parameters gemeten: de hoeveelheid ontstekingseiwitten in het bloed en de productie van 
ontstekingseiwitten door ontstekingscellen uit het bloed, die in het lab gestimuleerd werden 
met verschillende activerende stoffen. Voor geen van deze parameters werden er verschillen 
waargenomen tussen patiënten met influenza-infecties en de andere groepen. Dit suggereert 
dat influenza geen systemische immuunparalyse veroorzaakt zoals bij sepsis het geval is, en 
dat er geen specifiek immuundefect lijkt op te treden wat de verhoogde vatbaarheid voor 
Aspergillus fumigatus bij patiënten met influenza-infecties kan verklaren. Een interessante 
bevinding was dat één van de patiënten met een influenza-infectie kenmerken van zowel 
hyperinflammatie als immuunsuppressie vertoonde. Zo’n gemengd immunologisch beeld 
bemoeilijkt het onderzoek evenals het ontwikkelen en toepassen van gepersonaliseerde 
therapieën bij deze patiëntencategorie in ernstige mate. 
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In hoofdstuk 9 hebben we ons gericht op de vraag of de reactivatie van virussen, zoals 
waargenomen wordt bij patiënten met sepsis, ook optreedt bij een zogenaamde ‘steriele’ 
ontstekingsreactie (d.w.z. niet veroorzaakt door een ziekteverwekker). Hiervoor hebben we 
onderzoek gedaan bij patiënten die een trauma (bijvoorbeeld een verkeersongeval) hebben 
doorgemaakt. Bij deze traumapatiënten werd inderdaad reactivatie van verschillende virussen 
waargenomen, waarbij reactivatie van het epstein barr virus (EBV) het meest voorkwam, 
gevolgd door het cytomegalovirus (CMV) en het herpes simplex virus (HSV). Bacteriële 
infecties kwamen bovendien vaker voor bij traumapatiënten waarbij virale reactivatie werd 
vastgesteld. Indicatoren voor immuunsuppressie, zoals HLA-DR en de concentratie IL-10 in het 
bloed waren ook gerelateerd aan virale reactivatie. Deze resultaten suggereren een causaal 
verband tussen een onderdrukt immuunsysteem en de reactivatie van virussen die latent in 
het lichaam aanwezig zijn. Uit dit onderzoek kunnen we concluderen dat traumapatiënten, 
evenals sepsispatiënten, een ernstig onderdrukt immuunsysteem kunnen hebben en dat 
dit verband houdt met het optreden van bacteriële infecties. Deze infecties dragen op hun 
beurt weer bij aan een verhoogde sterftekans. Virale reactivatie zou daarom mogelijk een 
belangrijke nieuwe marker voor een onderdrukt immuunsysteem bij traumapatiënten 
kunnen zijn. 
Deel III Methodologische overwegingen en bredere toepasbaarheid van experimentele 
virale en bacteriële modellen 
Patiënten met zeer ernstige infecties worden over het algemeen langdurig blootgesteld 
aan ziekteverwekkers. Om dit zo nauwkeurig mogelijk na te bootsen in een experimenteel 
model, hebben we een nieuwe vorm van het experimentele endotoxinemiemodel bij 
gezonde vrijwilligers opgezet, waarin LPS drie uur lang via een infuus wordt toegediend in 
plaats van de eerder gebruikte eenmalige toediening gedurende 1 minuut. In hoofdstuk 10 
hebben we dit ‘continue LPS model’ vergeleken met de effecten van eenmalige toediening 
van verschillende doses LPS. De continue LPS infusie werd goed verdragen door de 
proefpersonen en zowel de productie van ontstekingseiwitten alsmede koorts en klinische 
symptomen waren meer uitgesproken aanwezig en bleven langer verhoogd, vergeleken met 
een eenmalige toediening van LPS. Dit nieuwe model brengt nieuwe inzichten met betrekking 
tot het verloop van ontstekingsreacties. Dit is relevant voor onderzoek naar infecties, maar 
ook voor onderzoek naar (auto)immuunziekten en ernstig trauma. Tevens biedt het continue 
model een grotere tijdspanne voor het toepassen van interventies, zoals medicijnen die het 
immuunsysteem beïnvloeden. 
In hoofdstuk 11 hebben we het experimentele endotoxinemiemodel gebruikt voor een 
bredere toepassing, namelijk om te onderzoeken hoe de ontstekingsreactie veroorzaakt door 
toediening van LPS motivatie en gedrag kan beïnvloeden. Dit hebben we bepaald door de 
mate van inspanning en gevoeligheid voor beloning op verschillende tijdstippen voor en na 
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LPS toediening te meten en dit tevens te vergelijken met een placebogroep. Zoals verwacht 
leidde LPS toediening tot verhoogde concentraties van ontstekingseiwitten in het bloed, 
ziekteverschijnselen en koorts. De proefpersonen rapporteerden tevens een toegenomen 
gevoel van depressie en vermoeidheid na LPS toediening en deze gevoelens waren ook 
toegenomen ten opzichte van de placebogroep. Dit ging gepaard met een verminderde 
motivatie om moeilijke taken uit te voeren twee uur na de toediening van LPS, zonder dat de 
gevoeligheid voor beloning beïnvloed werd. Deze veranderingen in motivatie waren vijf uur na 
LPS toediening weer deels hersteld. In combinatie met bevindingen uit eerder onderzoek lijkt 
het waarschijnlijk dat deze effecten veroorzaakt worden door veranderde concentraties van 
de signaalstof dopamine in bepaalde gebieden van de hersenen (het mesolimbisch systeem) 
ten gevolge van de LPS toediening. Dit wordt onderschreven door onderzoek met dopamine-
verhogende medicijnen zoals methylfenidaat en levodopa wat aangetoond heeft dat deze 
middelen ontstekingsverschijnselen en vermoeidheid kunnen tegengaan. Uit ons onderzoek 
blijkt dat, naast toepassing bij gezonde vrijwilligers, het experimentele endotoxinemiemodel 
tevens gebruikt zou kunnen worden om de effecten van een ontstekingsreactie op motivatie 
en gedrag te onderzoeken bij bijvoorbeeld patiënten met chronische en psychiatrische 
ziekten. 
Het experimentele HRV model, opgezet gedurende de totstandkoming van dit proefschrift (zie 
hoofdstuk 5), hebben we in hoofdstuk 12 gebruikt om de effecten van serostatus (d.w.z. of je 
antistoffen bij je draagt gericht tegen HRV) en geslacht te onderzoeken op de ontstekingsreactie 
veroorzaakt door infectie met HRV. Dit met als doel de methodologie te optimaliseren voor 
toekomstige onderzoeken met dit model. Zoals eerder beschreven veroorzaakte een HRV 
infectie een toename in de hoeveelheid virus in de neus; deze was echter meer uitgesproken 
bij seronegatieve dan bij seropositieve proefpersonen. Tevens werd er een meer uitgesproken 
toename van de ontstekingseiwitten IP-10, IL-6 en IL-10 en witte bloedcellen in de neus gezien 
bij seronegative proefpersonen vergeleken met seropositieve proefpersonen. Geslacht had 
geen invloed op deze of andere ontstekingsparameters. Deze resultaten hebben een grote 
invloed met betrekking tot de opzet van toekomstige onderzoeken met het HRV model. Ten 
eerste, vanwege de uitgesproken effecten die serostatus op de lokale immuunrespons heeft 
zouden er alleen seronegatieve personen onderzocht moeten worden wanneer er metingen 
aan het immuunsysteem worden verricht. Ten tweede zouden zowel mannen als vrouwen 
geïncludeerd kunnen en moeten worden. 
Het HRV model werd opnieuw gebruikt in hoofdstuk 13 om een nieuwe methode om de 
bacteriesamenstelling in het slijmlies van de neus te onderzoeken. Deze methode maakt 
gebruik van de kwantitatieve real-time polymerase kettingreactie (ook wel PCR genoemd), 
en kan differentiëren tussen verschillende soorten bacteriën (Gram-positieve en Gram-
negatieve). Bovendien is deze nieuwe methode snel, goedkoop en makkelijk in gebruik. In 
dit onderzoek hebben we middels validatie-experimenten aangetoond dat real-time PCR 
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een hoge specificiteit en sensitiviteit heeft voor het detecteren van verschillende soorten 
bacteriën in het slijmvlies van de neus. Vervolgens hebben we deze methode gebruikt om 
veranderingen in de bacteriesamenstelling te onderzoeken voor en na een infectie met zowel 
HRV als infectie met pneumokokken (een veelvoorkomende bacteriële luchtweginfectie). 
De variatie in de bacteriesamenstelling nam sterk toe na infectie met HRV vergeleken met 
een placebogroep. De bacteriesamenstelling veranderde ook op dag 2 en dag 7 na een 
pneumokokkeninfectie, en normaliseerde weer op dag 14 na infectie. Deze resultaten komen 
overeen met eerdere vergelijkbare onderzoeken die duurdere en complexere methoden voor 
de bepaling van de bacteriesamenstelling gebruikten. Real-time PCR is dus een aantrekkelijke 
nieuwe methode om de bacteriesamenstelling in slijmvliezen te analyseren, bijvoorbeeld 
om de effecten van vaccinaties en voeding op deze samenstelling te onderzoeken. 
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